*circRNA Name*Region*Strand*Gene Symbol*CircBase Link*Disease Name*Expression Pattern*Experimental Techniques*Species*Brief description*Year*PMID*Unnamed: 12*all*Source*disease
0*hsa_circ_0000977*chr2:10784445-10808849*-*NOL10*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000977*Carcinoma, Pancreatic Ductal*Upregulated*qRT-PCR, Western blot, Luciferase reporter assay,Immunohistochemistry, FISH  etc.*Human*Silencing hsa_circ_0000977 suppresses progression of pancreatic cancer by interacting with hsa-miR-874-3p and decreasing inhibiting PLK1 expression.*2018-05-01*29454093.0**hsa_circ_0000977/chr2:10784445-10808849*CircR2Disease*pancreatic ductal adenocarcinoma
1*hsa_circ_0006220*chr17:35800605-35800763*+*TADA2A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006220*Carcinoma, Pancreatic Ductal*Upregulated*qRT-PCR, Western blot, Luciferase reporter assay,Immunohistochemistry, FISH  etc.*Human*The expression of five mostly upregulated circRNAs are validated in five matched cancer and adjacent non-cancer tissues.*2018-05-01*29454093.0**hsa_circ_0006220/chr17:35800605-35800763*CircR2Disease*pancreatic ductal adenocarcinoma
2*hsa_circ_0001666*chr6:170626457-170639638*+*FAM120B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001666*Carcinoma, Pancreatic Ductal*Upregulated*qRT-PCR, Western blot, Luciferase reporter assay,Immunohistochemistry, FISH  etc.*Human*The expression of five mostly upregulated circRNAs are validated in five matched cancer and adjacent non-cancer tissues.*2018-05-01*29454093.0**hsa_circ_0001666/chr6:170626457-170639638*CircR2Disease*pancreatic ductal adenocarcinoma
3*hsa_circ_0043278*chr17:35797838-35800763*+*TADA2A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0043278*Carcinoma, Pancreatic Ductal*Upregulated*qRT-PCR, Western blot, Luciferase reporter assay,Immunohistochemistry, FISH  etc.*Human*The expression of five mostly upregulated circRNAs are validated in five matched cancer and adjacent non-cancer tissues.*2018-05-01*29454093.0**hsa_circ_0043278/chr17:35797838-35800763*CircR2Disease*pancreatic ductal adenocarcinoma
4*hsa_circ_0078297*chr6:151336015-151336829*+*MTHFD1L*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0078297*Carcinoma, Pancreatic Ductal*Upregulated*qRT-PCR, Western blot, Luciferase reporter assay,Immunohistochemistry, FISH  etc.*Human*The expression of five mostly upregulated circRNAs are validated in five matched cancer and adjacent non-cancer tissues.*2018-05-01*29454093.0**hsa_circ_0078297/chr6:151336015-151336829*CircR2Disease*pancreatic ductal adenocarcinoma
5*hsa_circ_0089810*chrX:2637701-2644414*+*CD99*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0089810**Downregulated*qRT-PCR etc.*Human*To validate the predicted circRNAs, 6 downregulated circRNAs were selected for subsequent qRT-PCR validation in all vein samples: hsa_circ_0089810 (CD99), hsa_circ_0000378 (LRP6), hsa_circ_0006427 (BCAR3), hsa_circ_0003171 (PTK2), circ_SDHA and hsa_circ_0005267 (GPATCH2L). The relative expression levels of the circRNAs were downregulated by 2.5-fold, 2.1-fold, 9.8-fold, 1.6-fold, 2.5-fold and 3.3-fold in the PGSVV group as compared to control group, respectively*2018-05-01*29577902.0**hsa_circ_0089810/chrX:2637701-2644414*CircR2Disease*primary great saphenous vein varicosities
6*hsa_circ_0000378*chr12:12397195-12397589*-*LRP6*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000378**Downregulated*qRT-PCR etc.*Human*To validate the predicted circRNAs, 6 downregulated circRNAs were selected for subsequent qRT-PCR validation in all vein samples: hsa_circ_0089810 (CD99), hsa_circ_0000378 (LRP6), hsa_circ_0006427 (BCAR3), hsa_circ_0003171 (PTK2), circ_SDHA and hsa_circ_0005267 (GPATCH2L). The relative expression levels of the circRNAs were downregulated by 2.5-fold, 2.1-fold, 9.8-fold, 1.6-fold, 2.5-fold and 3.3-fold in the PGSVV group as compared to control group, respectively*2018-05-01*29577902.0**hsa_circ_0000378/chr12:12397195-12397589*CircR2Disease*primary great saphenous vein varicosities
7*hsa_circ_0006427*chr1:94032835-94033408*-*BCAR3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006427**Downregulated*qRT-PCR etc.*Human*To validate the predicted circRNAs, 6 downregulated circRNAs were selected for subsequent qRT-PCR validation in all vein samples: hsa_circ_0089810 (CD99), hsa_circ_0000378 (LRP6), hsa_circ_0006427 (BCAR3), hsa_circ_0003171 (PTK2), circ_SDHA and hsa_circ_0005267 (GPATCH2L). The relative expression levels of the circRNAs were downregulated by 2.5-fold, 2.1-fold, 9.8-fold, 1.6-fold, 2.5-fold and 3.3-fold in the PGSVV group as compared to control group, respectively*2018-05-01*29577902.0**hsa_circ_0006427/chr1:94032835-94033408*CircR2Disease*primary great saphenous vein varicosities
8*hsa_circ_0003171*chr8:141749116-141762415*-*PTK2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003171**Downregulated*qRT-PCR etc.*Human*To validate the predicted circRNAs, 6 downregulated circRNAs were selected for subsequent qRT-PCR validation in all vein samples: hsa_circ_0089810 (CD99), hsa_circ_0000378 (LRP6), hsa_circ_0006427 (BCAR3), hsa_circ_0003171 (PTK2), circ_SDHA and hsa_circ_0005267 (GPATCH2L). The relative expression levels of the circRNAs were downregulated by 2.5-fold, 2.1-fold, 9.8-fold, 1.6-fold, 2.5-fold and 3.3-fold in the PGSVV group as compared to control group, respectively*2018-05-01*29577902.0**hsa_circ_0003171/chr8:141749116-141762415*CircR2Disease*primary great saphenous vein varicosities
9*circ_SDHA***SDHA***Downregulated*qRT-PCR etc.*Human*To validate the predicted circRNAs, 6 downregulated circRNAs were selected for subsequent qRT-PCR validation in all vein samples: hsa_circ_0089810 (CD99), hsa_circ_0000378 (LRP6), hsa_circ_0006427 (BCAR3), hsa_circ_0003171 (PTK2), circ_SDHA and hsa_circ_0005267 (GPATCH2L). The relative expression levels of the circRNAs were downregulated by 2.5-fold, 2.1-fold, 9.8-fold, 1.6-fold, 2.5-fold and 3.3-fold in the PGSVV group as compared to control group, respectively*2018-05-01*29577902.0**circ_SDHA*CircR2Disease*primary great saphenous vein varicosities
10*hsa_circ_0005267*chr14:76633005-76647192*+*C14orf118*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005267**Downregulated*qRT-PCR etc.*Human*To validate the predicted circRNAs, 6 downregulated circRNAs were selected for subsequent qRT-PCR validation in all vein samples: hsa_circ_0089810 (CD99), hsa_circ_0000378 (LRP6), hsa_circ_0006427 (BCAR3), hsa_circ_0003171 (PTK2), circ_SDHA and hsa_circ_0005267 (GPATCH2L). The relative expression levels of the circRNAs were downregulated by 2.5-fold, 2.1-fold, 9.8-fold, 1.6-fold, 2.5-fold and 3.3-fold in the PGSVV group as compared to control group, respectively*2018-05-01*29577902.0**hsa_circ_0005267/chr14:76633005-76647192*CircR2Disease*primary great saphenous vein varicosities
11*hsa_circRNA_100571*****Carcinoma, Hepatocellular*Downregulated*qRT-PCR etc.*Human*The results showed that the expression levels of hsa_circ_100571 and hsa_circ_400031 pre-transplantation were lower than those of NCs*2018-04-01*29609527.0**hsa_circRNA_100571*CircR2Disease*primary hepatic carcinoma
12*hsa_circRNA_400031*****Carcinoma, Hepatocellular*Downregulated*qRT-PCR etc.*Human*The results showed that the expression levels of hsa_circ_100571 and hsa_circ_400031 pre-transplantation were lower than those of NCs*2018-04-01*29609527.0**hsa_circRNA_400031*CircR2Disease*primary hepatic carcinoma
13*hsa_circRNA_102032*****Carcinoma, Hepatocellular*Upregulated*qRT-PCR etc.*Human*The expression levels of hsa_circ_102032, hsa_circ_103096, and hsa_circ_102347 pre-transplantation were significantly higher than those of NCs*2018-04-01*29609527.0**hsa_circRNA_102032*CircR2Disease*primary hepatic carcinoma
14*hsa_circRNA_103096*****Carcinoma, Hepatocellular*Upregulated*qRT-PCR etc.*Human*The expression levels of hsa_circ_102032, hsa_circ_103096, and hsa_circ_102347 pre-transplantation were significantly higher than those of NCs*2018-04-01*29609527.0**hsa_circRNA_103096*CircR2Disease*primary hepatic carcinoma
15*hsa_circRNA_102347*****Carcinoma, Hepatocellular*Upregulated*qRT-PCR etc.*Human*The expression levels of hsa_circ_102032, hsa_circ_103096, and hsa_circ_102347 pre-transplantation were significantly higher than those of NCs*2018-04-01*29609527.0**hsa_circRNA_102347*CircR2Disease*primary hepatic carcinoma
16*circMAN2B2***MAN2B2**Lung Neoplasms*Upregulated*qRT-PCR, Luciferase reporter assay etc.*Human*circMAN2B2 acts as an oncogenic role in lung cancer through promoting FOXK1 expression by sponging miR-1275.*2018-04-01*29550475.0**circMAN2B2/hsa_circRNA_103595*CircR2Disease*lung cancer
17*hsa_circ_0037911*chr16:11988810-11991892*-*GSPT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0037911*Essential Hypertension*Upregulated*qRT-PCR etc.*Human*The levels of hsa_circ_0037911 were significantly differences in gender, BMI, smoking and drinking among EH cases.*2018-04-01*29526758.0**hsa_circ_0037911/chr16:11988810-11991892*CircR2Disease*essential hypertension
18*hsa_circ_0002161*chr16:11988810-11990642*-*GSPT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002161*Essential Hypertension*Upregulated*qRT-PCR etc.*Human*hsa_circ_0037911 relative fold showed significant differences between gender (p < 0.0001), smoking (p = 0.001) and drinking (p = 0.049). However hsa_circ_0002161 have no significant difference in different state.*2018-04-01*29526758.0**hsa_circ_0002161/chr16:11988810-11990642*CircR2Disease*essential hypertension
19*circRNA.1030*****Diabetes, Gestational*Upregulated*qRT-PCR etc.*Human*Six differential circRNAs, three up-regulated circRNAs (circRNA.1030, circRNA.5333, and circRNA.33299) and three down-regulated circRNAs (circRNA.20159, circRNA.37134, and circRNA.22054), were selected to verify the sequencing results.*2018-04-01*29526755.0**circRNA.1030*CircR2Disease*gestational diabetes mellitus
20*circRNA.5333*****Diabetes, Gestational*Upregulated*qRT-PCR etc.*Human*Six differential circRNAs, three up-regulated circRNAs (circRNA.1030, circRNA.5333, and circRNA.33299) and three down-regulated circRNAs (circRNA.20159, circRNA.37134, and circRNA.22054), were selected to verify the sequencing results.*2018-04-01*29526755.0**circRNA.5333*CircR2Disease*gestational diabetes mellitus
21*circRNA.33299*****Diabetes, Gestational*Upregulated*qRT-PCR etc.*Human*Six differential circRNAs, three up-regulated circRNAs (circRNA.1030, circRNA.5333, and circRNA.33299) and three down-regulated circRNAs (circRNA.20159, circRNA.37134, and circRNA.22054), were selected to verify the sequencing results.*2018-04-01*29526755.0**circRNA.33299*CircR2Disease*gestational diabetes mellitus
22*circRNA.20159*****Diabetes, Gestational*Downregulated*qRT-PCR etc.*Human*Six differential circRNAs, three up-regulated circRNAs (circRNA.1030, circRNA.5333, and circRNA.33299) and three down-regulated circRNAs (circRNA.20159, circRNA.37134, and circRNA.22054), were selected to verify the sequencing results.*2018-04-01*29526755.0**circRNA.20159*CircR2Disease*gestational diabetes mellitus
23*circRNA.37134*****Diabetes, Gestational*Downregulated*qRT-PCR etc.*Human*Six differential circRNAs, three up-regulated circRNAs (circRNA.1030, circRNA.5333, and circRNA.33299) and three down-regulated circRNAs (circRNA.20159, circRNA.37134, and circRNA.22054), were selected to verify the sequencing results.*2018-04-01*29526755.0**circRNA.37134*CircR2Disease*gestational diabetes mellitus
24*circRNA.22054*****Diabetes, Gestational*Downregulated*qRT-PCR etc.*Human*Six differential circRNAs, three up-regulated circRNAs (circRNA.1030, circRNA.5333, and circRNA.33299) and three down-regulated circRNAs (circRNA.20159, circRNA.37134, and circRNA.22054), were selected to verify the sequencing results.*2018-04-01*29526755.0**circRNA.22054*CircR2Disease*gestational diabetes mellitus
25*hsa_circ_0007385*chr2:32142994-32157204*-*MEMO1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007385*Carcinoma, Non-Small-Cell Lung*Upregulated*qPCR, CCK-8 assay, Colony formation assay, Dual-luciferase assay, Xenograft assay etc.*Human*In vitro experiments with hsa_circ_0007385 knockdown resulted in significant suppression of the proliferation, migration and invasion of NSCLC cells. In vivo xenograft assay using hsa_circ_0007385 knockdown, significantly reduced tumor growth. Bioinformatics analysis and luciferase reporter assay verified the potential target miR-181, suggesting a possible regulatory pathway for hsa_circ_0007385.*2018-04-01*29372377.0**hsa_circ_0007385/chr2:32142994-32157204*CircR2Disease*non-small cell lung cancer
26*hsa_circ_400011*chr1:68151221-68151421*+*GADD45A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0092374*Lupus Erythematosus, Systemic*Upregulated*qRT-PCR etc.*Human*"We found that the expression levels of hsa:circ_102584, hsa:circ_400011 and hsa:circ_101471 were significantly higher in SLE patients than in corresponding normal subjects (Fig. 2C, *p < 0.05, **p < 0.01). "*2018-03-01*29360436.0**hsa_circ_400011/hsa_circ_0092374/chr1:68151221-68151421*CircR2Disease*systemic lupus erythematosus
27*hsa_circRNA_000167*chr14*-*RPPH1**Pancreatic Neoplasms*Downregulated*qRT-PCR etc.*Human*The RT‑qPCR results are consistent with microarray data.*2018-03-01*29620241.0**hsa_circRNA_000167/chr14*CircR2Disease*pancreatic cancer
28*hsa_circRNA_100433*****Pancreatic Neoplasms*Upregulated*qRT-PCR etc.*Human*The RT‑qPCR results are consistent with microarray data.*2018-03-01*29620241.0**hsa_circRNA_100433*CircR2Disease*pancreatic cancer
29*hsa_circRNA_101717*chr16*+* ABCC1**Pancreatic Neoplasms*Upregulated*qRT-PCR etc.*Human*The RT‑qPCR results are consistent with microarray data.*2018-03-01*29620241.0**hsa_circRNA_101717/chr16*CircR2Disease*pancreatic cancer
30*hsa_circRNA_102049*chr17*+* TADA2A**Pancreatic Neoplasms*Upregulated*qRT-PCR etc.*Human*The RT‑qPCR results are consistent with microarray data.*2018-03-01*29620241.0**hsa_circRNA_102049/chr17*CircR2Disease*pancreatic cancer
31*hsa_circRNA_102049*chr17*+* TADA2A**Pancreatic Neoplasms*Upregulated*qRT-PCR etc.*Human*The RT‑qPCR results are consistent with microarray data.*2018-03-01*29620241.0**hsa_circRNA_102051/chr17*CircR2Disease*pancreatic cancer
32*hsa_circRNA_102619*chr2*-*NOL10 **Pancreatic Neoplasms*Upregulated*qRT-PCR etc.*Human*The RT‑qPCR results are consistent with microarray data.*2018-03-01*29620241.0**hsa_circRNA_102619/chr2*CircR2Disease*pancreatic cancer
33*hsa_circRNA_103076*chr20*-*CSE1L**Pancreatic Neoplasms*Upregulated*qRT-PCR etc.*Human*The RT‑qPCR results are consistent with microarray data.*2018-03-01*29620241.0**hsa_circRNA_103076/chr20*CircR2Disease*pancreatic cancer
34*hsa_circRNA_103390*****Pancreatic Neoplasms*Upregulated*qRT-PCR etc.*Human*The RT‑qPCR results are consistent with microarray data.*2018-03-01*29620241.0**hsa_circRNA_103390*CircR2Disease*pancreatic cancer
35*hsa_circRNA_104084*chr6*+*LINC00340**Pancreatic Neoplasms*Upregulated*qRT-PCR etc.*Human*The RT‑qPCR results are consistent with microarray data.*2018-03-01*29620241.0**hsa_circRNA_104084/chr6*CircR2Disease*pancreatic cancer
36*hsa_circRNA_104084*chr6*+*FAM120B **Pancreatic Neoplasms*Upregulated*qRT-PCR etc.*Human*The RT‑qPCR results are consistent with microarray data.*2018-03-01*29620241.0**hsa_circRNA_104270/chr6*CircR2Disease*pancreatic cancer
37*circ-Foxo3***FOXO3**Carcinoma, Non-Small-Cell Lung*Downregulated*qRT-PCR, Western blot etc.*Human*The functional relevance was further examined by biological assays. circRNA‑FOXO3 significantly promoted the ability of cell proliferation, migration and invasion of NSCLC cells. The linear isomer of circRNA‑FOXO3, FOXO3 gene, was identified as a downstream target. RNA immunoprecipitation indicated that circRNA‑FOXO3 sequestering miR‑155, which further promoted linear FOXO3 expression. In addition, gain and loss functional assays indicated that circRNA‑FOXO3 served an anti‑oncogenic role through sequestering miR‑155 and enhancing FOXO3 expression. *2018-03-01*29620202.0**circ-Foxo3*CircR2Disease*non-small cell lung cancer
38*hsa_circ_102584*chr19:48229068-48229481*+*EHD2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003146*Lupus Erythematosus, Systemic*Upregulated*qRT-PCR etc.*Human*"We found that the expression levels of hsa:circ_102584, hsa:circ_400011 and hsa:circ_101471 were significantly higher in SLE patients than in corresponding normal subjects (Fig. 2C, *p < 0.05, **p < 0.01). "*2018-03-01*29360436.0**hsa_circ_102584/hsa_circ_0003146/chr19:48229068-48229481*CircR2Disease*systemic lupus erythematosus
39*hsa_circ_101471*chr15:36936478-36950106*+*C15orf41*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0034398*Lupus Erythematosus, Systemic*Upregulated*qRT-PCR etc.*Human*"We found that the expression levels of hsa:circ_102584, hsa:circ_400011 and hsa:circ_101471 were significantly higher in SLE patients than in corresponding normal subjects (Fig. 2C, *p < 0.05, **p < 0.01). "*2018-03-01*29360436.0**hsa_circ_101471/hsa_circ_0034398/chr15:36936478-36950106*CircR2Disease*systemic lupus erythematosus
40*hsa_circ_104807*chr9:86293355-86297981*-*UBQLN1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001866*Lupus Erythematosus, Systemic*Downregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29360436.0**hsa_circ_104807/hsa_circ_0001866/chr9:86293355-86297981*CircR2Disease*systemic lupus erythematosus
41*hsa_circ_102571*chr19:45901262-45901597*-*PPP1R13L*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008615*Lupus Erythematosus, Systemic*Upregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29360436.0**hsa_circ_102571/hsa_circ_0008615/chr19:45901262-45901597*CircR2Disease*systemic lupus erythematosus
42*hsa_circ_100226*chr1:51868106-51874004*-*EPS15*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005567*Lupus Erythematosus, Systemic*Downregulated*qRT-PCR etc.*Human*"We found that the expression levels of hsa:circ_102584, hsa:circ_400011 and hsa:circ_101471 were significantly higher in SLE patients than in corresponding normal subjects (Fig. 2C, *p < 0.05, **p < 0.01). "*2018-03-01*29360436.0**hsa_circ_100226/hsa_circ_0005567/chr1:51868106-51874004*CircR2Disease*systemic lupus erythematosus
43*hsa_circ_100775*chr11:30516842-30557722*-*MPPED2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0021549*Lupus Erythematosus, Systemic*Downregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29360436.0**hsa_circ_100775/hsa_circ_0021549/chr11:30516842-30557722*CircR2Disease*systemic lupus erythematosus
44*hsa_circ_101889*chr16:84792321-84801964*+*USP10*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0040705*Lupus Erythematosus, Systemic*Downregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29360436.0**hsa_circ_101889/hsa_circ_0040705/chr16:84792321-84801964*CircR2Disease*systemic lupus erythematosus
45*hsa_circ_0001649*chr6:146209155-146216113*-*SHPRH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001649*Glioma*Downregulated*qRT-PCR etc.*Human*Both circ-SHPRH and SHPRH-146aa are abundantly expressed in normal human brains and are down-regulated in glioblastoma. The overexpression of SHPRH-146aa in U251 and U373 glioblastoma cells reduces their malignant behavior and tumorigenicity in vitro and in vivo.*2018-03-01*29343848.0**hsa_circ_0001649/chr6:146209155-146216113*CircR2Disease*glioma
46*hsa_circ_0007534*chr17:61869771-61877977*+*DDX42*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007534*Glioma*Upregulated*qRT-PCR etc.*Human*hsa_circ_0007534 serves as an oncogene in glioma via promoting ZIC5 expression by repressing miR-761 availability.*2018-03-01*29605301.0**hsa_circ_0007534/chr17:61869771-61877977*CircR2Disease*glioma
47*circRNA_102231*****Lung Neoplasms*Upregulated*qRT-PCR etc.*Human*QRT-PCR showed that circRNA_102231 expression was significantly upregulated in LAC tissues and associated with the advanced TNM stage, lymph node metastasis, and poor overall survival of lung cancer patients.*2018-03-01*29602132.0**circRNA_102231*CircR2Disease*lung cancer
48*circRNA_0084927*chr8:95676924-95677424*+*ESRP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0084927*Acne Vulgaris*Downregulated*qRT-PCR etc.*Human*5 candidate circRNAs (circRNA_0084927, circRNA_0001073, circRNA_0005941, circRNA_0086376, and circRNA_0018168) were validated to have significant decreased in severe acne by PCR, Sanger sequencing, and qRT-PCR*2018-03-01*29573483.0**circRNA_0084927/hsa_circ_0084927/chr8:95676924-95677424*CircR2Disease*acne
49*circRNA_0001073*chr2:148653869-148657467*+*ACVR2A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001073*Acne Vulgaris*Downregulated*qRT-PCR etc.*Human*5 candidate circRNAs (circRNA_0084927, circRNA_0001073, circRNA_0005941, circRNA_0086376, and circRNA_0018168) were validated to have significant decreased in severe acne by PCR, Sanger sequencing, and qRT-PCR*2018-03-01*29573483.0**circRNA_0001073/hsa_circ_0001073/chr2:148653869-148657467*CircR2Disease*acne
50*circRNA_0005941*chr16:53907697-53922863*+*FTO*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005941*Acne Vulgaris*Downregulated*qRT-PCR etc.*Human*5 candidate circRNAs (circRNA_0084927, circRNA_0001073, circRNA_0005941, circRNA_0086376, and circRNA_0018168) were validated to have significant decreased in severe acne by PCR, Sanger sequencing, and qRT-PCR*2018-03-01*29573483.0**circRNA_0005941/hsa_circ_0005941/chr16:53907697-53922863*CircR2Disease*acne
51*circRNA_0086376*chr9:14146687-14179779*-*NFIB*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0086376*Acne Vulgaris*Downregulated*qRT-PCR etc.*Human*5 candidate circRNAs (circRNA_0084927, circRNA_0001073, circRNA_0005941, circRNA_0086376, and circRNA_0018168) were validated to have significant decreased in severe acne by PCR, Sanger sequencing, and qRT-PCR*2018-03-01*29573483.0**circRNA_0086376/hsa_circ_0086376/chr9:14146687-14179779*CircR2Disease*acne
52*circRNA_0018168*chr10:34558584-34573173*-*PARD3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0018168*Acne Vulgaris*Downregulated*qRT-PCR etc.*Human*5 candidate circRNAs (circRNA_0084927, circRNA_0001073, circRNA_0005941, circRNA_0086376, and circRNA_0018168) were validated to have significant decreased in severe acne by PCR, Sanger sequencing, and qRT-PCR*2018-03-01*29573483.0**circRNA_0018168/hsa_circ_0018168/chr10:34558584-34573173*CircR2Disease*acne
53*hsa_circ_0000172*chr1:201475259-201475620*-*CSRP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000172*Urinary Bladder Neoplasms*Upregulated*qRT-PCR etc.*Human*Hsa_circ_0000172, Hsa_circ_0002495, Chr22: 28943661, and Chr5: 158368701 were up-regulated in tumor, while Chr9: 74522734 was down-regulated*2018-03-01*29558461.0**hsa_circ_0000172/chr1:201475259-201475620*CircR2Disease*bladder cancer
54*hsa_circ_0002495*chr15:61386554-61404318*-*RORA*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002495*Urinary Bladder Neoplasms*Upregulated*qRT-PCR etc.*Human*Hsa_circ_0000172, Hsa_circ_0002495, Chr22: 28943661, and Chr5: 158368701 were up-regulated in tumor, while Chr9: 74522734 was down-regulated*2018-03-01*29558461.0**hsa_circ_0002495/chr15:61386554-61404318*CircR2Disease*bladder cancer
55*Chr22: 28943661*chr22: 28943661-28946139****Urinary Bladder Neoplasms*Upregulated*qRT-PCR etc.*Human*Hsa_circ_0000172, Hsa_circ_0002495, Chr22: 28943661, and Chr5: 158368701 were up-regulated in tumor, while Chr9: 74522734 was down-regulated*2018-03-01*29558461.0**Chr22: 28943661/chr22: 28943661-28946139*CircR2Disease*bladder cancer
56*Chr5: 158368701*chr5: 158368701-158368987****Urinary Bladder Neoplasms*Upregulated*qRT-PCR etc.*Human*Hsa_circ_0000172, Hsa_circ_0002495, Chr22: 28943661, and Chr5: 158368701 were up-regulated in tumor, while Chr9: 74522734 was down-regulated*2018-03-01*29558461.0**Chr5: 158368701/chr5: 158368701-158368987*CircR2Disease*bladder cancer
57*Chr9: 74522734*chr9:74522734-74523039****Urinary Bladder Neoplasms*Downregulated*qRT-PCR etc.*Human*Hsa_circ_0000172, Hsa_circ_0002495, Chr22: 28943661, and Chr5: 158368701 were up-regulated in tumor, while Chr9: 74522734 was down-regulated*2018-03-01*29558461.0**Chr9: 74522734/chr9:74522734-74523039*CircR2Disease*bladder cancer
58*hsa_circ_0011946*chr1:41578954-41618413*-*SCMH1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0011946*Breast Neoplasms*Upregulated*qRT-PCR etc.*Human*hsa_circ_0011946 loss-of-function significantly suppressed the migration and invasion of Michigan Cancer Foundation-7 cells.*2018-03-01*29593432.0**hsa_circ_0011946/chr1:41578954-41618413*CircR2Disease*breast cancer
59*hsa_circ_0007534*chr17:61869771-61877977*+*DDX42*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007534*Breast Neoplasms*Upregulated*qRT-PCR etc.*Human*hsa_circ_0093859, hsa_circ_0007534, and hsa_circ_0011946 had an obviously higher expression in the MCF-7 cell line than in other cell lines.*2018-03-01*29593432.0**hsa_circ_0007534/chr17:61869771-61877977*CircR2Disease*breast cancer
60*hsa_circ_0093859*chr10:64966354-64968995*-*JMJD1C*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0093859*Breast Neoplasms*Upregulated*qRT-PCR etc.*Human*hsa_circ_0093859, hsa_circ_0007534, and hsa_circ_0011946 had an obviously higher expression in the MCF-7 cell line than in other cell lines.*2018-03-01*29593432.0**hsa_circ_0093859/chr10:64966354-64968995*CircR2Disease*breast cancer
61*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Colorectal Neoplasms*Upregulated*qRT-PCR etc.*Human*circHIPK3 may have considerable potential as a prognostic biomarker in CRC, and support the notion that therapeutic targeting of the c-Myb/circHIPK3/miR-7 axis may be a promising treatment approach for CRC patients.*2018-03-01*29549306.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*colorectal cancer
62*circHECTD1***HECTD1**Silicosis*Upregulated*qRT-PCR, Western blotting, Immunocytochemistry, FISH, RNA interference etc.*Human*Our study has elucidated a link between the SiO2-induced EndMT and the circHECTD1/HECTD1 pathway, thereby providing insights into the potential use of HECTD1 for developing novel therapeutic strategies for silicosis*2018-03-01*29540674.0**circHECTD1*CircR2Disease*silicosis
63*circ_0004712*chr6:136468488-136476896*+*PDE7B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004712*Carcinoma, Endometrioid*Upregulated*qRT-PCR etc.*Human*circRNAs are candidate factors in the activation of endometriosis. circ_0002198 and circ_0004712 may be potential novel biomarkers for the diagnosis of ovarian endometriosis.*2018-03-01*29483390.0**circ_0004712/hsa_circ_0004712/chr6:136468488-136476896*CircR2Disease*ovarian endometriosis
64*circ_0002198*chr6:136472297-136476896*+*PDE7B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002198*Carcinoma, Endometrioid*Upregulated*qRT-PCR etc.*Human*circRNAs are candidate factors in the activation of endometriosis. circ_0002198 and circ_0004712 may be potential novel biomarkers for the diagnosis of ovarian endometriosis.*2018-03-01*29483390.0**circ_0002198/hsa_circ_0002198/chr6:136472297-136476896*CircR2Disease*ovarian endometriosis
65*hsa_circ_0067934*chr3:170013698-170015181*+*PRKCI*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0067934*Carcinoma, Hepatocellular*Upregulated*qRT-PCR, Luciferase reporter assay, In vivo tumor growth and metastasis assays etc.*Human*circ_0067934/miR-1324/FZD5/β-catenin signaling axis might serve as a promising therapeutic target for HCC intervention.*2018-03-01*29458020.0**hsa_circ_0067934/chr3:170013698-170015181*CircR2Disease*hepatocellular carcinoma
66*circHLA-C*chr6:31239010-31324103*-*HLA-C **Lupus Nephritis*Upregulated*qRT-PCR, Luciferase reporter assay, In vivo tumor growth and metastasis assays etc.*Human*Bio-informatic analysis predicted miR-150 was regulated by circHLA-C and displayed one perfect match seed between circHLA-C and miR-150. The renal miR-150 showed a tendency of negative correlation with circHLA-C in LN patients. In conclusion, circHLA-C may play an important role in the pathogenesis of lupus nephritis by sponging miR-150.*2018-03-01*29499937.0**circHLA-C/chr6:31239010-31324103*CircR2Disease*lupus nephritis
67*circZNF609*chr15:64791491-64792365*+*ZNF609*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000615*Lupus Nephritis*Upregulated*qRT-PCR, Luciferase reporter assay, In vivo tumor growth and metastasis assays etc.*Human*These seven validated circRNAs includes circHLA-C, circZNF609, circEKL4, circFAM188A,circUBR5, circPDE4B, and circSP100 were significantly upregulated in LN renal biopsies compared with NC kidneys.*2018-03-01*29499937.0**circZNF609/hsa_circ_0000615/chr15:64791491-64792365*CircR2Disease*lupus nephritis
68*circEKL4*chr1:205585605-205593019*-*ELK4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000175*Lupus Nephritis*Upregulated*qRT-PCR, Luciferase reporter assay, In vivo tumor growth and metastasis assays etc.*Human*These seven validated circRNAs includes circHLA-C, circZNF609, circEKL4, circFAM188A,circUBR5, circPDE4B, and circSP100 were significantly upregulated in LN renal biopsies compared with NC kidneys.*2018-03-01*29499937.0**circEKL4/hsa_circ_0000175/chr1:205585605-205593019*CircR2Disease*lupus nephritis
69*circFAM188A*chr10:15858833-15889942*-*FAM188A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000219*Lupus Nephritis*Upregulated*qRT-PCR, Luciferase reporter assay, In vivo tumor growth and metastasis assays etc.*Human*These seven validated circRNAs includes circHLA-C, circZNF609, circEKL4, circFAM188A,circUBR5, circPDE4B, and circSP100 were significantly upregulated in LN renal biopsies compared with NC kidneys.*2018-03-01*29499937.0**circFAM188A/hsa_circ_0000219/chr10:15858833-15889942*CircR2Disease*lupus nephritis
70*circUBR5*chr8:103372298-103373854*-*UBR5*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001819*Lupus Nephritis*Upregulated*qRT-PCR, Luciferase reporter assay, In vivo tumor growth and metastasis assays etc.*Human*These seven validated circRNAs includes circHLA-C, circZNF609, circEKL4, circFAM188A,circUBR5, circPDE4B, and circSP100 were significantly upregulated in LN renal biopsies compared with NC kidneys.*2018-03-01*29499937.0**circUBR5/hsa_circ_0001819/chr8:103372298-103373854*CircR2Disease*lupus nephritis
71*circPDE4B*chr1:66378927-66384518*+*PDE4B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008433*Lupus Nephritis*Upregulated*qRT-PCR, Luciferase reporter assay, In vivo tumor growth and metastasis assays etc.*Human*These seven validated circRNAs includes circHLA-C, circZNF609, circEKL4, circFAM188A,circUBR5, circPDE4B, and circSP100 were significantly upregulated in LN renal biopsies compared with NC kidneys.*2018-03-01*29499937.0**circPDE4B/hsa_circ_0008433/chr1:66378927-66384518*CircR2Disease*lupus nephritis
72*circSP100*chr2:231307651-231314970*+*SP100*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003922*Lupus Nephritis*Upregulated*qRT-PCR, Luciferase reporter assay, In vivo tumor growth and metastasis assays etc.*Human*These seven validated circRNAs includes circHLA-C, circZNF609, circEKL4, circFAM188A,circUBR5, circPDE4B, and circSP100 were significantly upregulated in LN renal biopsies compared with NC kidneys.*2018-03-01*29499937.0**circSP100/hsa_circ_0003922/chr2:231307651-231314970*CircR2Disease*lupus nephritis
77*circRNA-000911*****Breast Neoplasms*Downregulated*qRT-PCR, Dual-luciferase reporter assay, FACS apoptosis assay, Colony formation assays, Western blot etc.*Human*Gain- and loss-of-function assays indicated that miR‑449a antagonized circRNA-000911 to regulate breast cancer progression. Subsequently, Notch1 was identified as the functional target of miR‑449a, and the overexpression of circRNA-000911 in breast cancer elevated Notch1 expression. Furthermore, Cignal Signal Transduction Reporter Array and western blot analysis identified nuclear factor-κB (NF-κB) signaling as a functional target of the circRNA-000911/miR‑449a pathway. On the whole, our findings indicate that circRNA-000911 plays an anti-oncogenic role in breast cancer and may thus serve as a promising therapeutic target for patients with breast cancer. *2018-03-01*29431182.0**circRNA-000911*CircR2Disease*breast cancer
78*circRNA-001283*****Breast Neoplasms*Downregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29431182.0**circRNA-001283*CircR2Disease*breast cancer
79*circRNA-001175*****Breast Neoplasms*Upregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29431182.0**circRNA-001175*CircR2Disease*breast cancer
80*circRNA-100438*****Breast Neoplasms*Upregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29431182.0**circRNA-100438*CircR2Disease*breast cancer
81*circC3P1***C3P1**Carcinoma, Hepatocellular*Downregulated*qRT-PCR, Luciferase reporter assay etc.*Human*circC3P1 acts as a tumor suppressor via enhancing PCK1 expression by sponging miR-4641 in HCC.*2018-03-01*29608893.0**circC3P1*CircR2Disease*hepatocellular carcinoma
82*hsa_circ_0067934*chr3:170013698-170015181*+*PRKCI*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0067934*Adenocarcinoma of Lung*Upregulated*qRT-PCR, RNA immunoprecipitation, 0 Luciferase reporter assays, Western blot etc.*Human*circPRKCI functioned as a sponge for both miR-545 and miR-589 and abrogated their suppression of the pro-tumorigenic transcription factor E2F7. Intra-tumor injection of cholesterol-conjugated siRNA specifically targeting circPRKCI inhibited tumor growth in a patient-derived LAC xenograft model. In summary, circPRKCI is crucial for tumorigenesis and may serve as a potential therapeutic target in LAC patients.*2018-03-01*29588350.0**circPRKCI/hsa_circ_0067934/chr3:170013698-170015181*CircR2Disease*lung adenocarcinoma
83*hsa_circ_0087537*chr9:96233422-96320292*+*FAM120A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0087537*Zygapophyseal Joint*Upregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29470979.0**hsa_circ_0087537/chr9:96233422-96320292*CircR2Disease*facet joint osteoarthritis
84*hsa_circ_0072668*chr5:64510224-64769779*-*ADAMTS6*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0072668*Zygapophyseal Joint*Upregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29470979.0**hsa_circ_0072668/chr5:64510224-64769779*CircR2Disease*facet joint osteoarthritis
85*hsa_circ_0071896*chr5:14286979-14378236*+*TRIO*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0071896*Zygapophyseal Joint*Upregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29470979.0**hsa_circ_0071896/chr5:14286979-14378236*CircR2Disease*facet joint osteoarthritis
86*hsa_circ_0063781*chr22:46594238-46594488*+*PPARA*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0063781*Zygapophyseal Joint*Upregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29470979.0**hsa_circ_0063781/chr22:46594238-46594488*CircR2Disease*facet joint osteoarthritis
87*hsa_circ_0053743*chr2:32702435-32718734*+*BIRC6*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0053743*Zygapophyseal Joint*Upregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29470979.0**hsa_circ_0053743/chr2:32702435-32718734*CircR2Disease*facet joint osteoarthritis
88*hsa_circ_0029067*chr12:122819194-122826244*-*CLIP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0029067*Zygapophyseal Joint*Downregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29470979.0**hsa_circ_0029067/chr12:122819194-122826244*CircR2Disease*facet joint osteoarthritis
89*hsa_circ_0005127*chr11:114314577-114320888*+*REXO2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005127*Zygapophyseal Joint*Downregulated*qRT-PCR etc.*Human*Unclear*2018-03-01*29470979.0**hsa_circ_0005127/chr11:114314577-114320888*CircR2Disease*facet joint osteoarthritis
90*circ-SHKBP1***SHKBP1**Glioma*Upregulated*qRT-PCR, Dual-luciferase reporter assay  etc.*Human*circ-SHKBP1 regulated the angiogenesis of GECs through miR-544a/FOXP1 and miR-379/FOXP2 pathways, and these findings might provide a potential target and effective strategy for combined therapy of gliomas.*2018-03-01*29499945.0**circ-SHKBP1*CircR2Disease*glioma
91*circ-FBXW7***FBXW7**Glioma*Downregulated*qPCR, FISH, Northern blot etc.*Human*Upregulation of FBXW7-185aa in cancer cells inhibited proliferation and cell cycle acceleration, while knockdown of FBXW7-185aa promoted malignant phenotypes invitro and invivo. FBXW7-185aa reduced the half-life of c-Myc by antagonizing USP28-induced c-Myc stabilization. Moreover, circ-FBXW7 and FBXW7-185aa levels were reduced in glioblastoma clinical samples compared with their paired tumor-adjacent tissues (P < .001). *2018-03-01*28903484.0**circ-FBXW7*CircR2Disease*glioma
93*hsa_circ_0046701*chr18:745707-751804*-*YES1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0046701*Glioma*Upregulated*qPCR, Luciferase reporter assay etc.*Human*hsa_circ_0046701 was significantly upregulated in glioma tissues and cell lines, and knockdown of hsa_circ_0046701 inhibited cell proliferation and invasion. Luciferase reporter assays indicated that hsa_circ_0046701 functions as a sponge for miR-142-3p and regulates the expression of ITGB8. Subsequently, functional assays revealed that silencing of hsa_circ_0046701 could upregulate miR-142-3p, resulting in downregulation of ITGB8. *2018-03-01*29337055.0**hsa_circ_0046701/chr18:745707-751804*CircR2Disease*glioma
94*hsa_circ_0001649*chr6:146209155-146216113*-*SHPRH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001649*Glioma*Downregulated*qPCR, ISH, Northern blot etc.*Human*Both circ-SHPRH and SHPRH-146aa are abundantly expressed in normal human brains and are down-regulated in glioblastoma. The overexpression of SHPRH-146aa in U251 and U373 glioblastoma cells reduces their malignant behavior and tumorigenicity in vitro and in vivo. Mechanistically, SHPRH-146aa protects full-length SHPRH from degradation by the ubiquitin proteasome. Stabilized SHPRH sequentially ubiquitinates proliferating cell nuclear antigen (PCNA) as an E3 ligase, leading to inhibited cell proliferation and tumorigenicity. *2018-03-01*29343848.0**hsa_circ_0001649/chr6:146209155-146216113*CircR2Disease*glioma
95*CircDOCK1*chr10**DOCK1**Squamous Cell Carcinoma of Head and Neck*Downregulated*qPCR etc.*Human*The presence of circDOCK1 with qRT‑PCR and circRNA sequencing.The knockdown of the expression of circDOCK1 led to the increase of apoptosis.Both the silencing of circDOCK1 with small interfering RNA and the upregulation of the expression of miR‑196a‑5p with mimics led OSCC cells to increase apoptosis and decrease BIRC3 formation. *2018-03-01*29286141.0**CircDOCK1/hsa_circ_100721/chr10*CircR2Disease*oral squamous cell carcinoma
96*hsa_circ_0003159*chr7:81689743-81746489*-*CACNA2D1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003159*Stomach Neoplasms*Downregulated*qPCR etc.*Human*hsa_circ_0003159 expression levels were significantly negatively associated with gender, distal metastasis, and tumor-node-metastasis stage*2018-03-01*28618205.0**hsa_circ_0003159/chr7:81689743-81746489*CircR2Disease*gastric cancer
97*hsa_circRNA_001937***CHD9**Tuberculosis*Upregulated*qRT-PCR etc.*Human*Hsa_circRNA_001937 was significantly increased in patients with TB compared with patients with pneumonia, COPD and lung cancer. Hsa_ circRNA_001937 was correlated with TB severity (r = 0.4053, P = 0.010) and its expression significantly decreased after treatment.*2018-02-01*29448254.0**hsa_circRNA_001937*CircR2Disease*tuberculosis
98*hsa_circRNA_009024***TXLNGY**Tuberculosis*Upregulated*qRT-PCR etc.*Human*Compared with healthy controls, hsa_circRNA_102101, hsa_circRNA_104964 and hsa_circRNA_104296 were significantly decreased, while hsa_circRNA_001937, hsa_circRNA_009024 and hsa_circRNA_005086 were overexpressed in TB patients. *2018-02-01*29448254.0**hsa_circRNA_009024*CircR2Disease*tuberculosis
99*hsa_ circRNA_005086***RNF10**Tuberculosis*Upregulated*qRT-PCR etc.*Human*Compared with healthy controls, hsa_circRNA_102101, hsa_circRNA_104964 and hsa_circRNA_104296 were significantly decreased, while hsa_circRNA_001937, hsa_circRNA_009024 and hsa_circRNA_005086 were overexpressed in TB patients. *2018-02-01*29448254.0**hsa_ circRNA_005086*CircR2Disease*tuberculosis
100*hsa_circRNA_102101***CDC27**Tuberculosis*Downregulated*qRT-PCR etc.*Human*Compared with healthy controls, hsa_circRNA_102101, hsa_circRNA_104964 and hsa_circRNA_104296 were significantly decreased, while hsa_circRNA_001937, hsa_circRNA_009024 and hsa_circRNA_005086 were overexpressed in TB patients. *2018-02-01*29448254.0**hsa_circRNA_102101*CircR2Disease*tuberculosis
101*hsa_circRNA_104964***DPH7**Tuberculosis*Downregulated*qRT-PCR etc.*Human*Compared with healthy controls, hsa_circRNA_102101, hsa_circRNA_104964 and hsa_circRNA_104296 were significantly decreased, while hsa_circRNA_001937, hsa_circRNA_009024 and hsa_circRNA_005086 were overexpressed in TB patients. *2018-02-01*29448254.0**hsa_circRNA_104964*CircR2Disease*tuberculosis
102*hsa_circRNA_104296***RNF216**Tuberculosis*Downregulated*qRT-PCR etc.*Human*Compared with healthy controls, hsa_circRNA_102101, hsa_circRNA_104964 and hsa_circRNA_104296 were significantly decreased, while hsa_circRNA_001937, hsa_circRNA_009024 and hsa_circRNA_005086 were overexpressed in TB patients. *2018-02-01*29448254.0**hsa_circRNA_104296*CircR2Disease*tuberculosis
103*circATP2B1*chr12:90035934-90049884*-*ATP2B1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000426*Carcinoma, Renal Cell*Downregulated*qRT-PCR, ChIP, Luciferase reporter assays etc.*Human*ERβ promotes ccRCC cell invasion by altering the ERβ/circATP2B1/miR-204-3p/FN1 axis, and that therapeutic targeting of this newly identified pathway may better prevent ccRCC progression.*2018-02-01*29490945.0**circATP2B1/hsa_circ_000826/hsa_circ_0000426/chr12:90035934-90049884*CircR2Disease*clear cell renal cell carcinoma
104*hsa_circ_0001649*chr6:146209155-146216113*-*SHPRH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001649*Colorectal Neoplasms*Downregulated*qRT-PCR etc.*Human*The expression level of hsa_circ_0001649 was down-regulated in CRC and could use it as a new biomarker for specific and sensitive inspection of CRC.*2018-02-01*29421663.0**hsa_circ_0001649/chr6:146209155-146216113*CircR2Disease*colorectal cancer
105*hsa_circ_0080210*chr7:50737418-50773020*-*GRB10*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0080210*Intervertebral Disc Degeneration*Downregulated*qRT-PCR etc.*Human*circ-GRB10 facilitated the survival of NP cells during nutrient deprivation by upregulating ERBB2 expression through inactivating miR-328-5p, and possibly through a pathway involving mTOR. *2018-02-01*29476072.0**hsa_circ_0080210/circ-GRB10/chr7:50737418-50773020*CircR2Disease*intervertebral disc degeneration
106*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Carcinoma, Hepatocellular*Upregulated*qRT-PCR, Western blot, Luciferase reporter assay etc.*Human*circular RNA HIPK3 (circHIPK3) acted as a miR-124 sponge and regulated the expression of the miR-124 target gene AQP3. circHIPK3 was upregulated in HCC tissues and positively correlated with AQP3 expression. Thus, silencing circHIPK3 inhibited cell proliferation and migration by downregulating AQP3 expression. Moreover, miR-124 inhibition rescued circHIPK3 knockdown induced reduction in cell proliferation and migration, as well as AQP3 expression.*2018-02-01*29415990.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*hepatocellular carcinoma
107*circSMARCA5*chr4:144464661-144465125*+*SMARCA5*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001445*Glioblastoma*Downregulated*qRT-PCR, Immunohistochemistry, Northern Blotting etc.*Human*circSMARCA5 as a promising druggable tumor suppressor in GBM and suggest that it may exert its function by tethering the RBP SRSF1.*2018-02-01*29415469.0**circSMARCA5/hsa_circ_0001445/chr4:144464661-144465125*CircR2Disease*glioblastoma multiforme
108*hsa_circ_0014717*chr1:156290629-156304709*-*CCT3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0014717*Colorectal Neoplasms*Downregulated*qRT-PCR etc.*Human*hsa_circ_0014717 acts as a potential tumor suppressor that inhibits CRC growth, partly at least, through upregulating p16 expression.*2018-02-01*29571246.0**hsa_circ_0014717/chr1:156290629-156304709*CircR2Disease*colorectal cancer
115*circRNA-000284*****Uterine Cervical Neoplasms*Upregulated*qRT-PCR, RNA FISH, Dual-luciferase reporter assay, Western blot etc.*Human*Knockdown of circRNA-000284 suppressed cell proliferation and invasion, and caused G0/G1 phase cell cycle arrest. By performing anti-AGO2 RNA precipitation and luciferase reporter assay, we identified miR-506 as the circRNA-000284-associated miRNA. Furthermore, Snail-2 was identified as a direct target of miR-506, and circRNA-000284 could positively regulate the expression of Snail-2. Finally, the tumor promoting effect of circRNA-000284 was abolished by co-expression of miR-506 mimics or Snail-2 silencing vector.*2018-02-01*29511454.0**circRNA-000284*CircR2Disease*cervical cancer
116*hsa_circ_0014130*chr1:151206672-151212515*+*PIP5K1A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0014130*Carcinoma, Non-Small-Cell Lung*Upregulated*qRT-PCR etc.*Human*Gene oncology analysis and pathway analysis revealed that hsa_circ_0014130 could participate in NSCLC development. In summary, our findings indicated that hsa_circ_0014130 could be used as a potential NSCLC biomarker and might be closely related to the carcinogenesis of NSCLC.*2018-02-01*29440731.0**hsa_circ_0014130/chr1:151206672-151212515*CircR2Disease*non-small cell lung cancer
117*hsa_circ_0016760*chr1:227935392-227947186*+*SNAP47*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0016760*Carcinoma, Non-Small-Cell Lung*Upregulated*qRT-PCR etc.*Human*Unclear*2018-02-01*29440731.0**hsa_circ_0016760/chr1:227935392-227947186*CircR2Disease*non-small cell lung cancer
118*circPVT1*chr8:128902834-128903244*+*PVT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001821*Osteosarcoma*Upregulated*qRT-PCR, CCK8 assay, Western blot etc.*Human*circPVT1 was significantly up-regulated in the OS tissues, serums and chemoresistant cell lines, correlated with poor prognosis of OS patients. Besides, ROC curve demonstrated that circPVT1 may be a better diagnostic biomarker than alkaline phosphatase (ALP) in OS with more sensitivity and specificity. In addition, functional assays revealed that circPVT1 knockdown by siRNA could weaken the resistance to doxorubicin and cisplatin of OS cells through decreasing the expression of classical drug resistance-related gene ABCB1. These findings may provide a new insight into the role of circPVT1 as a biomarker for the diagnosis and treatment target of OS.*2018-02-01*29559849.0**circPVT1/hsa_circ_0001821/chr8:128902834-128903244*CircR2Disease*osteosarcoma
119*hsa_circ_0109046*chr19:12057995-12061434*+*ZNF700*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0109046*Endometrial Neoplasms*Upregulated*qPCR etc.*Human*The RT-qPCR results showed that the expression level of hsa circ 0109046 (p = 0.01; Figure 4A) and hsa circ 0002577 (p < 0.01; Figure 4B) was higher in EVs from serum of patients with endometrial cancer than those from healthy controls.*2018-02-01*29334253.0**hsa_circ_0109046/chr19:12057995-12061434*CircR2Disease*endometrial cancer
120*hsa_circ_0002577*chr1:224599128-224607317*-*WDR26*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002577*Endometrial Neoplasms*Upregulated*qPCR etc.*Human*The RT-qPCR results showed that the expression level of hsa circ 0109046 (p = 0.01; Figure 4A) and hsa circ 0002577 (p < 0.01; Figure 4B) was higher in EVs from serum of patients with endometrial cancer than those from healthy controls.*2018-02-01*29334253.0**hsa_circ_0002577/chr1:224599128-224607317*CircR2Disease*endometrial cancer
121*hsa_circ_0012673*chr1:55340765-55341720*-*DHCR24*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0012673*Adenocarcinoma of Lung*Upregulated*qPCR, Western blot, Luciferase reporter assay, FISH, Xenograft model etc.*Human*hsa_circ_0012673 was primarily localized in the cytoplasm and promoted cell proliferation of LAC cells by sponging miR-22, which targeted erb-b2 receptor tyrosine kinase 3 (ErbB3) in LAC*2018-02-01*29366790.0**hsa_circ_0012673/chr1:55340765-55341720*CircR2Disease*lung adenocarcinoma
122*hsa_circ_0067531*chr3:138413627-138417937*-*PIK3CB*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0067531*Carcinoma, Hepatocellular*Downregulated*qPCR, Western blot, Flow cytometry etc.*Human*hsa_circ_0067531 in HCC tissues was significantly decreased compared with normal adjacent tissues*2018-02-01*29251325.0**hsa_circ_0067531/chr3:138413627-138417937*CircR2Disease*hepatocellular carcinoma
123*hsa_circ_0001649*chr6:146209155-146216113*-*SHPRH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001649*Cholangiocarcinoma*Downregulated*qPCR, Western blot, Tumor xenograft study, Immunohistochemistry etc.*Human*hsa_circ_0001649 was aberrantly downregulated in CCA tissues and cells, and this downregulation was associated with tumor size and differentiation grade in CCA. In addition, hsa_circ_0001649 overexpression caused tumor suppressive effects via inhibiting cell proliferation, migration and invasion; inducing cell apoptosis in KMBC and Huh-28 cells. On the contrary, silencing of hsa_circ_0001649 caused the opposite phenotypes. *2018-02-01*29337065.0**hsa_circ_0001649/chr6:146209155-146216113*CircR2Disease*cholangiocarcinoma
131*hsa_circ_0000520*chr14:20811436-20811559*-*RPPH1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000520*Stomach Neoplasms*Downregulated*qPCR etc.*Human*Clinicopathological features showed that hsa_circ_0000520 level in GC tissues was negatively associated with TNM stage and in GC plasma linked with CEA expression.Finally, a total of 9 miRNAs and 9 candidate mRNA were predicted to have an interaction with hsa_circ_0000520.*2018-02-01*29103021.0**hsa_circ_0000520/chr14:20811436-20811559*CircR2Disease*gastric cancer
132*hsa_circ_0001859*chr9:37086664-37121125*+*TCONS_l2_00028722*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001859*Arthritis, Rheumatoid*Upregulated*qPCR, Luciferase Reporter Assays, RNA Interference, Western Blot etc.*Human*Silencing of hsa_circ_0001859 suppressed ATF2 expression and decreased inflammatory activity in SW982 cells. Hsa_circ_0001859 could compete with ATF2 for miR-204/211.*2018-01-01*29577053.0**hsa_circ_0001859/chr9:37086664-37121125*CircR2Disease*rheumatoid arthritis
134*hsa_circ_0015756*chr1:196706604-196712758*+*CFH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0015756*Hepatoblastoma*Upregulated*qPCR etc.*Human*circ_0015756 silencing decreased hepatoblastoma cell viability, proliferation, and invasion in vitro. circ_0015756 acted as miR-1250-3p sponge to regulate hepatoblastoma cell function.*2018-01-01*29414822.0**hsa_circ_0015756/chr1:196706604-196712758*CircR2Disease*hepatoblastoma
135*hsa_circ_0040081*chr16:69746930-69747032*-*NQO1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0040081*Hepatoblastoma*Downregulated*qPCR etc.*Human*circ_0040081 was significantly down-regulated in the hepatoblastoma tissues compared with the adjacent normal liver samples *2018-01-01*29414822.0**hsa_circ_0040081/chr16:69746930-69747032*CircR2Disease*hepatoblastoma
136*hsa_circ_0067745*chr3:153935657-153958368*+*ARHGEF26*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0067745*Hepatoblastoma*Upregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0067745/chr3:153935657-153958368*CircR2Disease*hepatoblastoma
137*hsa_circ_0062163*chr22:17982113-17984048*+*CECR2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0062163*Hepatoblastoma*Upregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0062163/chr22:17982113-17984048*CircR2Disease*hepatoblastoma
138*hsa_circ_0079549*chr7:22170654-22357656*-*RAPGEF5*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0079549*Hepatoblastoma*Upregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0079549/chr7:22170654-22357656*CircR2Disease*hepatoblastoma
139*hsa_circ_0017515*chr10:3818187-3824406*-*KLF6*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0017515*Hepatoblastoma*Upregulated*qPCR etc.*Human*Unclear*2018-01-01*29414822.0**hsa_circ_0017515/chr10:3818187-3824406*CircR2Disease*hepatoblastoma
140*hsa_circ_0045510*chr17:66972275-66980316*-*ABCA9*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0045510*Hepatoblastoma*Upregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0045510/chr17:66972275-66980316*CircR2Disease*hepatoblastoma
141*hsa_circ_0005931*chr9:130863374-130869458*+*SLC25A25*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005931*Hepatoblastoma*Upregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0005931/chr9:130863374-130869458*CircR2Disease*hepatoblastoma
142*hsa_circ_0078710*chr6:169625239-169654137*-*THBS2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0078710*Hepatoblastoma*Upregulated*qPCR etc.*Human*Unclear*2018-01-01*29414822.0**hsa_circ_0078710/chr6:169625239-169654137*CircR2Disease*hepatoblastoma
143*hsa_circ_0041731*chr17:6347734-6353392*+*FAM64A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0041731*Hepatoblastoma*Downregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0041731/chr17:6347734-6353392*CircR2Disease*hepatoblastoma
144*hsa_circ_0043534*chr17:38544772-38559306*-*TOP2A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0043534*Hepatoblastoma*Downregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0043534/chr17:38544772-38559306*CircR2Disease*hepatoblastoma
145*hsa_circ_0023110*chr11:67351065-67354124*+*GSTP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023110*Hepatoblastoma*Downregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0023110/chr11:67351065-67354124*CircR2Disease*hepatoblastoma
146*hsa_circ_0023114*chr11:67351934-67352243*+*GSTP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023114*Hepatoblastoma*Downregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0023114/chr11:67351934-67352243*CircR2Disease*hepatoblastoma
147*hsa_circ_0066077*chr3:52562198-52567793*-*NT5DC2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0066077*Hepatoblastoma*Downregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0066077/chr3:52562198-52567793*CircR2Disease*hepatoblastoma
148*hsa_circ_0023117*chr11:67352155-67354124*+*GSTP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023117*Hepatoblastoma*Downregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0023117/chr11:67352155-67354124*CircR2Disease*hepatoblastoma
149*hsa_circ_0057336*chr2:188343304-188343530*-*TFPI*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0057336*Hepatoblastoma*Downregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0057336/chr2:188343304-188343530*CircR2Disease*hepatoblastoma
150*hsa_circ_0072359*chr5:41749628-41850281*-*OXCT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0072359*Hepatoblastoma*Downregulated*qPCR etc.*Human*May bind with miRNAs*2018-01-01*29414822.0**hsa_circ_0072359/chr5:41749628-41850281*CircR2Disease*hepatoblastoma
151*hsa_circ_0062557*chr22:24108020-24109780*-*CHCHD10*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0062557*Carcinoma, Endometrioid*Upregulated*qPCR etc.*Human*The circRNA 0062557 and circRNA 0026143 were overexpressed in EC, consistent with the data from microarray; however, there is no statistical significance. The data confirmed that circRNA 0023115 and circRNA 0000673 were significantly lower expressed, with 5.7- and 1.7 fold change downregulated in EC compared with EU (p < 0.05).*2018-01-01*29334789.0**hsa_circ_0062557/chr22:24108020-24109780*CircR2Disease*ovarian endometriosis
152*hsa_circ_0026143*chr12:49722709-49723237*+*TROAP*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0026143*Carcinoma, Endometrioid*Upregulated*qPCR etc.*Human*The circRNA 0062557 and circRNA 0026143 were overexpressed in EC, consistent with the data from microarray; however, there is no statistical significance. The data confirmed that circRNA 0023115 and circRNA 0000673 were significantly lower expressed, with 5.7- and 1.7 fold change downregulated in EC compared with EU (p < 0.05).*2018-01-01*29334789.0**hsa_circ_0026143/chr12:49722709-49723237*CircR2Disease*ovarian endometriosis
153*hsa_circ_0023115*chr11:67351934-67352712*+*GSTP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023115*Carcinoma, Endometrioid*Downregulated*qPCR etc.*Human*The circRNA 0062557 and circRNA 0026143 were overexpressed in EC, consistent with the data from microarray; however, there is no statistical significance. The data confirmed that circRNA 0023115 and circRNA 0000673 were significantly lower expressed, with 5.7- and 1.7 fold change downregulated in EC compared with EU (p < 0.05).*2018-01-01*29334789.0**hsa_circ_0023115/chr11:67351934-67352712*CircR2Disease*ovarian endometriosis
154*hsa_circ_0000673*chr16:11940357-11940700*-*RSL1D1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000673*Carcinoma, Endometrioid*Downregulated*qPCR etc.*Human*The circRNA 0062557 and circRNA 0026143 were overexpressed in EC, consistent with the data from microarray; however, there is no statistical significance. The data confirmed that circRNA 0023115 and circRNA 0000673 were significantly lower expressed, with 5.7- and 1.7 fold change downregulated in EC compared with EU (p < 0.05).*2018-01-01*29334789.0**hsa_circ_0000673/chr16:11940357-11940700*CircR2Disease*ovarian endometriosis
155*hsa_circ_0009910*chr1:12049221-12052747*+*MFN2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0009910*Osteosarcoma*Upregulated*qRT-PCR, Luciferase reporter assay etc.*Human*Knockdown of circ_0009910 induced cell proliferation inhibition, cell cycle arrest, and apoptosis in OS cells. circ_0009910 acted as a sponge of miR-449a and upregulated miR-449a functional target IL6R, thereby contributed to carcinogenesis of OS.*2018-01-01*29117539.0**hsa_circ_0009910/chr1:12049221-12052747*CircR2Disease*osteosarcoma
157*circDLGAP4***DLGAP4**Ischemic Stroke*Downregulated*qPCR, Immunofluorescence staining, Western blot, Northern Blot, FISH, Pull-down assay, Luciferase activity assay etc.*Human*CircDLGAP4 levels were significantly decreased in the plasma of acute ischemic stroke patients (13 females and 13 males) *2018-01-01*29114076.0**circDLGAP4*CircR2Disease*acute ischemic stroke
158*hsa_circ_0074362*chr5:142264862-142311690*+*ARHGAP26*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0074362*Stomach Neoplasms*Downregulated*qPCR etc.*Human*Hsa_circ_0074362 levels were significantly downregulated in gastric cancer tissues, gastritis tissues and gastric cancer cell lines. Its levels were associated with lymphatic metastasis.*2018-01-01*29240459.0**hsa_circ_0074362/chr5:142264862-142311690*CircR2Disease*gastric cancer
159*hsa_circ_0001017*chr2:61749745-61761038*+*XPO1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001017*Stomach Neoplasms*Downregulated*qPCR, RT-ddPCR etc.*Human*Patients with low plasma hsa_circ_0001017 or hsa_circ_0061276 had a much shorter overall survival than those with high levels. Patients whose plasma hsa_circ_0001017 or hsa_circ_0061276 levels recovered to normal after operation had a longer disease-free survival. *2018-01-01*29098316.0**hsa_circ_0001017/chr2:61749745-61761038*CircR2Disease*gastric cancer
160*hsa_circ_0061276*chr21:16415815-16415895*-*NRIP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0061276*Stomach Neoplasms*Downregulated*qPCR, RT-ddPCR etc.*Human*Patients with low plasma hsa_circ_0001017 or hsa_circ_0061276 had a much shorter overall survival than those with high levels. Patients whose plasma hsa_circ_0001017 or hsa_circ_0061276 levels recovered to normal after operation had a longer disease-free survival. *2018-01-01*29098316.0**hsa_circ_0061276/chr21:16415815-16415895*CircR2Disease*gastric cancer
161*hsa_circ_0007534*chr17:61869771-61877977*+*DDX42*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007534*Colorectal Neoplasms*Upregulated*qRT-PCR, Western blot, CCK-8 proliferation assay etc.*Human*hsa_circ_0007534 expression was correlated with tumor stage and lymph node metastasis. Furthermore, the silence of hsa_circ_0007534 by siRNA significantly inhibited proliferation and induced apoptosis of CRC cells.*2018-01-01*29364478.0**hsa_circ_0007534/chr17:61869771-61877977*CircR2Disease*colorectal cancer
167*hsa_circ_0000567*chr14:99924615-99932150*-*SETD3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000567*Colorectal Neoplasms*Downregulated*qPCR, MTT proliferation assay etc.*Human*The decreased hsa_circ_0000567 expression in CRC was negatively correlated with tumor size (P = .011), lymph metastasis (P = .003), distal metastasis (P < .0001), and tumor-node-metastasis (TNM) stage (P = .003) in CRC. Moreover, knockdown of hsa_circ_0000567 promoted CRC cells proliferation and migration in vitro.*2018-01-01*29333615.0**hsa_circ_0000567/chr14:99924615-99932150*CircR2Disease*colorectal cancer
168*hsa_circ_0001564*chr5:179132679-179137066*+*CANX*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001564*Osteosarcoma*Upregulated*qPCR, Colony formation assay, Cell apoptosis assay etc.*Human*hsa_circ_001564 knockdown significantly suppressed the proliferation activity, induced cell cycle arrest in G0/G1 phase, and promoted apoptosis in HOS and MG-63 cells.  hsa_circ_0001564 acts as miR-29c-3p sponge to mediate the tumorigenicity.*2018-01-01*29229385.0**hsa_circ_0001564/chr5:179132679-179137066*CircR2Disease*osteosarcoma
169*circSMARCA5*chr4:144464661-144465125*+*SMARCA5*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001445*Carcinoma, Hepatocellular*Downregulated*qPCR, Luciferase reporter assay, FISH etc.*Human*Results reveal an important role of cSMARCA5 in the growth and metastasis of HCC and provide a fresh perspective on circRNAs in HCC progression. (223 words) LAY SUMMARY: cSMARCA5, a circular RNA, inhibits the growth and metastasis of HCC and appears to be a potential therapeutic target for HCC.*2018-01-01*29378234.0**circSMARCA5/hsa_circ_0001445/chr4:144464661-144465125*CircR2Disease*hepatocellular carcinoma
170*circ-ZFR***ZFR**Stomach Neoplasms*Downregulated*qPCR, Western blot, Flow cytometry, Dual-luciferase reporter assay, RNA immunoprecipitation assay, Xenograft mice model etc.*Human*Circ-ZFR restrained GC cell proliferation, induced cell cycle arrest and promoted apoptosis by sponging miR-130a/miR-107 and regulating PTEN.*2018-01-01*29361817.0**circ-ZFR*CircR2Disease*gastric cancer
171*CDR1as*chrX:139865339-139866824*+*CDR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001946*Stomach Neoplasms*Upregulated*qPCR, Western blot, Colony formation assay, Xenograft in mice etc.*Human*The expression of ciRS-7 was significantly upregulated in GC tissues compared with the matched para-carcinoma tissues (P = 0.0023), and the upregulation of ciRS-7 was linked to poor survival in the testing (P = 0.0143) and validation cohort (P = 0.0061). Multivariate survival analysis revealed that ciRS-7 was probably an independent risk factor of overall survival (P < 0.05). Furthermore, overexpression of ciRS-7 blocked the miR-7-induced tumor suppression in MGC-803 and HGC-27 cells and led to a more aggressive oncogenic phenotype, via antagonizing miR-7-mediated PTEN/PI3K/AKT pathway.*2018-01-01*28608528.0**CDR1as/ciRS-7/hsa_circ_0001946/chrX:139865339-139866824*CircR2Disease*gastric cancer
172*circVMA21*chrX:150573387-150577836*+*VMA21*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0091702*Intervertebral Disc Degeneration*Downregulated*qPCR, FISH, Luciferase reporter assay, Pull-down assay, Rat model of IVDD etc.*Human*CircVMA21 could alleviate inflammatory cytokines-induced NP cell apoptosis and imbalance between anabolism and catabolism of extracellular matrix through miR-200c-XIAP pathway. It provides a potentially effective therapeutic strategy for IVDD.*2018-01-01*29343508.0**circVMA21/hsa_circ_0091702/chrX:150573387-150577836*CircR2Disease*intervertebral disc degeneration
173*Cir-ITCH*chr20:33001547-33037285*+*ITCH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001141*Urinary Bladder Neoplasms*Downregulated*qPCR, Western blot, Northern blot, FISH,  Luciferase reporter assay, Xenografts in mice, Immunohistochemistry etc.*Human*Enforced- expression of circ-ITCH inhibited cells proliferation, migration, invasion and metastasis both in vitro and in vivo. Mechanistically, we demonstrated that circ-ITCH up-regulates the expression of miR-17 and miR-224 target gene p21 and PTEN through 'sponging' miR-17 and miR-224, which suppressed the aggressive biological behaviors of BCa.*2018-01-01*29386015.0**Cir-ITCH/hsa_circ_0001141/hsa_circ_001763/chr20:33001547-33037285*CircR2Disease*bladder cancer
174*circRNA_0046366* chr17:80048757-80048945*-*FASN*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0046366*Fatty Liver*Downregulated*qPCR, Luciferase reporter assay, Western blot etc.*Human*Dysregulation of circRNA_0046366/miR-34a/PPARα signaling may be a novel epigenetic mechanism underlying hepatocellular steatosis. circRNA_0046366 serves as a potential target for the treatment of hepatic steatosis.*2018-01-01*29391755.0**circRNA_0046366/ chr17:80048757-80048945*CircR2Disease*hepatic steatosis
175*hsa_circ_0000681*chr16:23999828-24046868*+*PRKCB*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000681*Tuberculosis, Pulmonary*Upregulated*qPCR etc.*Human*Associated KEGG pathway: Chemokine signaling pathway; Fc gamma R-mediated phagocytosis*2018-01-01*29248507.0**hsa_circ_0000681/chr16:23999828-24046868*CircR2Disease*pulmonary tuberculosis
176*hsa_circ_0008797*chr3:119582265-119624699*-*GSK3B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008797*Tuberculosis, Pulmonary*Upregulated*qPCR etc.*Human*Associated KEGG pathway: Chemokine signaling pathway; Neurotrophin signaling pathway*2018-01-01*29248507.0**hsa_circ_0008797/chr3:119582265-119624699*CircR2Disease*pulmonary tuberculosis
177*hsa_circ_0002113*chr21:34793786-34805178*+*IFNGR2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002113*Tuberculosis, Pulmonary*Upregulated*qPCR etc.*Human*Associated KEGG pathway: Cytokine-cytokine receptor interaction*2018-01-01*29248507.0**hsa_circ_0002113/chr21:34793786-34805178*CircR2Disease*pulmonary tuberculosis
178*hsa_circ_0002362*chr2:9458652-9468040*+*ASAP2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002362*Tuberculosis, Pulmonary*Upregulated*qPCR etc.*Human*Associated KEGG pathway: Fc gamma R-mediated phagocytosis*2018-01-01*29248507.0**hsa_circ_0002362/chr2:9458652-9468040*CircR2Disease*pulmonary tuberculosis
179*hsa_circ_0000414*chr12:66597490-66605377*+*IRAK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000414*Tuberculosis, Pulmonary*Downregulated*qPCR etc.*Human*Associated KEGG pathway: Neurotrophin signaling pathway*2018-01-01*29248507.0**hsa_circ_0000414/chr12:66597490-66605377*CircR2Disease*pulmonary tuberculosis
180*hsa_circ_0063179*chr22:37328806-37330036*+*CSF2RB*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0063179*Tuberculosis, Pulmonary*Upregulated*qPCR etc.*Human*Associated KEGG pathway: Cytokine-cytokine receptor interaction*2018-01-01*29248507.0**hsa_circ_0063179/chr22:37328806-37330036*CircR2Disease*pulmonary tuberculosis
181*hsa_circ_0002908*chr8:141840570-141874498*-*PTK2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002908*Tuberculosis, Pulmonary*Upregulated*qPCR etc.*Human*Associated KEGG pathway: Chemokine signaling pathway; Bacterial invasion of epithelial cells*2018-01-01*29248507.0**hsa_circ_0002908/chr8:141840570-141874498*CircR2Disease*pulmonary tuberculosis
182*circUBAP2***UBAP2**Lung Neoplasms*Upregulated*qPCR, Western blot, Luciferase report gene assay, CCK-8 assay, Fow cytometry, Transwell invasion assay etc.*Human*Results of cell cycle detected by flow cytometry showed that cell cycle arrestd at G0/G1 after circUBAP2 silencing, cell apoptosis rate increased also.the activities of JNK and ERK1/2 were inhibited because of circUBAP2 silencing, the target genes were miR-339-5p, miR-96-3p and miR-135b-3p*2017-12-01*29277177.0**circUBAP2*CircR2Disease*lung cancer
183*hsa_circRNA_404833*****Adenocarcinoma of Lung*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-12-01*29241190.0**hsa_circRNA_404833*CircR2Disease*lung adenocarcinoma
184*hsa_circRNA_006411*****Adenocarcinoma of Lung*Downregulated*qPCR etc.*Human*May as miRNA sponges*2017-12-01*29241190.0**hsa_circRNA_006411*CircR2Disease*lung adenocarcinoma
185*hsa_circRNA_401977*****Adenocarcinoma of Lung*Downregulated*qPCR etc.*Human*May as miRNA sponges*2017-12-01*29241190.0**hsa_circRNA_401977*CircR2Disease*lung adenocarcinoma
186*circWDR77*chr1:111984646-111986543*-*WDR77*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0013509*Cardiovascular Diseases*Upregulated*qPCR, MTT assay, Western blot, Dual-luciferase reporter assay, RIP, Transwell migration assays, Wound-healing assay etc.*Human*circRNAs expression profiles in high glucose induced VSMCs and identifies the role of circWDR77-miR-124-FGF2 regulatory pathway in VSMCs proliferation and migration*2017-12-01*29042195.0**circWDR77/hsa_circ_0013509/chr1:111984646-111986543*CircR2Disease*cardiovascular disease
188*circRNA_100782*chr11:33307958–33309057****Carcinoma, Pancreatic Ductal*Upregulated*qPCR, Western blot, Luciferase reporter assay etc.*Human*CircRNA_100782 was found upregulated in PDAC and in the PDAC cell line BxPC3 instead of human pancreatic duct epithelial cells (HPDE).circRNA_100782 downregulation inhibited BxPC3 cell proliferation and colony formation.*2017-12-01*29255366.0**circRNA_100782/chr11:33307958–33309057*CircR2Disease*pancreatic ductal adenocarcinoma
189*hsa_circ_0000064*chr1:44446997-44447136*-*B4GALT2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000064*Lung Neoplasms*Upregulated*qPCR, FISH, MTT assay, Western blot etc.*Human*hsa_circ_0000064 was up-regulated in lung cancer tissues and lung cancer cell lines (A549 and H1229).  its aberrant expression was correlated with several clinical characteristics, including T stage, lymphatic metastasis, and TNM stage.*2017-12-01*29223555.0**hsa_circ_0000064/chr1:44446997-44447136*CircR2Disease*lung cancer
190*hsa_circ_0005105*chr5:134022479-134023989*+*SEC24A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005105*Osteoarthritis*Upregulated*qRT-PCR, Dual luciferase assay, Western blot, Enzyme-linked immunosorbent assay (ELISA) etc.*Human*hsa_circ_0005105 can inhibit the expression of type II collagen and aggrecan, promote the expression of MMP-13 and ADAMTS-4, and the generation of PGE2, IL-6, and IL-8, but the linear sequence of hsa_circ_0005105 cannot. MiR-26a has the opposite effect, and hsa_circ_0005105 can antagonize the function of miR-26a. When NAMPT expression was downregulated, the above function of hsa_circ_0005105 was significantly weakened.*2017-12-01*28276108.0**hsa_circ_0005105/chr5:134022479-134023989*CircR2Disease*osteoarthritis
191*hsa_circ_0075001*chr5:170817054-170827214*+*NPM1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0075001*Leukemia, Myeloid, Acute*Upregulated*qPCR etc.*Human*Hsa_circ_0075001 expression correlates positively with total NPM1 expression, but is independent of the NPM1 mutational status. High versus low hsa_circ_0075001 expression defines patient subgroups characterized by distinct gene expression patterns, such as lower expression of components of the Toll-like receptor signaling pathway in high hsa_circ_0075001 expression cases.*2017-12-01*28971903.0**hsa_circ_0075001/circNPM1/chr5:170817054-170827214*CircR2Disease*acute myeloid leukemia
192*circRNA BCRC4*chr6:13632601-13644961*-*RANBP9*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001577*Urinary Bladder Neoplasms*Downregulated*qPCR etc.*Human*BCRC4 functions as a tumor suppressor in BC, and mediates anticancer function, at least in part, by up-regulating the expression of miR-101.*2017-12-01*29270748.0**circRNA BCRC4/hsa_circ_001598/hsa_circ_0001577/chr6:13632601-13644961*CircR2Disease*bladder cancer
193*hsa_circ_0005015*chr8:122640953-122641580*-*HAS2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005015*Diabetic Retinopathy*Upregulated*qPCR etc.*Human*Circ_0005015 was verified to be upregulated in the plasma, vitreous sample, and fibrovascular membranes of DR patients. Circ_0005015 facilitated retinal endothelial angiogenic function via regulating endothelial cell proliferation, migration, and tube formation. Circ_0005015 acted as miR-519d-3p sponge to inhibit miR-519d-3p activity, leading to increased MMP-2, XIAP, and STAT3 expression.*2017-12-01*29288268.0**hsa_circ_0005015/chr8:122640953-122641580*CircR2Disease*diabetes retinopathy
194*circZNF609*chr15:64791491-64792365*+*ZNF609*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000615*Diabetic Retinopathy*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-12-01*29288268.0**hsa_circ_0000615/chr15:64791491-64792365*CircR2Disease*diabetes retinopathy
195*hsa_circ_0019069*chr10:91195816-91222381*-*SLC16A12*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0019069*Diabetic Retinopathy*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-12-01*29288268.0**hsa_circ_0019069/chr10:91195816-91222381*CircR2Disease*diabetes retinopathy
196*hsa_circ_0066922*chr3:120365113-120366758*-*HGD*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0066922*Diabetic Retinopathy*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-12-01*29288268.0**hsa_circ_0066922/chr3:120365113-120366758*CircR2Disease*diabetes retinopathy
197*hsa_circ_0081108*chr7:94035561-94055363*+*COL1A2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0081108*Diabetic Retinopathy*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-12-01*29288268.0**hsa_circ_0081108/chr7:94035561-94055363*CircR2Disease*diabetes retinopathy
198*hsa_circ_0081162*chr7:94053647-94057789*+*COL1A2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0081162*Diabetic Retinopathy*Upregulated*qPCR etc.*Human*Unclear*2017-12-01*29288268.0**hsa_circ_0081162/chr7:94053647-94057789*CircR2Disease*diabetes retinopathy
199*hsa_circ_0087206*chr9:75520873-75524675*-*ALDH1A1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0087206*Diabetic Retinopathy*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-12-01*29288268.0**hsa_circ_0087206/chr9:75520873-75524675*CircR2Disease*diabetes retinopathy
200*hsa_circ_0087215*chr9:75781012-75781108*+*ANXA1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0087215*Diabetic Retinopathy*Upregulated*qPCR etc.*Human*Unclear*2017-12-01*29288268.0**hsa_circ_0087215/chr9:75781012-75781108*CircR2Disease*diabetes retinopathy
201*hsa_circ_0041796*chr17:7157901-7158228*+*C17orf81*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0041796*Diabetic Retinopathy*Downregulated*qPCR etc.*Human*Unclear*2017-12-01*29288268.0**hsa_circ_0041796/chr17:7157901-7158228*CircR2Disease*diabetes retinopathy
202*hsa_circ_0072410*chr5:43624133-43677908*+*NNT*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0072410*Diabetic Retinopathy*Downregulated*qPCR etc.*Human*May as miRNA sponges*2017-12-01*29288268.0**hsa_circ_0072410/chr5:43624133-43677908*CircR2Disease*diabetes retinopathy
203*hsa_circ_0026388*chr12:52817853-52827036*-*KRT75*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0026388*Diabetic Retinopathy*Downregulated*qPCR etc.*Human*Unclear*2017-12-01*29288268.0**hsa_circ_0026388/chr12:52817853-52827036*CircR2Disease*diabetes retinopathy
204*hsa_circ_0057093*chr2:173426947-173427528*+*PDK1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0057093*Diabetic Retinopathy*Downregulated*qPCR etc.*Human*Unclear*2017-12-01*29288268.0**hsa_circ_0057093/chr2:173426947-173427528*CircR2Disease*diabetes retinopathy
205*hsa_circ_0030055*chr13:41797391-41837620*-*MTRF1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0030055*Diabetic Retinopathy*Downregulated*qPCR etc.*Human*Unclear*2017-12-01*29288268.0**hsa_circ_0030055/chr13:41797391-41837620*CircR2Disease*diabetes retinopathy
206*hsa_circ_0026372*chr12:52679696-52680606*-*KRT81*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0026372*Diabetic Retinopathy*Downregulated*qPCR etc.*Human*Unclear*2017-12-01*29288268.0**hsa_circ_0026372/chr12:52679696-52680606*CircR2Disease*diabetes retinopathy
207*hsa_circ_0068489*chr3:186951869-187003844*-*MASP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0068489*Diabetic Retinopathy*Downregulated*qPCR etc.*Human*May as miRNA sponges*2017-12-01*29288268.0**hsa_circ_0068489/chr3:186951869-187003844*CircR2Disease*diabetes retinopathy
208*hsa_circ_0008305*chr8:141799572-141840625*-*PTK2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008305*Intervertebral Disc Degeneration*Upregulated*qPCR etc.*Human*hsa_circ_0008305 upregulation and hsa_circ_0041946 downregulation were validated in IDD using reverse transcription‑quantitative polymerase chain reaction.*2017-12-01*28990083.0**hsa_circ_0008305/chr8:141799572-141840625*CircR2Disease*intervertebral disc degeneration
209*hsa_circ_0041946*chr17:7573926-7577608*-*TP53*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0041946*Intervertebral Disc Degeneration*Downregulated*qPCR etc.*Human*hsa_circ_0008305 upregulation and hsa_circ_0041946 downregulation were validated in IDD using reverse transcription‑quantitative polymerase chain reaction.*2017-12-01*28990083.0**hsa_circ_0041946/chr17:7573926-7577608*CircR2Disease*intervertebral disc degeneration
210*circ_0004712*chr6:136468488-136476896*+*PDE7B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004712*Arthritis, Rheumatoid*Upregulated*qPCR etc.*Human*Unclear*2017-12-01*28983619.0**hsa_circRNA_104194/hsa_circ_0004712/chr6:136468488-136476896*CircR2Disease*rheumatoid arthritis
211*hsa_circRNA_104593*chr8:37985808-37986469*+*ASH2L*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0083964*Arthritis, Rheumatoid*Upregulated*qPCR etc.*Human*Unclear*2017-12-01*28983619.0**hsa_circRNA_104593/hsa_circ_0083964/chr8:37985808-37986469*CircR2Disease*rheumatoid arthritis
212*hsa_circRNA_103334*chr3:43341245-43373802*+*SNRK*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0064996*Arthritis, Rheumatoid*Upregulated*qPCR etc.*Human*Unclear*2017-12-01*28983619.0**hsa_circRNA_103334/hsa_circ_0064996/chr3:43341245-43373802*CircR2Disease*rheumatoid arthritis
213*hsa_circRNA_101407*chr14:75590748-75590926*-*NEK9*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0032683*Arthritis, Rheumatoid*Upregulated*qPCR etc.*Human*Unclear*2017-12-01*28983619.0**hsa_circRNA_101407/hsa_circ_0032683/chr14:75590748-75590926*CircR2Disease*rheumatoid arthritis
214*hsa_circRNA_102594*chr19:50902107-50902741*+*POLD1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0052012*Arthritis, Rheumatoid*Downregulated*qPCR etc.*Human*Unclear*2017-12-01*28983619.0**hsa_circRNA_102594/hsa_circ_0052012/chr19:50902107-50902741*CircR2Disease*rheumatoid arthritis
215*circ-LDLRAD3*chr11:36248634-36248980*+*LDLRAD3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006988*Pancreatic Neoplasms*Upregulated*qPCR etc.*Human*High expression of circ-LDLRAD3 was significantly associated with venous invasion, lymphatic invasion, and metastasis.*2017-12-01*29307994.0**circ-LDLRAD3/hsa_circ_0006988/chr11:36248634-36248980*CircR2Disease*pancreatic cancer
216*hsa_circ_0043256*chr9:27168492-27173360*+***Carcinoma, Non-Small-Cell Lung*Upregulated*qPCR, Western blot, CCK-8 assay, RIP, Xenograft nude mouse model etc.*Human*Hsa_circ_0043256 could inhibit cell proliferation and induce apoptosis, while hsa_circ_0043256 knock-down could promote cell proliferation and restrain apoptosis induced by CA. Bioinformatics analysis predicted that hsa_circ_0043256 could work as a miR-1252 sponge, which could in turn directly target a vital negative regulator of Canonical Wnt signaling, Itchy E3 ubiquitin protein ligase (ITCH), as validated by dual-luciferase assay. Western blot results further confirmed that hsa_circ_0043256 could upregulate ITCH expression, whereas miR-1252 could partially abolish this effect. Interestingly, hsa_circ_0043256 knock-down could weaken Wnt/β-catenin pathway inhibition induced by CA. Finally, we discovered that CA induced apoptosis and meanwhile upregulated hsa_circ_0043256 expression in vivo. Immunohistochemical analysis revealed that ITCH expression was positively association with hsa_circ_0043256 levels.*2017-11-01*28958934.0**hsa_circ_0043256/chr9:27168492-27173360*CircR2Disease*non-small cell lung cancer
217*hsa_circ_0021001*chr11:6499967-6501693*-*ARFIP2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0021001*Intracranial Aneurysm*Downregulated*qPCR etc.*Human*Hsa_circ_0021001 level in the peripheral blood of IA patients was relatively lower than that in the control group (P=0.002). The area under ROC (AUC) was 0.87, indicating that hsa_circ_0021001 was highly effective in the diagnosis of IA. In addition, hsa_circ_0021001 expression was correlated with aneurysm rupture, Hunt, Hess level, and timing of surgery (P= 0.041, 0.013, and 0.001, respectively). Patients with high expression of hsa_circ_0021001 had longer disease-free survival (DFS) and overall survival (OS) (P < 0.05). *2017-11-01*29291016.0**hsa_circ_0021001/chr11:6499967-6501693*CircR2Disease*intracranial aneurysms
218*hsa-circRNA11783-2*chr18:28650691–28672263**ENST00000251081**Coronary Artery Disease*Downregulated*qPCR etc.*Human*hsa-circRNA11783-2 had a stronger correlation with CAD and T2DM*2017-11-01*28777011.0**hsa-circRNA11783-2/chr18:28650691–28672263*CircR2Disease*coronary artery disease
219*hsa-circRNA11783-2*chr18:28650691–28672263**ENST00000251081**Diabetes Mellitus, Type 2*Downregulated*qPCR etc.*Human*hsa-circRNA11783-2 had a stronger correlation with CAD and T2DM*2017-11-01*28777011.0**hsa-circRNA11783-2/chr18:28650691–28672263*CircR2Disease*type 2 diabetes mellitus
220*hsa-circRNA11806-28*****Coronary Artery Disease*Downregulated*qPCR etc.*Human*The levels of hsa-circRNA11806-28, hsa-circRNA6510-1 and hsa-circRNA11783-2 were significantly lower in both the T2DM group and CAD group compared with the control group*2017-11-01*28777011.0**hsa-circRNA11806-28*CircR2Disease*coronary artery disease
221*hsa-circRNA11806-28*****Diabetes Mellitus, Type 2*Downregulated*qPCR etc.*Human*The levels of hsa-circRNA11806-28, hsa-circRNA6510-1 and hsa-circRNA11783-2 were significantly lower in both the T2DM group and CAD group compared with the control group*2017-11-01*28777011.0**hsa-circRNA11806-28*CircR2Disease*type 2 diabetes mellitus
222*hsa-circRNA6510-1*****Coronary Artery Disease*Downregulated*qPCR etc.*Human*The levels of hsa-circRNA11806-28, hsa-circRNA6510-1 and hsa-circRNA11783-2 were significantly lower in both the T2DM group and CAD group compared with the control group*2017-11-01*28777011.0**hsa-circRNA6510-1*CircR2Disease*coronary artery disease
223*hsa-circRNA6510-1*****Diabetes Mellitus, Type 2*Downregulated*qPCR etc.*Human*The levels of hsa-circRNA11806-28, hsa-circRNA6510-1 and hsa-circRNA11783-2 were significantly lower in both the T2DM group and CAD group compared with the control group*2017-11-01*28777011.0**hsa-circRNA6510-1*CircR2Disease*type 2 diabetes mellitus
224*hsa_circ_0003575*chr9:33271149-33278223*+*CHMP5*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003575*Atherosclerosis*Upregulated*qPCR etc.*Human*circRNA microarray analysis reveals the expression profiles of HUVECs and verifies the role of hsa_circ_0003575 on HUVECs, providing a therapeutic strategy for vascular endothelial cell injury of atherosclerosis.*2017-11-01*28946214.0**hsa_circ_0003575/chr9:33271149-33278223*CircR2Disease*atherosclerosis
225*circSMARCA5*chr4:144464661-144465125*+*SMARCA5*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001445*Prostatic Neoplasms*Upregulated*qPCR etc.*Human*Circ-SMARCA5 silencing suppressed cell proliferation but promoted cell apoptosis in PCa cell lines*2017-11-01*28765045.0**circSMARCA5/hsa_circ_0001445/chr4:144464661-144465125*CircR2Disease*prostate cancer
226*circRNA-chr19*chr19: 30547942-30549514**ZNF536**Hemorrhagic Fever, Ebola*Upregulated*qPCR etc.*Human*circRNA-chr19 targeting miR-30b-3p regulated CLDN18 expression by functioning as a ceRNA. *2017-11-01*29209594.0**circRNA-chr19/chr19: 30547942-30549514*CircR2Disease*ebola virus disease
227*circRNA_14623*****Tuberculosis, Pulmonary*Upregulated*qPCR etc.*Human*hsa_ circRNA_14623, hsa_circ_09585, hsa_circ_005538, hsa_circ_09993, hsa_circ_00074 and hsa_circ_13478 were confirmed as significantly dysregulated in PTB.*2017-11-01*29371930.0**circRNA_14623*CircR2Disease*pulmonary tuberculosis
228*circRNA_09585*****Tuberculosis, Pulmonary*Upregulated*qPCR etc.*Human*hsa_ circRNA_14623, hsa_circ_09585, hsa_circ_005538, hsa_circ_09993, hsa_circ_00074 and hsa_circ_13478 were confirmed as significantly dysregulated in PTB.*2017-11-01*29371930.0**circRNA_09585*CircR2Disease*pulmonary tuberculosis
229*circRNA_05538*****Tuberculosis, Pulmonary*Downregulated*qPCR etc.*Human*hsa_ circRNA_14623, hsa_circ_09585, hsa_circ_005538, hsa_circ_09993, hsa_circ_00074 and hsa_circ_13478 were confirmed as significantly dysregulated in PTB.*2017-11-01*29371930.0**circRNA_05538*CircR2Disease*pulmonary tuberculosis
230*circRNA_09993*****Tuberculosis, Pulmonary*Downregulated*qPCR etc.*Human*hsa_ circRNA_14623, hsa_circ_09585, hsa_circ_005538, hsa_circ_09993, hsa_circ_00074 and hsa_circ_13478 were confirmed as significantly dysregulated in PTB.*2017-11-01*29371930.0**circRNA_09993*CircR2Disease*pulmonary tuberculosis
231*circRNA_13478*****Tuberculosis, Pulmonary*Downregulated*qPCR etc.*Human*hsa_ circRNA_14623, hsa_circ_09585, hsa_circ_005538, hsa_circ_09993, hsa_circ_00074 and hsa_circ_13478 were confirmed as significantly dysregulated in PTB.*2017-11-01*29371930.0**circRNA_13478*CircR2Disease*pulmonary tuberculosis
232*circRNA_00074*****Tuberculosis, Pulmonary*Upregulated*qPCR etc.*Human*hsa_ circRNA_14623, hsa_circ_09585, hsa_circ_005538, hsa_circ_09993, hsa_circ_00074 and hsa_circ_13478 were confirmed as significantly dysregulated in PTB.*2017-11-01*29371930.0**circRNA_00074*CircR2Disease*pulmonary tuberculosis
233*CircARSP91*chr8:101721360-101721451*-*PABPC1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0085154*Carcinoma, Hepatocellular*Downregulated*qPCR, Western blot, Luciferase assays, ChIP assay, MTT assay, Colony formation assay, Invasion assay etc.*Human*CircARSP91 (hsa_circ_0085154), one of the circRNAs downregulated by AR in an ADAR1-dependent manner, could inhibit HCC tumor growth both in vitro and in vivo*2017-11-01*29144509.0**CircARSP91/hsa_circ_0085154/chr8:101721360-101721451*CircR2Disease*hepatocellular carcinoma
234*hsa_circRNA_070616*chr4:108608194-108622441*-*PAPSS1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0070616**Upregulated*qPCR etc.*Human*hsa_circRNA_070616 may function as sponge of hsa-miR-574-5p*2017-11-01*29132137.0**hsa_circRNA_070616/hsa_circ_0070616/chr4:108608194-108622441*CircR2Disease*repeated implantation failure
235*hsa_circRNA_103716*chr4:108603170-108622441*-*PAPSS1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006935**Upregulated*qPCR etc.*Human*hsa_ circRNA_103716 may function as sponge of hsa-miR-574-5p*2017-11-01*29132137.0**hsa_circRNA_103716/hsa_circ_0006935/chr4:108603170-108622441*CircR2Disease*repeated implantation failure
236*hsa_circRNA_104001******Upregulated*qPCR etc.*Human*The up-regulated expression of hsa_circRNA_070616, hsa_circRNA_103716, hsa_circRNA_104001, hsa_circRNA_104854 and the down-regulated expression of hsa_circRNA_004183, hsa_circRNA_044353, hsa_circRNA_404686 were further validated by qRT-PCR. *2017-11-01*29132137.0**hsa_circRNA_104001*CircR2Disease*repeated implantation failure
237*hsa_circRNA_104854******Upregulated*qPCR etc.*Human*The up-regulated expression of hsa_circRNA_070616, hsa_circRNA_103716, hsa_circRNA_104001, hsa_circRNA_104854 and the down-regulated expression of hsa_circRNA_004183, hsa_circRNA_044353, hsa_circRNA_404686 were further validated by qRT-PCR. *2017-11-01*29132137.0**hsa_circRNA_104854*CircR2Disease*repeated implantation failure
238*CircDOCK1******Downregulated*qPCR etc.*Human*The up-regulated expression of hsa_circRNA_070616, hsa_circRNA_103716, hsa_circRNA_104001, hsa_circRNA_104854 and the down-regulated expression of hsa_circRNA_004183, hsa_circRNA_044353, hsa_circRNA_404686 were further validated by qRT-PCR. *2017-11-01*29132137.0**hsa_circRNA_004183*CircR2Disease*repeated implantation failure
239*hsa_circRNA_044353******Downregulated*qPCR etc.*Human*The up-regulated expression of hsa_circRNA_070616, hsa_circRNA_103716, hsa_circRNA_104001, hsa_circRNA_104854 and the down-regulated expression of hsa_circRNA_004183, hsa_circRNA_044353, hsa_circRNA_404686 were further validated by qRT-PCR. *2017-11-01*29132137.0**hsa_circRNA_044353*CircR2Disease*repeated implantation failure
240*hsa_circRNA_404686******Downregulated*qPCR etc.*Human*The up-regulated expression of hsa_circRNA_070616, hsa_circRNA_103716, hsa_circRNA_104001, hsa_circRNA_104854 and the down-regulated expression of hsa_circRNA_004183, hsa_circRNA_044353, hsa_circRNA_404686 were further validated by qRT-PCR. *2017-11-01*29132137.0**hsa_circRNA_404686*CircR2Disease*repeated implantation failure
241*circRNA120*chrX:120439076-120441894*-*LAMP2**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA120/chrX:120439076-120441894*CircR2Disease*esophageal squamous cell carcinoma
242*circRNA167*chrX:154350909-154368090*-*FLNA**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA167/chrX:154350909-154368090*CircR2Disease*esophageal squamous cell carcinoma
243*circRNA2918*chr15:60355919-60382441*-*ANXA2**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA2918/chr15:60355919-60382441*CircR2Disease*esophageal squamous cell carcinoma
244*circRNA3341*chr14:102083034-102086378*-*HSP90AA1**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA3341/chr14:102083034-102086378*CircR2Disease*esophageal squamous cell carcinoma
245*circRNA3594*chr19:58392976-58393487*+*RPS5**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA3594/chr19:58392976-58393487*CircR2Disease*esophageal squamous cell carcinoma
246*circRNA3703*chr18:23901127-23907935*+*LAMA3**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA3703/chr18:23901127-23907935*CircR2Disease*esophageal squamous cell carcinoma
247*circRNA3706*chr18:23909153-23939386*+*LAMA3**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA3706/chr18:23909153-23939386*CircR2Disease*esophageal squamous cell carcinoma
248*circRNA3707*chr18:23943788-23946284*+*LAMA3**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA3707/chr18:23943788-23946284*CircR2Disease*esophageal squamous cell carcinoma
249*circRNA378*chr13:113309643-113309862*+*LAMP1**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA378/chr13:113309643-113309862*CircR2Disease*esophageal squamous cell carcinoma
250*circRNA4628*chr7:55142286-55165437*+*EGFR**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA4628/chr7:55142286-55165437*CircR2Disease*esophageal squamous cell carcinoma
251*circRNA5669*chr5:136046851-136062687*+*TGFBI**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA5669/chr5:136046851-136062687*CircR2Disease*esophageal squamous cell carcinoma
252*circRNA666*chr12:103938340-103939625*+*HSP90B1**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA666/chr12:103938340-103939625*CircR2Disease*esophageal squamous cell carcinoma
253*circRNA7534*chr2:160107679-160107845*-*ITGB6**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA7534/chr2:160107679-160107845*CircR2Disease*esophageal squamous cell carcinoma
254*circRNA7535*chr2:160123791-160126601*-*ITGB6**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA7535/chr2:160123791-160126601*CircR2Disease*esophageal squamous cell carcinoma
255*circRNA7536*chr2:160169212-160196420*-*ITGB6**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA7536/chr2:160169212-160196420*CircR2Disease*esophageal squamous cell carcinoma
256*circRNA7537*chr2:160196216-160199258*-*ITGB6**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA7537/chr2:160196216-160199258*CircR2Disease*esophageal squamous cell carcinoma
257*circRNA7673*chr2:215371909-215379317*-*FN1**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA7673/chr2:215371909-215379317*CircR2Disease*esophageal squamous cell carcinoma
258*circRNA7674*chr2:215373322-215391814*-*FN1**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA7674/chr2:215373322-215391814*CircR2Disease*esophageal squamous cell carcinoma
259*circRNA7675*chr2:215386689-215399351*-*FN1**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA7675/chr2:215386689-215399351*CircR2Disease*esophageal squamous cell carcinoma
260*circRNA7676*chr2:215397137-215410114*-*FN1**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA7676/chr2:215397137-215410114*CircR2Disease*esophageal squamous cell carcinoma
261*circRNA7679*chr2:215407127-215428338*-*FN1**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA7679/chr2:215407127-215428338*CircR2Disease*esophageal squamous cell carcinoma
262*circRNA8505*chr1:183114531-183115637*+*LAMC1**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA8505/chr1:183114531-183115637*CircR2Disease*esophageal squamous cell carcinoma
263*circRNA8506*chr1:183133406-183135156*+*LAMC1**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA8506/chr1:183133406-183135156*CircR2Disease*esophageal squamous cell carcinoma
264*circRNA8507*chr1:183232187-183238421*+*LAMC2**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA8507/chr1:183232187-183238421*CircR2Disease*esophageal squamous cell carcinoma
265*circRNA904*chr11:18402840-18403811*+*LDHA**Esophageal Squamous Cell Carcinoma*Upregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA904/chr11:18402840-18403811*CircR2Disease*esophageal squamous cell carcinoma
266*circRNA9227*chr9:134690912-134701333*+*COL5A1**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA9227/chr9:134690912-134701333*CircR2Disease*esophageal squamous cell carcinoma
267*circRNA9652*chr12:20621296-20654205*+*PDE3A**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA9652/chr12:20621296-20654205*CircR2Disease*esophageal squamous cell carcinoma
268*circRNA9656*chr12:53016473-53022627*+*EIF4B**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA9656/chr12:53016473-53022627*CircR2Disease*esophageal squamous cell carcinoma
269*circRNA9658*chr12:64424599-64445131*+*XPOT**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA9658/chr12:64424599-64445131*CircR2Disease*esophageal squamous cell carcinoma
270*circRNA9671*chr11:32097144-32098528*+*RCN1**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA9671/chr11:32097144-32098528*CircR2Disease*esophageal squamous cell carcinoma
271*circRNA9771*chr14:69975715-70023447*+*SMOC1**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA9771/chr14:69975715-70023447*CircR2Disease*esophageal squamous cell carcinoma
272*circRNA9777*chr19:16081913-16093753*+*TPM4**Esophageal Squamous Cell Carcinoma*Downregulated*qPCR etc.*Human*The differentially expressed circRNAs were found to be associated with pathways involved in metabolism, cell apoptosis, proliferation and migration, which are commonly altered in cancer cells.*2017-11-01*29218114.0**circRNA9777/chr19:16081913-16093753*CircR2Disease*esophageal squamous cell carcinoma
278*hsa_circ_0003221*chr8:141856358-141900868*-*PTK2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003221*Urinary Bladder Neoplasms*Upregulated*qPCR, Cell proliferation assay, BrdU staining, Cell migration assay etc.*Human*Quantitative PCR results confirmed that circPTK2 is highly expressed in migrated cells separated by Transwell assay and in metastatic lymph nodes of tumors transplanted in nude mice. In vitro silence of circPTK2 by small interfering RNA inhibited the proliferation and migration of bladder cancer cells. On the contrary, circPTK2 overexpression promoted proliferation and migration.*2017-11-01*29125888.0**hsa_circ_0003221/circPTK2/chr8:141856358-141900868*CircR2Disease*bladder cancer
279*circRNA0047905*chr9*+*SERPINB5**Stomach Neoplasms*Upregulated*qPCR, FISH, Western blot etc.*Human*Knockdown of hsa_circ_0047905, hsa_circ_0138960 and has-circRNA7690-15 in GC cells, resulted in downregulation of parental gene expression.inhibition of these three circular RNAs suppresses GC cell proliferation and invasion in vitro*2017-11-01*28980874.0**circRNA0047905/hsa_circ_0047905/chr9*CircR2Disease*gastric cancer
280*circRNA0047905*chr9*+*GDA**Stomach Neoplasms*Upregulated*qPCR, FISH, Western blot assay etc.*Human*Knockdown of hsa_circ_0047905, hsa_circ_0138960 and has-circRNA7690-15 in GC cells, resulted in downregulation of parental gene expression.inhibition of these three circular RNAs suppresses GC cell proliferation and invasion in vitro*2017-11-01*28980874.0**circRNA0138960/hsa_circ_0138960/chr9*CircR2Disease*gastric cancer
281*circRNA0047905*chr18*+*GDA**Stomach Neoplasms*Upregulated*qPCR, FISH, Western blot assay etc.*Human*Knockdown of hsa_circ_0047905, hsa_circ_0138960 and has-circRNA7690-15 in GC cells, resulted in downregulation of parental gene expression.inhibition of these three circular RNAs suppresses GC cell proliferation and invasion in vitro*2017-11-01*28980874.0**circRNA0138960/has-circRNA7690-15/chr18*CircR2Disease*gastric cancer
282*hsa_circRNA_100933*chr11:89133184-89135710*-*NOX4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023984**Upregulated*qPCR etc.*Human*hsa_circRNA_100933-targeted genes were primarily involved in the physiological processes including epithelial cell migration, epithelium migration, vasculature development, and tissue migration*2017-11-01*29095957.0**hsa_circRNA_100933/hsa_circ_0023984/chr11:89133184-89135710*CircR2Disease*infantile hemangioma
283*hsa_circRNA_100709*chr10:126370175-126384781*-*FAM53B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003570**Upregulated*qPCR etc.*Human*Down-regulated circRNA (hsa_circRNA_104310) was confirmed by qRT-PCR*2017-11-01*29095957.0**hsa_circRNA_100709/hsa_circ_0003570/chr10:126370175-126384781*CircR2Disease*infantile hemangioma
284*hsa_circRNA_104310*chr7:6624646-6624891*+*ZDHHC4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0079385**Downregulated*qPCR etc.*Human*The significant GO terms of hsa_circRNA_104310 included growth, developmental growth, cellular lipid metabolic processes, and intracellular signal transduction*2017-11-01*29095957.0**hsa_circRNA_104310/hsa_circ_0079385/chr7:6624646-6624891*CircR2Disease*infantile hemangioma
285*hsa_circRNA_102116*chr17:47388673-47389404*-*ZNF652*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003258**Upregulated*qPCR etc.*Human*Unclear*2017-11-01*29095957.0**hsa_circRNA_102116/hsa_circ_0003258/chr17:47388673-47389404*CircR2Disease*infantile hemangioma
286*hsa_circRNA_051239*chr19:41938372-41945481*-*ATP5SL*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0051239**Upregulated*qPCR etc.*Human*Unclear*2017-11-01*29095957.0**hsa_circRNA_051239/hsa_circ_0051239/chr19:41938372-41945481*CircR2Disease*infantile hemangioma
287*hsa_circRNA_102039*chr17:34147027-34149837*+*TAF15*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0043138**Upregulated*qPCR etc.*Human*Unclear*2017-11-01*29095957.0**hsa_circRNA_102039/hsa_circ_0043138/chr17:34147027-34149837*CircR2Disease*infantile hemangioma
288*hsa_circ_0001982*chr15:59323002-59323901*+*RNF111*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001982*Breast Neoplasms*Upregulated*qPCR, Dual-luciferase assay, CCK-8 assay and Colony formation assay, Invasion assay etc.*Human*Bioinformatics analysis predicted that miR-143 acted as target of hsa_circ_0001982, which was confirmed by Dual-luciferase reporter assay. Loss-of-function and rescue experiments revealed that hsa_circ_0001982 knockdown suppressed breast cancer cell proliferation and invasion and induced apoptosis by targeting miR-143.*2017-11-01*28933584.0**hsa_circ_0001982/chr15:59323002-59323901*CircR2Disease*breast cancer
289*hsa_circRNA_102619*chr2*+*CCNYL1**Liver Cirrhosis, Biliary*Upregulated*qPCR etc.*Human*hsa_circ_402458 may target hsa-miR-522-3p and hsa-miR-943 and thus competitively suppress miRNA activity to participate in the pathogenesis of PBC. The expression levels of hsa_ circ_402458 (P=0.0033) and hsa_circ_406329 (P=0.0185) were significantly higher in the PBC group than in the healthy group; these results were consistent with the microarray data*2017-11-01*29183005.0**hsa_circ_402458 /chr2*CircR2Disease*primary biliary cholangitis
290*rno_circRNA_010705*chr3*+*FSTL1**Liver Cirrhosis, Biliary*Upregulated*qPCR etc.*Human*The expression levels of hsa_ circ_402458 (P=0.0033) and hsa_circ_406329 (P=0.0185) were significantly higher in the PBC group than in the healthy group; these results were consistent with the microarray data*2017-11-01*29183005.0**hsa_circ_406329/chr3*CircR2Disease*primary biliary cholangitis
291*circRNA0047905*chr9*+*ZCCHC7**Liver Cirrhosis, Biliary*Downregulated*qPCR etc.*Human*Hsa_circ_407176 (P=0.0066) and hsa_circ_082319 had lower expression levels in the PBC group than in the healthy group*2017-11-01*29183005.0**hsa_circ_407176/chr9*CircR2Disease*primary biliary cholangitis
292*hsa_circ_082319*chr7*-*ZC3HC1**Liver Cirrhosis, Biliary*Downregulated*qPCR etc.*Human*Hsa_circ_407176 (P=0.0066) and hsa_circ_082319 had lower expression levels in the PBC group than in the healthy group*2017-11-01*29183005.0**hsa_circ_082319/chr7*CircR2Disease*primary biliary cholangitis
293*circZFR***ZFR**Liver Neoplasms*Upregulated*qPCR etc.*Human*Expression levels of circZFR, circFUT8 and circIPO11 in liver cancer tissues were significantly higher than those in the corresponding non-tumorous tissues. circZFR was found to potentially interact with miR-511–5p, miR-130b-5p, miR-642a-5p, miR-532–3p and miR-329–5p.*2017-11-01*28727484.0**circZFR/hsa_circRNA_103809/hsa_circ_10072088*CircR2Disease*liver cancer
294*circFUT8*chr14:66028054-66028484*+*FUT8*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003028*Liver Neoplasms*Upregulated*qPCR etc.*Human*Expression levels of circZFR, circFUT8 and circIPO11 in liver cancer tissues were significantly higher than those in the corresponding non-tumorous tissues. circFUT8 might competitively bind with miR-570–3p, miR-17–3p, and miR-552–3p, and abrogate the inhibitory effect on the associated target genes.*2017-11-01*28727484.0**circFUT8/hsa_circRNA_101368/hsa_circ_0003028/chr14:66028054-66028484*CircR2Disease*liver cancer
295*circIPO11*chr5:61745753-61747760*+*IPO11*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007915*Liver Neoplasms*Upregulated*qPCR etc.*Human*Expression levels of circZFR, circFUT8 and circIPO11 in liver cancer tissues were significantly higher than those in the corresponding non-tumorous tissues. circIPO11 was found to interact with miR-659–3p, miR-424–5p, and miR-106a-3p.*2017-11-01*28727484.0**circIPO11/hsa_circRNA_103847/hsa_circ_0007915/chr5:61745753-61747760*CircR2Disease*liver cancer
296*circZNF609*chr15:64791491-64792365*+*ZNF609*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000615*Myocardial Infarction*Downregulated*qPCR etc.*Human*Eighty seven patients (18%) had a reduced EF, 106 (22%) had a mid-range EF and 279 (59%) had a preserved EF at 4 months. MICRA classified patients into EF groups with an adjusted odds ratio [95% confidence interval] of 0.78 [0.64–0.95]. MICRA improved the predictive value of a multivariable clinical model as attested by a decrease of the Akaike Information Criteria (p = 0.012). Bootstrap internal validation confirmed the incremental prognostic value of MICRA.*2017-11-01*29159270.0**hsa_circ_0000615/MICRA/chr15:64791491-64792365*CircR2Disease*myocardial infarction
297*hsa_circ_0043497*chr17:38209550-38209888*-*MED24*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0043497*Tuberculosis*Upregulated*qPCR etc.*Human*hsa_circ_0043497 and hsa_circ_0001204 were identified as potential non-invasive molecular markers for rapid diagnosis of TB. The potential miRNAs targets of hsa_circ_0043497 include miR-335-3p, miR-186-5p, miR-380-5p, miR-296-3p and miR-522-3p.*2017-10-01*29057952.0**hsa_circ_0043497/chr17:38209550-38209888*CircR2Disease*tuberculosis
298*hsa_circ_0030045*chr13:41367293-41373451*+*SLC25A15*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0030045*Tuberculosis*Upregulated*qPCR etc.*Human*hsa_circ_0030045, hsa_circ_0001417 and hsa_circ_0043497 are significantly up-regulated in Mtb-infected group*2017-10-01*29057952.0**hsa_circ_0030045/chr13:41367293-41373451*CircR2Disease*tuberculosis
299*hsa_circ_0001417*chr4:73950965-73958017*-*ANKRD17*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001417*Tuberculosis*Upregulated*qPCR etc.*Human*hsa_circ_0030045, hsa_circ_0001417 and hsa_circ_0043497 are significantly up-regulated in Mtb-infected group*2017-10-01*29057952.0**hsa_circ_0001417/chr4:73950965-73958017*CircR2Disease*tuberculosis
300*hsa_circ_0030569*chr13:95686858-95735544*-*ABCC4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0030569*Tuberculosis*Downregulated*qPCR etc.*Human*hsa_circ_0030569 and hsa_circ_0001204 are significantly down-regulated in Mtb-infected group*2017-10-01*29057952.0**hsa_circ_0030569/chr13:95686858-95735544*CircR2Disease*tuberculosis
301*hsa_circ_0001204 *chr22:20070853-20070981*+*DGCR8*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001204*Tuberculosis*Downregulated*qPCR etc.*Human*hsa_circ_0043497 and hsa_circ_0001204 were identified as potential non-invasive molecular markers for rapid diagnosis of TB. hsa_circ_0001204, the potential miRNAs targets include miR-612, miR-657, miR-362-3p, miR-377-3p and miR-136-5p.*2017-10-01*29057952.0**hsa_circ_0001204 /chr22:20070853-20070981*CircR2Disease*tuberculosis
302*hsa_circ_0001785*chr8:28013458-28019595*+*ELP3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001785*Breast Neoplasms*Upregulated*qPCR etc.*Human*It was found hsa_circ_0001785 plasma had better diagnostic accuracy (AUC=0.784) than CEA (AUC=0.562) and CA15-3 (AUC=0.629). Besides, hsa_circ_0001785 plasma level was closely related to histological grade (P=0.013), TNM stage (P=0.008) and distant metastasis (P=0.016). Furthermore, hsa_circ_0001785 plasma level in postoperative patients (0.283±0.043) was significantly lower than that of preoperative patients (0.109±0.037, P<0.01).*2017-10-01*29045858.0**hsa_circ_0001785/chr8:28013458-28019595*CircR2Disease*breast cancer
303*hsa_circ_0108942*chr18:9182379-9200642*+*ANKRD12*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0108942*Breast Neoplasms*Upregulated*qPCR etc.*Human*Expression of hsa_circ_0001785 and hsa_circ_0108942 were significantly increased in breast cancer patients, while hsa_circ_0068033 was decreased.*2017-10-01*29045858.0**hsa_circ_0108942/chr18:9182379-9200642*CircR2Disease*breast cancer
304*hsa_circ_0068033*chr3:175165016-175455187*+*NAALADL2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0068033*Breast Neoplasms*Downregulated*qPCR etc.*Human*Expression of hsa_circ_0001785 and hsa_circ_0108942 were significantly increased in breast cancer patients, while hsa_circ_0068033 was decreased.*2017-10-01*29045858.0**hsa_circ_0068033/chr3:175165016-175455187*CircR2Disease*breast cancer
305*circ-NT5C2*chr10:104850367-104850753*-*NT5C2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0092509*Osteosarcoma*Upregulated*qPCR, Luciferase reporter assay, Xenograft model etc.*Human*Functional validation experiments verified that circ-NT5C2 silencing suppressed the proliferation and invasion, and promoted apoptosis of osteosarcoma cells in vitro. In vivo, circ-NT5C2 silencing inhibited the tumor growth. Bioinformatics analysis and rescue experiments indicated that circ-NT5C2 sponged miR-448, which was confirmed by luciferase reporter assay and RT-PCR assay.*2017-10-01*29383123.0**circ-NT5C2/hsa_circ_0092509/chr10:104850367-104850753*CircR2Disease*osteosarcoma
306*circMTO1*chr6:74175931-74176329*+*MTO1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007874*Carcinoma, Hepatocellular*Downregulated*qRT-PCR, ISH , FISH, IHC etc.*Human*HCC patients with low circMTO1 expression had shortened survival. By using a biotin-labeled circMTO1 probe to perform RNA in vivo precipitation in HCC cells, we identified miR-9 as the circMTO1-associated miRNA. Furthermore, silencing of circMTO1 in HCC could down-regulate p21, the target of oncogenic miR-9, resulting in the promotion of HCC cell proliferation and invasion. In addition, the tumor-promoting effect of circMTO1 silencing was blocked by miR9 inhibitor. Intratumoral administration of cholesterol-conjugated circMTO1 small interfering RNA promoted tumor growth in HCC-bearing mice in vivo*2017-10-01*28520103.0**circMTO1/hsa_circRNA_0007874/hsa_circRNA_104135/chr6:74175931-74176329*CircR2Disease*hepatocellular carcinoma
307*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Diabetes Mellitus*Upregulated*qPCR, FISH, Northern blot, MTT assay etc.*Human*circHIPK3 silencing or overexpressing circHIPK3 changed retinal endothelial cell viability, proliferation, migration, and tube formation in vitro. circHIPK3 silencing in vivo alleviated retinal vascular dysfunction, as shown by decreased retinal acellular capillaries, vascular leakage, and inflammation. circHIPK3 acted as an endogenous miR-30a-3p sponge to sequester and inhibit miR-30a-3p activity, which led to increased vascular endothelial growth factor-C, FZD4, and WNT2 expression.*2017-10-01*28860123.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*diabetes mellitus
308*hsa_circ_0000284*chr2:104310905-104312004*-*Hipk3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=mmu_circ_0001052*Diabetes Mellitus*Upregulated*qPCR, FISH, Northern blot, MTT assay etc.*Human*circHIPK3 silencing or overexpressing circHIPK3 changed retinal endothelial cell viability, proliferation, migration, and tube formation in vitro. circHIPK3 silencing in vivo alleviated retinal vascular dysfunction, as shown by decreased retinal acellular capillaries, vascular leakage, and inflammation. circHIPK3 acted as an endogenous miR-30a-3p sponge to sequester and inhibit miR-30a-3p activity, which led to increased vascular endothelial growth factor-C, FZD4, and WNT2 expression.*2017-10-01*28860123.0**mmu_circ_0001052/circHIPK3/chr2:104310905-104312004*CircR2Disease*diabetes mellitus
309*hsa_circ_000984*chr7:92462409-92463134*-*CDK6*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001724*Colorectal Neoplasms*Upregulated*qPCR, Luciferase reporter assay etc.*Human*hsa_circ_000984 knockdown could inhibit cell proliferation, migration, invasion in vitro and tumor formation in vivo in CRC cell lines. Mechanically,  hsa_circ_000984 was found may act as a competing endogenous RNA (ceRNA) by competitively binding miR-106b and effectively upregulate the expression of CDK6, thereby inducing a series of malignant phenotypes of tumor cells. Taken together, these observations suggest that the hsa_circ_000984 could mediate the expression of gene CDK6 by acting as a ceRNA*2017-10-01*29207676.0**hsa_circ_000984/hsa_circ_0001724/chr7:92462409-92463134*CircR2Disease*colorectal cancer
310*hsa_circRNA_100914*chr11:85692171-85742653*-*PICALM*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023903*Moyamoya Disease*Downregulated*qPCR etc.*Human*Differentially expressed circRNAs were primarily involved in angiogenesis, metabolism, and immune responses in MMD. In addition, the mitogen-activated protein kinase signaling pathway was found to be the core regulatory pathway associated with disease pathogenesis.*2017-10-01*28991692.0**hsa_circRNA_100914/hsa_circ_0023903/chr11:85692171-85742653*CircR2Disease*moyamoya disease
311*hsa_circRNA_103343*chr3:47098310-47108608*-*SETD2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002569*Moyamoya Disease*Downregulated*qPCR etc.*Human*Differentially expressed circRNAs were primarily involved in angiogenesis, metabolism, and immune responses in MMD. In addition, the mitogen-activated protein kinase signaling pathway was found to be the core regulatory pathway associated with disease pathogenesis.*2017-10-01*28991692.0**hsa_circRNA_103343/hsa_circ_0002569/chr3:47098310-47108608*CircR2Disease*moyamoya disease
312*hsa_circRNA_050898*chr19:39138266-39219794*+*ACTN4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0050898*Moyamoya Disease*Downregulated*qPCR etc.*Human*Differentially expressed circRNAs were primarily involved in angiogenesis, metabolism, and immune responses in MMD. In addition, the mitogen-activated protein kinase signaling pathway was found to be the core regulatory pathway associated with disease pathogenesis.*2017-10-01*28991692.0**hsa_circRNA_050898/hsa_circ_0050898/chr19:39138266-39219794*CircR2Disease*moyamoya disease
313*hsa_circRNA_101720*chr16:16126965-16130460*+*ABCC1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002078*Moyamoya Disease*Upregulated*qPCR etc.*Human*Differentially expressed circRNAs were primarily involved in angiogenesis, metabolism, and immune responses in MMD. In addition, the mitogen-activated protein kinase signaling pathway was found to be the core regulatory pathway associated with disease pathogenesis.*2017-10-01*28991692.0**hsa_circRNA_101720/hsa_circ_0002078/chr16:16126965-16130460*CircR2Disease*moyamoya disease
314*hsa_circRNA_067209*chr3:127965678-127983624*+*EEFSEC*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0067209*Moyamoya Disease*Upregulated*qPCR etc.*Human*Differentially expressed circRNAs were primarily involved in angiogenesis, metabolism, and immune responses in MMD. In addition, the mitogen-activated protein kinase signaling pathway was found to be the core regulatory pathway associated with disease pathogenesis.*2017-10-01*28991692.0**hsa_circRNA_067209/hsa_circ_0067209/chr3:127965678-127983624*CircR2Disease*moyamoya disease
315*hsa_circ_0005836*chr14:39623414-39627606*-*TRAPPC6B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005836*Tuberculosis, Pulmonary*Downregulated*qPCR etc.*Human*hsa_circ_0005836 was down-regulated by 2.586 folds in the APTB patients compared to the health control group *2017-10-01*28846924.0**hsa_circ_0005836/chr14:39623414-39627606*CircR2Disease*active pulmonary tuberculosis
316*hsa_circ_0009128*chr16:11815432-11830089*-*TXNDC11*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0009128*Tuberculosis, Pulmonary*Downregulated*qPCR etc.*Human*The expression of hsa_circ_0005836, hsa_circ_0009128, hsa_circ_0003519, hsa_circ_0023956, hsa_circ_0078768, hsa_circ_0088452 which were differentially expressed (fold change >20, P-value <0.05) in 10 APTB and 10 HC samples using qRT-PCR.*2017-10-01*28846924.0**hsa_circ_0009128/chr16:11815432-11830089*CircR2Disease*active pulmonary tuberculosis
317*hsa_circ_0023956*chr11:86017286-86017524*+*C11orf73*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023956*Tuberculosis, Pulmonary*Downregulated*qPCR etc.*Human*The expression of hsa_circ_0005836, hsa_circ_0009128, hsa_circ_0003519, hsa_circ_0023956, hsa_circ_0078768, hsa_circ_0088452 which were differentially expressed (fold change >20, P-value <0.05) in 10 APTB and 10 HC samples using qRT-PCR.*2017-10-01*28846924.0**hsa_circ_0023956/chr11:86017286-86017524*CircR2Disease*active pulmonary tuberculosis
318*hsa_circ_0078768*chr6:170626457-170632347*+*FAM120B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0078768*Tuberculosis, Pulmonary*Downregulated*qPCR etc.*Human*The expression of hsa_circ_0005836, hsa_circ_0009128, hsa_circ_0003519, hsa_circ_0023956, hsa_circ_0078768, hsa_circ_0088452 which were differentially expressed (fold change >20, P-value <0.05) in 10 APTB and 10 HC samples using qRT-PCR.*2017-10-01*28846924.0**hsa_circ_0078768/chr6:170626457-170632347*CircR2Disease*active pulmonary tuberculosis
319*hsa_circ_0088452*chr9:126345447-126641300*-*DENND1A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0088452*Tuberculosis, Pulmonary*Downregulated*qPCR etc.*Human*The expression of hsa_circ_0005836, hsa_circ_0009128, hsa_circ_0003519, hsa_circ_0023956, hsa_circ_0078768, hsa_circ_0088452 which were differentially expressed (fold change >20, P-value <0.05) in 10 APTB and 10 HC samples using qRT-PCR.*2017-10-01*28846924.0**hsa_circ_0088452/chr9:126345447-126641300*CircR2Disease*active pulmonary tuberculosis
320*circRNA0003906*chr6:29989443–30003760****Colorectal Neoplasms*Downregulated*qPCR etc.*Human*The downregulation of circRNA0003906 level significantly correlated with lymphatic metastasis and poor differentiation*2017-10-01*29123417.0**circRNA0003906/chr6:29989443–30003760*CircR2Disease*colorectal cancer
321*circGFRA1***GFRA1**Triple Negative Breast Neoplasms*Upregulated*qPCR, CCK8 assay, Mouse xenograft model, Luciferase reporter assay, RIP, Western blot etc.*Human*circGFRA1 and GFRA1 regulated the expression of each other by sponging miR-34a*2017-10-01*29037220.0**circGFRA1/hsa_circ_005239*CircR2Disease*triple negative breast cancer
322*hsa_circ_0045714*chr17:73808192-73809959*+*UNK*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0045714*Osteoarthritis*Downregulated*qPCR, Dual-luciferase assay, Western blot etc.*Human*hsa_circ_0045714 can regulate extracellular matrix synthesis as well as proliferation and apoptosis of chondrocytes by promoting the expression of miR-193b target gene IGF1R. *2017-10-01*28795385.0**hsa_circ_0045714/chr17:73808192-73809959*CircR2Disease*osteoarthritis
323*CDR1as*chrX:139865339-139866824*+*CDR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001946*Carcinoma, Hepatocellular*Downregulated*qPCR, Western blot, Immunofluorescence microscopy, RNA-FISH etc.*Human*In total, we identified 330 differentially expressed proteins (DEPs) upon enhanced CDR1as expression in HepG2 cells, indicating that they could be proteins regulated by CDR1as. Bioinformatic analysis revealed that many DEPs were involved in cell proliferation and the cell cycle. Further functional studies of epidermal growth factor receptor (EGFR) found that CDR1as exerts its effects on cell proliferation at least in part through the regulation of EGFR expression. We further confirmed that CDR1as could inhibit the expression of microRNA-7 (miR-7). EGFR is a validated target of miR-7; therefore, CDR1as may exert its function by regulating EGFR expression via targeting miR-7 in HCC cells.*2017-10-01*28892615.0**CDR1as/ciRS-7/hsa_circ_0001946/chrX:139865339-139866824*CircR2Disease*hepatocellular carcinoma
324*circAmotl1*chr11:94532555-94533477*+*AMOTL1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004214*Breast Neoplasms*Upregulated*qPCR, Northern blot, Single-cell inoculations,  Agarose colony-formation assays, Routine in vitro and in vivo assays etc.*Human*Circ-Amotl1 is highly expressed in patient tumor samples and cancer cell lines. Single-cell inoculations using circ-Amotl1-transfected tumor cells showed a 30-fold increase in proliferative capacity relative to control. Agarose colony-formation assays similarly revealed a 142-fold increase.*2017-09-01*28622299.0**circAmotl1/hsa_circ_0004214/chr11:94532555-94533477*CircR2Disease*breast cancer
325*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Urinary Bladder Neoplasms*Downregulated*qPCR, Northern blot, FISH, Pull-down assay, Western blot, Immunohistochemistry etc.*Human*circHIPK3 negatively correlated with bladder cancer grade, invasion and lymph node metastasis.Sponges miR-558 to suppress heparanase expression*2017-09-01*28794202.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*bladder cancer
326*hsa_circRNA_103801*****Osteosarcoma*Upregulated*qPCR etc.*Human*The expression of hsa_circRNA_103801 was up-regulated in osteosarcoma tissue samples*2017-09-01*28957794.0**hsa_circRNA_103801*CircR2Disease*osteosarcoma
327*hsa_circRNA_102049*****Osteosarcoma*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*28957794.0**hsa_circRNA_102049*CircR2Disease*osteosarcoma
328*hsa_circRNA_103309*****Osteosarcoma*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*28957794.0**hsa_circRNA_103309*CircR2Disease*osteosarcoma
329*hsa_circRNA_101113*****Osteosarcoma*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*28957794.0**hsa_circRNA_101113*CircR2Disease*osteosarcoma
330*hsa_circRNA_102485*****Osteosarcoma*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*28957794.0**hsa_circRNA_102485*CircR2Disease*osteosarcoma
331*hsa_circRNA_100241*****Osteosarcoma*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*28957794.0**hsa_circRNA_100241*CircR2Disease*osteosarcoma
332*hsa_circRNA_104980*****Osteosarcoma*Downregulated*qPCR etc.*Human*The expression of hsa_circRNA_104980 was down-regulated in osteosarcoma tissue samples*2017-09-01*28957794.0**hsa_circRNA_104980*CircR2Disease*osteosarcoma
333*hsa_circRNA_104692*****Osteosarcoma*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28957794.0**hsa_circRNA_104692*CircR2Disease*osteosarcoma
334*hsa_circRNA_104892*****Osteosarcoma*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28957794.0**hsa_circRNA_104892*CircR2Disease*osteosarcoma
335*hsa_circRNA_102678*****Osteosarcoma*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28957794.0**hsa_circRNA_102678*CircR2Disease*osteosarcoma
336*hsa_circRNA_103110*****Osteosarcoma*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28957794.0**hsa_circRNA_103110*CircR2Disease*osteosarcoma
337*hsa_circRNA_100258*****Osteosarcoma*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28957794.0**hsa_circRNA_100258*CircR2Disease*osteosarcoma
338*hsa_circ_0091017*chrX:70601592-70607311*+*TAF1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0091017*Urinary Bladder Neoplasms*Downregulated*qPCR etc.*Human*The expression level changes of hsa_circ_0091017 and hsa_circ_0002024 in the 32 paired samples*2017-09-01*29151929.0**hsa_circ_0091017/chrX:70601592-70607311*CircR2Disease*bladder cancer
339*hsa_circ_0002024*chr2:191523883-191537878*+*NAB1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002024*Urinary Bladder Neoplasms*Downregulated*qPCR etc.*Human*The expression level changes of hsa_circ_0091017 and hsa_circ_0002024 in the 32 paired samples*2017-09-01*29151929.0**hsa_circ_0002024/chr2:191523883-191537878*CircR2Disease*bladder cancer
340*hsa_circ_0018289*chr10:46968580-46969453*-*SYT15*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0018289*Uterine Cervical Neoplasms*Upregulated*qPCR, Luciferase reporter assay, Xenograft mouse model etc.*Human*hsa_circ_0018289 was observed to directly bind to miR-497, which was validated by luciferase reporter assays. Although the further functional experiments are absent, the interaction within hsa_circ_0018289 and miR-497 could indicate the sponge role of hsa_circ_0018289 to miR-497.*2017-09-01*29156822.0**hsa_circ_0018289/chr10:46968580-46969453*CircR2Disease*cervical cancer
341*hsa_circ_0011021*chr1:27117249-27121725*+*PIGV*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0011021*Uterine Cervical Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*29156822.0**hsa_circ_0011021/chr1:27117249-27121725*CircR2Disease*cervical cancer
342*hsa_circ_0034912*chr15:43294752-43294902*-*UBR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0034912*Uterine Cervical Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*29156822.0**hsa_circ_0034912/chr15:43294752-43294902*CircR2Disease*cervical cancer
343*hsa_circ_0091822*chrX:153275956-153285342*-*IRAK1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0091822*Uterine Cervical Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*29156822.0**hsa_circ_0091822/chrX:153275956-153285342*CircR2Disease*cervical cancer
344*hsa_circ_0089231*chr9:134353130-134363483*+*PRRC2B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0089231*Uterine Cervical Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*29156822.0**hsa_circ_0089231/chr9:134353130-134363483*CircR2Disease*cervical cancer
345*hsa_circ_0087432*chr9:91041296-91083520*+*SPIN1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0087432*Uterine Cervical Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*29156822.0**hsa_circ_0087432/chr9:91041296-91083520*CircR2Disease*cervical cancer
346*hsa_circ_0000181*chr1:212977661-212981190*+*TATDN3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000181*Stomach Neoplasms*Downregulated*qPCR etc.*Human*hsa_circ_0000181 expression in gastric cancer tissues was significantly correlated with tumor diameter (P = .027), lymphatic metastasis (P = .044), distal metastasis (P = .023), and carbohydrate antigen 19-9 (P = .031). Its decreased levels in patients' plasma were significantly associated with differentiation (P = .038) and carcinoembryonic antigen (P = .037).*2017-09-01*28940688.0**hsa_circ_0000181/chr1:212977661-212981190*CircR2Disease*gastric cancer
347*hsa_circ_0000745*chr17:20107645-20109225*+*SPECC1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000745*Stomach Neoplasms*Downregulated*qPCR etc.*Human*hsa_circ_0000745 was down-regulated in GC tissues vs non-tumorous tissues (P < 0.001) and in plasma samples from patients with GC vs healthy controls (P < 0.001)*2017-09-01*28974900.0**hsa_circ_0000745/chr17:20107645-20109225*CircR2Disease*gastric cancer
348*hsa_circ_0085616*chr8:131370262-131374017*-*ASAP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0085616*Stomach Neoplasms*Upregulated*qPCR etc.*Human*The qRT-PCR results showed that circ_0085616 was up-regulated, while circ_0000745 and chr16:30740286-30740893|+ were down-regulated in the GC tissues compared to the paired adjacent non-tumor tissues*2017-09-01*28974900.0**hsa_circ_0085616/chr8:131370262-131374017*CircR2Disease*gastric cancer
349*hsa_circ_0006127*chr16:30740286-30740893*+*SRCAP*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006127*Stomach Neoplasms*Downregulated*qPCR etc.*Human*The qRT-PCR results showed that circ_0085616 was up-regulated, while circ_0000745 and chr16:30740286-30740893|+ were down-regulated in the GC tissues compared to the paired adjacent non-tumor tissues*2017-09-01*28974900.0**hsa_circ_0006127/chr16:30740286-30740893*CircR2Disease*gastric cancer
350*hsa_circ_0006528*chr5:145197456-145205763*-*PRELID2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006528*Breast Neoplasms*Upregulated*qPCR, Western blot etc.*Human*A total of seven upregulated (hsa circ 0002113, hsa circ 0002874, hsa circ 0006528, hsa circ 0001667, hsa circ 0085495, hsa circ 0086241 and hsa circ 0092276) and one downregulated (hsa circ 0003838) circRNAs were verified.Discovered a regulatory role of the circ_0006528-miR-7–5p-Raf1 axis in ADM-resistant breast cancer. *2017-09-01*28803498.0**hsa_circ_0006528/chr5:145197456-145205763*CircR2Disease*breast cancer
351*hsa_circ_0002113*chr21:34793786-34805178*+*IFNGR2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002113*Breast Neoplasms*Upregulated*qPCR etc.*Human*A total of seven upregulated (hsa circ 0002113, hsa circ 0002874, hsa circ 0006528, hsa circ 0001667, hsa circ 0085495, hsa circ 0086241 and hsa circ 0092276) and one downregulated (hsa circ 0003838) circRNAs were verified. May bind with miRNAs*2017-09-01*28803498.0**hsa_circ_0002113/chr21:34793786-34805178*CircR2Disease*breast cancer
352*hsa_circ_0002874*chr9:4286037-4286523*-*GLIS3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002874*Breast Neoplasms*Upregulated*qPCR etc.*Human*A total of seven upregulated (hsa circ 0002113, hsa circ 0002874, hsa circ 0006528, hsa circ 0001667, hsa circ 0085495, hsa circ 0086241 and hsa circ 0092276) and one downregulated (hsa circ 0003838) circRNAs were verified*2017-09-01*28803498.0**hsa_circ_0002874/chr9:4286037-4286523*CircR2Disease*breast cancer
353*hsa_circ_0001667*chr7:810107-814799*+*HEATR2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001667*Breast Neoplasms*Upregulated*qPCR etc.*Human*A total of seven upregulated (hsa circ 0002113, hsa circ 0002874, hsa circ 0006528, hsa circ 0001667, hsa circ 0085495, hsa circ 0086241 and hsa circ 0092276) and one downregulated (hsa circ 0003838) circRNAs were verified. May bind with miRNAs*2017-09-01*28803498.0**hsa_circ_0001667/chr7:810107-814799*CircR2Disease*breast cancer
354*hsa_circ_0085495*chr8:125332326-125339662*-*TMEM65*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0085495*Breast Neoplasms*Upregulated*qPCR etc.*Human*A total of seven upregulated (hsa circ 0002113, hsa circ 0002874, hsa circ 0006528, hsa circ 0001667, hsa circ 0085495, hsa circ 0086241 and hsa circ 0092276) and one downregulated (hsa circ 0003838) circRNAs were verified. May bind with miRNAs*2017-09-01*28803498.0**hsa_circ_0085495/chr8:125332326-125339662*CircR2Disease*breast cancer
355*hsa_circ_0086241*chr9:3330258-3330517*-*RFX3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0086241*Breast Neoplasms*Upregulated*qPCR etc.*Human*A total of seven upregulated (hsa circ 0002113, hsa circ 0002874, hsa circ 0006528, hsa circ 0001667, hsa circ 0085495, hsa circ 0086241 and hsa circ 0092276) and one downregulated (hsa circ 0003838) circRNAs were verified. May bind with miRNAs*2017-09-01*28803498.0**hsa_circ_0086241/chr9:3330258-3330517*CircR2Disease*breast cancer
356*hsa_circ_0092276*chr3:52524247-52524687*+*NISCH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0092276*Breast Neoplasms*Upregulated*qPCR etc.*Human*A total of seven upregulated (hsa circ 0002113, hsa circ 0002874, hsa circ 0006528, hsa circ 0001667, hsa circ 0085495, hsa circ 0086241 and hsa circ 0092276) and one downregulated (hsa circ 0003838) circRNAs were verified. May bind with miRNAs*2017-09-01*28803498.0**hsa_circ_0092276/chr3:52524247-52524687*CircR2Disease*breast cancer
357*hsa_circ_0003838*chr15:43086841-43109295*-*TTBK2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003838*Breast Neoplasms*Downregulated*qPCR etc.*Human*A total of seven upregulated (hsa circ 0002113, hsa circ 0002874, hsa circ 0006528, hsa circ 0001667, hsa circ 0085495, hsa circ 0086241 and hsa circ 0092276) and one downregulated (hsa circ 0003838) circRNAs were verified.  *2017-09-01*28803498.0**hsa_circ_0003838/chr15:43086841-43109295*CircR2Disease*breast cancer
358*hsa_circ_0071410*chr4:169812072-169837178*+*PALLD*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0071410*Chemical and Drug Induced Liver Injury*Upregulated*qPCR, Western blot etc.*Human*Decreased expression of hsa_circ_0071410 significantly inhibited the proliferation of LX2 after irradiation and the effect could be reversed by the inhibition of miR-9-5p*2017-09-01*28774651.0**hsa_circ_0071410/chr4:169812072-169837178*CircR2Disease*radiation-induced liver fibrosis
359*hsa_circ_0054345*chr2:44139570-44145537*-*LRPPRC*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0054345*Chemical and Drug Induced Liver Injury*Upregulated*qPCR etc.*Human*hsa_circ_0072765, hsa_circ_0071410, hsa_circ_0054345 were significantly up-regulated in irradiated HSC compared with normal HSC, while hsa_circ_0070963, hsa_circ_0061893, hsa_circ_0013255 were significantly down-regulated. *2017-09-01*28774651.0**hsa_circ_0054345/chr2:44139570-44145537*CircR2Disease*radiation-induced liver fibrosis
360*hsa_circ_0072765*chr5:68471223-68471364*+*CCNB1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0072765*Chemical and Drug Induced Liver Injury*Upregulated*qPCR etc.*Human*hsa_circ_0072765, hsa_circ_0071410, hsa_circ_0054345 were significantly up-regulated in irradiated HSC compared with normal HSC, while hsa_circ_0070963, hsa_circ_0061893, hsa_circ_0013255 were significantly down-regulated. *2017-09-01*28774651.0**hsa_circ_0072765/chr5:68471223-68471364*CircR2Disease*radiation-induced liver fibrosis
361*hsa_circ_0070963*chr4:129919028-129964622*-*SCLT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0070963*Chemical and Drug Induced Liver Injury*Downregulated*qPCR etc.*Human*hsa_circ_0072765, hsa_circ_0071410, hsa_circ_0054345 were significantly up-regulated in irradiated HSC compared with normal HSC, while hsa_circ_0070963, hsa_circ_0061893, hsa_circ_0013255 were significantly down-regulated. *2017-09-01*28774651.0**hsa_circ_0070963/chr4:129919028-129964622*CircR2Disease*radiation-induced liver fibrosis
362*hsa_circ_0061893*chr21:45153949-45168961*+*PDXK*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0061893*Chemical and Drug Induced Liver Injury*Downregulated*qPCR etc.*Human*hsa_circ_0072765, hsa_circ_0071410, hsa_circ_0054345 were significantly up-regulated in irradiated HSC compared with normal HSC, while hsa_circ_0070963, hsa_circ_0061893, hsa_circ_0013255 were significantly down-regulated. *2017-09-01*28774651.0**hsa_circ_0061893/chr21:45153949-45168961*CircR2Disease*radiation-induced liver fibrosis
363*hsa_circ_0013255*chr1:97543299-97915779*-*DPYD*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0013255*Chemical and Drug Induced Liver Injury*Downregulated*qPCR etc.*Human*hsa_circ_0072765, hsa_circ_0071410, hsa_circ_0054345 were significantly up-regulated in irradiated HSC compared with normal HSC, while hsa_circ_0070963, hsa_circ_0061893, hsa_circ_0013255 were significantly down-regulated. *2017-09-01*28774651.0**hsa_circ_0013255/chr1:97543299-97915779*CircR2Disease*radiation-induced liver fibrosis
364*hsa_circ_0020397*chr10:128768965-128926028*+*DOCK1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0020397*Colorectal Neoplasms*Upregulated*qPCR, Luciferase assay, Western blot, Cell invasion assay etc.*Human*Using a dual-luciferase reporter assay, we show evidence of miR-138-binding sites on hsa_circ_0020397, and that overexpression of hsa_circ_0020397 could inhibit the downregulation of luciferase activity by miR-138.  Although hsa_circ_0020397 did not influence miR-138 expression per se, hsa_circ_0020397 did inhibit miR-138 activity, as examined via the expression of miR-138 targets telomerase reverse transcriptase (TERT) and programmed death-ligand 1 (PD-L1). Hsa_circ_0020397 promoted cell viability and invasion of CRC cells and inhibited their apoptosis, whereas miR-138 had the opposite effect. Nevertheless, hsa_circ_0020397 antagonized miR-138 suppression of cell growth. When TERT or PD-L1 expression was suppressed with siRNAs, the above functions of hsa_circ_0020397 were attenuated, suggesting that hsa_circ_0020397 can regulate CRC cell viability, apoptosis and invasion by promoting the expression of miR-138 target genes.*2017-09-01*28707774.0**hsa_circ_0020397/chr10:128768965-128926028*CircR2Disease*colorectal cancer
365*circMylk*chr3:123471177-123512691*-*MYLK*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002768*Urinary Bladder Neoplasms*Upregulated*qPCR, RIP, Luciferase reporter assay, FISH, Western blot, Northern blot etc.*Human*circRNA-MYLK might function as competing endogenous RNA (ceRNA) for miR-29a, which could contribute to EMT and the development of BC through activating VEGFA/VEGFR2 and downstream Ras/ERK signaling pathway.*2017-09-01*28687357.0**circMylk/circRNA-MYLK/hsa_circ_0002768/chr3:123471177-123512691*CircR2Disease*bladder cancer
366*hsa_circ_0035560*chr15:60653139-60674640*-*ANXA2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0035560*Multiple Sclerosis*Downregulated*qPCR etc.*Human*circ_0035560, which is 4.17 times downregulated in arrays and 1.36 times in the first validation cohort. *2017-09-01*28651352.0**hsa_circ_0035560/chr15:60653139-60674640*CircR2Disease*multiple sclerosis
367*hsa_circ_0005402*chr15:60648117-60674640*-*ANXA2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005402*Multiple Sclerosis*Downregulated*qPCR etc.*Human*circ_0005402, which is 6.11 times downregulated in arrays and 2.53 times in the first validation cohort*2017-09-01*28651352.0**hsa_circ_0005402/chr15:60648117-60674640*CircR2Disease*multiple sclerosis
368*hsa_circRNA_000167*chr14:20811404-20811554*-*RPPH1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000518*Multiple Sclerosis*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*28651352.0**hsa_circ_0000518/chr14:20811404-20811554*CircR2Disease*multiple sclerosis
369*hsa_circ_0000517*chr14:20811404-20811492*-*RPPH1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000517*Multiple Sclerosis*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28651352.0**hsa_circ_0000517/chr14:20811404-20811492*CircR2Disease*multiple sclerosis
370*hsa_circ_0000519*chr14:20811436-20811534*-*RPPH1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000519*Multiple Sclerosis*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28651352.0**hsa_circ_0000519/chr14:20811436-20811534*CircR2Disease*multiple sclerosis
371*hsa_circ_0000520*chr14:20811436-20811559*-*RPPH1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000520*Multiple Sclerosis*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28651352.0**hsa_circ_0000520/chr14:20811436-20811559*CircR2Disease*multiple sclerosis
372*hsa_circ_0001400*chr4:37633006-37640126*-*RELL1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001400*Multiple Sclerosis*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28651352.0**hsa_circ_0001400/chr4:37633006-37640126*CircR2Disease*multiple sclerosis
373*hsa_circ_0056731*chr2:152698416-152717334*-*CACNB4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0056731*Multiple Sclerosis*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28651352.0**hsa_circ_0056731/chr2:152698416-152717334*CircR2Disease*multiple sclerosis
374*hsa_circ_0024892*chr11:130749518-130749606*-*SNX19*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0024892*Multiple Sclerosis*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28651352.0**hsa_circ_0024892/chr11:130749518-130749606*CircR2Disease*multiple sclerosis
375*circVRK1*chr14:97312431-97327072*+*VRK1**Breast Neoplasms*Downregulated*qPCR, Silencing of circVRK1 etc.*Human*circular RNA VRK1 (circVRK1) could suppress BCSC's expansion and self-renewal capacity*2017-09-01*29221160.0**circVRK1/chr14:97312431-97327072*CircR2Disease*breast cancer
376*circBRIP*chr17:59853761-59861785*-*BRIP1**Breast Neoplasms*Downregulated*qPCR etc.*Human*Uclear*2017-09-01*29221160.0**circBRIP/chr17:59853761-59861785*CircR2Disease*breast cancer
377*circOLA*chr2:174987907-175006728*-*OLA1**Breast Neoplasms*Downregulated*qPCR etc.*Human*Uclear*2017-09-01*29221160.0**circOLA/chr2:174987907-175006728*CircR2Disease*breast cancer
378*circETFA*chr15:76566752-76588078*-*ETFA**Breast Neoplasms*Downregulated*qPCR etc.*Human*Uclear*2017-09-01*29221160.0**circETFA/chr15:76566752-76588078*CircR2Disease*breast cancer
379*circMED13*chr17:60061531-60062451*-*MED13**Breast Neoplasms*Downregulated*qPCR etc.*Human*Uclear*2017-09-01*29221160.0**circMED13/chr17:60061531-60062451*CircR2Disease*breast cancer
380*circBCL11B*chr14:99723807-99724176*-*BCL11B**Breast Neoplasms*Downregulated*qPCR etc.*Human*Uclear*2017-09-01*29221160.0**circBCL11B/chr14:99723807-99724176*CircR2Disease*breast cancer
381*hsa_circ_0000026*chr1:21377358-21437876*-*EIF4G3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000026*Stomach Neoplasms*Downregulated*qPCR etc.*Human*circRNA-0026 expression was significantly different between the GC and control samples. The analysis revealed that circRNA‑0026 may regulate RNA transcription, RNA metabolism, gene expression, gene silencing and other biological functions in GC. *2017-09-01*28737829.0**hsa_circ_0000026/chr1:21377358-21437876*CircR2Disease*gastric cancer
382*hsa_circ_0000144*chr1:160472466-160472794*+*SLAMF6*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000144*Stomach Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*28737829.0**hsa_circ_0000144/chr1:160472466-160472794*CircR2Disease*gastric cancer
383*hsa_circ_0032821*chr14:81209418-81227957*-*CEP128*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0032821*Stomach Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28737829.0**hsa_circ_0032821/chr14:81209418-81227957*CircR2Disease*gastric cancer
384*hsa_circ_0005529*chr15:91542906-91543205*-*VPS33B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005529*Stomach Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*28737829.0**hsa_circ_0005529/chr15:91542906-91543205*CircR2Disease*gastric cancer
385*hsa_circ_0061274*chr21:16386664-16386787*-*NRIP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0061274*Stomach Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-09-01*28737829.0**hsa_circ_0061274/chr21:16386664-16386787*CircR2Disease*gastric cancer
386*hsa_circ_0005927*chr8:42259305-42260979*+*VDAC3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005927*Stomach Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28737829.0**hsa_circ_0005927/chr8:42259305-42260979*CircR2Disease*gastric cancer
387*hsa_circ_0092341*chr6:42071996-42072196*-*C6orf132*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0092341*Stomach Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28737829.0**hsa_circ_0092341/chr6:42071996-42072196*CircR2Disease*gastric cancer
388*hsa_circ_0001561*chr5:177652366-177652583*-*AGXT2L2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001561*Stomach Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-09-01*28737829.0**hsa_circ_0001561/chr5:177652366-177652583*CircR2Disease*gastric cancer
389*circLARP4*chr12:50848096-50855130*+*LARP4**Stomach Neoplasms*Downregulated*qPCR, Western blot, Luciferase reporter assay, EdU incorporation assay, RIP, FISH etc.*Human*Increased miR-424 expression or decreased LATS1 expression was associated with pathological stage and unfavorable prognosis of GC patients. Ectopic expression of miR-424 promoted proliferation and invasion of GC cells by targeting LATS1 gene.*2017-09-01*28893265.0**circLARP4/chr12:50848096-50855130*CircR2Disease*gastric cancer
393*hsa_circ_101396*****Leukoaraiosis*Upregulated*qPCR etc.*Human*GO enrichment analysis of the upregulated DE genes indicated that DE genes were primarily associated with metabolic processes, organelles and the activity of certain transferases.*2017-09-01*28677780.0**hsa_circ_101396*CircR2Disease*leukoaraiosis
394*hsa_circ_102533 *****Leukoaraiosis*Upregulated*qPCR etc.*Human*GO enrichment analysis of the upregulated DE genes indicated that DE genes were primarily associated with metabolic processes, organelles and the activity of certain transferases.*2017-09-01*28677780.0**hsa_circ_102533 *CircR2Disease*leukoaraiosis
395*hsa_circ_103783*****Leukoaraiosis*Upregulated*qPCR etc.*Human*GO enrichment analysis of the upregulated DE genes indicated that DE genes were primarily associated with metabolic processes, organelles and the activity of certain transferases.*2017-09-01*28677780.0**hsa_circ_103783*CircR2Disease*leukoaraiosis
396*hsa_circ_102470*****Leukoaraiosis*Downregulated*qPCR etc.*Human*hsa_circ_102470 was identified to exhibit the largest difference in expression between the LA and control groups.*2017-09-01*28677780.0**hsa_circ_102470*CircR2Disease*leukoaraiosis
397*has-circRNA_0046367*****Fatty Liver*Downregulated*qPCR, Luciferase reporter assay, Western blot etc.*Human*In contrast to its expression loss during the hepatocellular steatosis in vivo and in vitro, circRNA_0046367 normalization abolished miR-34a’s inhibitory effect on peroxisome proliferator-activated receptor α (PPARα) via blocking the miRNA/mRNA interaction with miRNA response elements (MREs).  Hepatotoxicity of steatosis-related lipid peroxidation, being characterized by mitochondrial dysfunction, growth arrest, and apoptosis, is resultantly prevented after the circRNA_0046367 administration. circRNA_0046367, therefore, is suggested to be potential approach to the therapy of lipid peroxidative damage.*2017-09-01*29018509.0**has-circRNA_0046367*CircR2Disease*hepatic steatosis
399*circRNA_100290*chr1: 101372407–101379362*+*SLC30A7*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0013339*Squamous Cell Carcinoma of Head and Neck*Upregulated*qPCR, Western blot, RNAi, MTT assay, BrdU incorporation assay, Luciferase and EGFP/RFP reporter assay etc.*Human*Knockdown of circRNA_100290 decreased expression of CDK6 and inhibited proliferation of OSCC cell lines in vitro and in vivo. Via luciferase reporter assays, circRNA_100290 was observed to directly bind to miR-29 family members. Further EGFP/RFP reporter assays showed that CDK6 was the direct target of miR-29b. *2017-08-01*28368401.0**circRNA_100290/hsa_circ_0013339/hsa_circ_100290/chr1: 101372407–101379362*CircR2Disease*oral squamous cell carcinomas
400*hsa_circ_0076304*chr6:41704448-41710227*-*PGC*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0076304*Stomach Neoplasms*Downregulated*qPCR etc.*Human*hsa_circ_0076304, hsa_circ_0035431, and hsa_circ_0076305 had the highest magnitude of change*2017-08-01*28831102.0**hsa_circ_0076304/chr6:41704448-41710227*CircR2Disease*gastric cancer
401*hsa_circ_0035431*chr15:57730182-57734676*+*CGNL1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0035431*Stomach Neoplasms*Downregulated*qPCR etc.*Human*hsa_circ_0076304, hsa_circ_0035431, and hsa_circ_0076305 had the highest magnitude of change*2017-08-01*28831102.0**hsa_circ_0035431/chr15:57730182-57734676*CircR2Disease*gastric cancer
402*hsa_circ_0076305*chr6:41704448-41712252*-*PGC*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0076305*Stomach Neoplasms*Downregulated*qPCR etc.*Human*hsa_circ_0076304, hsa_circ_0035431, and hsa_circ_0076305 had the highest magnitude of change*2017-08-01*28831102.0**hsa_circ_0076305/chr6:41704448-41712252*CircR2Disease*gastric cancer
403*hsa_circRNA_063981*chr22*-*SBF1**Diabetic Retinopathy*Upregulated*qPCR etc.*Human*We found that the serum levels of these circRNAs were significantly elevated in T2DR relative to the T2DM or control groups, which agrees with the microarray results and demonstrates high reliability of this circRNA profile.*2017-08-01*28817829.0**hsa_circRNA_063981/chr22*CircR2Disease*diabetic retinopathy
404*rno_circRNA_001167*chr1*-*TCEA3**Diabetic Retinopathy*Upregulated*qPCR etc.*Human*We found that the serum levels of these circRNAs were significantly elevated in T2DR relative to the T2DM or control groups, which agrees with the microarray results and demonstrates high reliability of this circRNA profile.*2017-08-01*28817829.0**hsa_circRNA_ 404457/chr1*CircR2Disease*diabetic retinopathy
405*hsa_circRNA_100750*chr11*+*STIM1**Diabetic Retinopathy*Upregulated*qPCR etc.*Human*We found that the serum levels of these circRNAs were significantly elevated in T2DR relative to the T2DM or control groups, which agrees with the microarray results and demonstrates high reliability of this circRNA profile.*2017-08-01*28817829.0**hsa_circRNA_100750/chr11*CircR2Disease*diabetic retinopathy
406*hsa_circ_082319*chr7*-*IGF2BP3**Diabetic Retinopathy*Upregulated*qPCR etc.*Human*We found that the serum levels of these circRNAs were significantly elevated in T2DR relative to the T2DM or control groups, which agrees with the microarray results and demonstrates high reliability of this circRNA profile.*2017-08-01*28817829.0**hsa_circRNA_406918/chr7*CircR2Disease*diabetic retinopathy
407*hsa_circ_082319*chr7*+*WBSCR17**Diabetic Retinopathy*Upregulated*qPCR etc.*Human*We found that the serum levels of these circRNAs were significantly elevated in T2DR relative to the T2DM or control groups, which agrees with the microarray results and demonstrates high reliability of this circRNA profile.*2017-08-01*28817829.0**hsa_ circRNA_104387/chr7*CircR2Disease*diabetic retinopathy
408*rno_circRNA_010705*chr3*-*LRIG1**Diabetic Retinopathy*Upregulated*qPCR etc.*Human*We found that the serum levels of these circRNAs were significantly elevated in T2DR relative to the T2DM or control groups, which agrees with the microarray results and demonstrates high reliability of this circRNA profile.*2017-08-01*28817829.0**hsa_circRNA_103410/chr3*CircR2Disease*diabetic retinopathy
409*rno_circRNA_001167*chr1*+*ST3GAL3**Diabetic Retinopathy*Upregulated*qPCR etc.*Human*We found that the serum levels of these circRNAs were significantly elevated in T2DR relative to the T2DM or control groups, which agrees with the microarray results and demonstrates high reliability of this circRNA profile.*2017-08-01*28817829.0**hsa_circRNA_ 100192/chr1*CircR2Disease*diabetic retinopathy
410*circDENND4C***DENND4C**Breast Neoplasms*Upregulated*qPCR, Western blot, CCK8 assay etc.*Human*In breast cancer cells, circDENND4C was increased under hypoxic conditions and decreased after knocking-down HIF1α. In addition, knocking-down circDENND4C inhibited proliferation of breast cancer cells in a hypoxic environment.*2017-08-01*28739726.0**circDENND4C*CircR2Disease*breast cancer
411*hsa_circRNA_003251******Upregulated*qPCR etc.*Human*KEGG pathway analysis predicted that upregulation of hsa-circRNA_003251, hsa-circRNA_015115, hsa-circRNA_100918, and hsa_circRNA_001520 may participate in the thyroid hormone, Wnt, ErbB, and mitogen-activated protein kinase signalling pathways.*2017-08-01*28779132.0**hsa_circRNA_003251*CircR2Disease*t2dm with depression
412*hsa_circRNA_015115******Upregulated*qPCR etc.*Human*KEGG pathway analysis predicted that upregulation of hsa-circRNA_003251, hsa-circRNA_015115, hsa-circRNA_100918, and hsa_circRNA_001520 may participate in the thyroid hormone, Wnt, ErbB, and mitogen-activated protein kinase signalling pathways.*2017-08-01*28779132.0**hsa_circRNA_015115*CircR2Disease*t2dm with depression
413*hsa_circRNA_100918******Upregulated*qPCR etc.*Human*KEGG pathway analysis predicted that upregulation of hsa-circRNA_003251, hsa-circRNA_015115, hsa-circRNA_100918, and hsa_circRNA_001520 may participate in the thyroid hormone, Wnt, ErbB, and mitogen-activated protein kinase signalling pathways.*2017-08-01*28779132.0**hsa_circRNA_100918*CircR2Disease*t2dm with depression
414*hsa_circRNA_005019 ******Downregulated*qPCR etc.*Human*KEGG pathway analysis predicted that upregulation of hsa-circRNA_003251, hsa-circRNA_015115, hsa-circRNA_100918, and hsa_circRNA_001520 may participate in the thyroid hormone, Wnt, ErbB, and mitogen-activated protein kinase signalling pathways.*2017-08-01*28779132.0**hsa_circRNA_005019 *CircR2Disease*t2dm with depression
415*hsa_circ_0000284******Upregulated*qPCR, Droplet digital PCR etc.*Human*May act as an inhibitor of miR-221/miR-222. Serum circR-284:miR-221 has potential as a diagnostic biomarker of carotid plaque rupture and stroke.*2017-08-01*28779016.0**circR-284*CircR2Disease*carotid disease and ischemic stroke
416*hsa_circ_0005986*chr1:14057494-14068652*+*PRDM2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005986*Carcinoma, Hepatocellular*Downregulated*qRT-PCR, Dual luciferase reporter assay etc.*Human*hsa_circ_0005986 levels in HCC cell lines, HepG2, SMMC7721, Huh7, MHCC97L, MHCC97H, and HCCLM3 were significantly lower than those in human normal hepatic cell line L02 (P < 0.001). In addition, the low expression level of hsa_circ_0005986 was correlated with chronic hepatitis B family history (P = 0.001), tumor diameters (P < 0.001), microvascular invasion (P = 0.026), and Barcelona Clinic Liver Cancer (BCLC) stage (P < 0.001). Further experiments demonstrated that both hsa_circ_0005986 and Notch1mRNA were targets of miR-129-5p, and that hsa_circ_0005986 downregulation liberated miR-129-5p and decreased the expression level of Notch1mRNA. More importantly, hsa_circ_0005986 downregulation accelerated cell proliferation by promoting the G0/G1 to S phase transition.*2017-07-01*28410211.0**hsa_circ_0005986/chr1:14057494-14068652*CircR2Disease*hepatocellular carcinoma
417*hsa_circ_0058106*chr2:216246934-216248907*-*FN1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0058106*Squamous Cell Carcinoma of Head and Neck*Upregulated*qPCR etc.*Human*The expression levels of hsa_circ_0058106, hsa_circ_0058107, and hsa_circ_0024108 were significantly higher in tumor tissues than in corresponding normal tissues*2017-07-01*28514762.0**hsa_circ_0058106/chr2:216246934-216248907*CircR2Disease*hypopharyngeal squamous cell carcinoma
418*hsa_circ_0058107*chr2:216246934-216256537*-*FN1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0058107*Squamous Cell Carcinoma of Head and Neck*Upregulated*qPCR etc.*Human*The expression levels of hsa_circ_0058106, hsa_circ_0058107, and hsa_circ_0024108 were significantly higher in tumor tissues than in corresponding normal tissues*2017-07-01*28514762.0**hsa_circ_0058107/chr2:216246934-216256537*CircR2Disease*hypopharyngeal squamous cell carcinoma
419*hsa_circ_0024108*chr11:102660640-102667893*-*MMP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0024108*Squamous Cell Carcinoma of Head and Neck*Upregulated*qPCR etc.*Human*The expression levels of hsa_circ_0058106, hsa_circ_0058107, and hsa_circ_0024108 were significantly higher in tumor tissues than in corresponding normal tissues*2017-07-01*28514762.0**hsa_circ_0024108/chr11:102660640-102667893*CircR2Disease*hypopharyngeal squamous cell carcinoma
420*hsa_circ_0036722*chr15:90019985-90030216*-*RHCG*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0036722*Squamous Cell Carcinoma of Head and Neck*Downregulated*qPCR etc.*Human*hsa_circ_0036722, hsa_circ_0002260, and hsa_circ_0001189 expression levels were significantly decreased in tumor tissues compared with normal controls*2017-07-01*28514762.0**hsa_circ_0036722/chr15:90019985-90030216*CircR2Disease*hypopharyngeal squamous cell carcinoma
421*hsa_circ_0002260*chr5:78936673-78964851*+*PAPD4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002260*Squamous Cell Carcinoma of Head and Neck*Downregulated*qPCR etc.*Human*hsa_circ_0036722, hsa_circ_0002260, and hsa_circ_0001189 expression levels were significantly decreased in tumor tissues compared with normal controls*2017-07-01*28514762.0**hsa_circ_0002260/chr5:78936673-78964851*CircR2Disease*hypopharyngeal squamous cell carcinoma
422*hsa_circ_0001189*chr21:37711076-37717005*+*MORC3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001189*Squamous Cell Carcinoma of Head and Neck*Downregulated*qPCR etc.*Human*hsa_circ_0036722, hsa_circ_0002260, and hsa_circ_0001189 expression levels were significantly decreased in tumor tissues compared with normal controls*2017-07-01*28514762.0**hsa_circ_0001189/chr21:37711076-37717005*CircR2Disease*hypopharyngeal squamous cell carcinoma
423*Cir-ITCH*chr20:33001547-33037285*+*ITCH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001141*Carcinoma, Hepatocellular*Downregulated*qPCR etc.*Human*The expression level of circ-ITCH was significantly lower in HCC tissues, compared with that in adjacent tissues*2017-07-01*28636993.0**Cir-ITCH/hsa_circ_0001141/hsa_circ_001763/chr20:33001547-33037285*CircR2Disease*hepatocellular carcinoma
424*hsa_circ_0013958*chr1:147131074-147131890*-*ACP6*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0013958*Adenocarcinoma of Lung*Upregulated*qPCR, Flow cytometry analysis, Western blot, Luciferase reporter assay, RNA-FISH etc.*Human*hsa_circ_0013958 promoted cell proliferation and invasion and inhibited cell apoptosis in LAC. hsa_circ_0013958 was identified as a sponge of miR-134, and thus it up-regulated oncogenic cyclin D1, which plays a pivotal role in the development of non-small cell lung cancer*2017-07-01*28685964.0**hsa_circ_0013958/chr1:147131074-147131890*CircR2Disease*lung adenocarcinoma
425*hsa_circRNA_103110*chr21:16386664-16415895*-*NRIP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004771*Breast Neoplasms*Upregulated*qPCR etc.*Human*hsa_circ_103110, hsa_circ_104689 and hsa_circ_104821 levels were elevated in breast cancer tissues, whereas hsa_circ_006054, hsa_circ_100219 and hsa_circ_406697 were downregulated. These circRNAs targeted complementary miRNA response elements.*2017-07-01*28484086.0**hsa_circ_103110/hsa_circ_0004771/chr21:16386664-16415895*CircR2Disease*breast cancer
426*hsa_circ_104689*chr8:131164981-131181313*-*ASAP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001824*Breast Neoplasms*Upregulated*qPCR etc.*Human*hsa_circ_103110, hsa_circ_104689 and hsa_circ_104821 levels were elevated in breast cancer tissues, whereas hsa_circ_006054, hsa_circ_100219 and hsa_circ_406697 were downregulated. These circRNAs targeted complementary miRNA response elements.*2017-07-01*28484086.0**hsa_circ_104689/hsa_circ_0001824/chr8:131164981-131181313*CircR2Disease*breast cancer
427*hsa_circ_104821*chr9:96233422-96261168*+*FAM120A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001875*Breast Neoplasms*Upregulated*qPCR etc.*Human*hsa_circ_103110, hsa_circ_104689 and hsa_circ_104821 levels were elevated in breast cancer tissues, whereas hsa_circ_006054, hsa_circ_100219 and hsa_circ_406697 were downregulated. These circRNAs targeted complementary miRNA response elements.*2017-07-01*28484086.0**hsa_circ_104821/hsa_circ_0001875/chr9:96233422-96261168*CircR2Disease*breast cancer
428*hsa_circ_006054*chr19:34818325-34821252*+*KIAA0355*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006054*Breast Neoplasms*Downregulated*qPCR etc.*Human*hsa_circ_103110, hsa_circ_104689 and hsa_circ_104821 levels were elevated in breast cancer tissues, whereas hsa_circ_006054, hsa_circ_100219 and hsa_circ_406697 were downregulated. These circRNAs targeted complementary miRNA response elements.*2017-07-01*28484086.0**hsa_circ_006054/hsa_circ_0006054/chr19:34818325-34821252*CircR2Disease*breast cancer
429*hsa_circ_100219*chr1:51121113-51210447*-*FAF1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004619*Breast Neoplasms*Downregulated*qPCR etc.*Human*hsa_circ_103110, hsa_circ_104689 and hsa_circ_104821 levels were elevated in breast cancer tissues, whereas hsa_circ_006054, hsa_circ_100219 and hsa_circ_406697 were downregulated. These circRNAs targeted complementary miRNA response elements.*2017-07-01*28484086.0**hsa_circ_100219/hsa_circ_0004619/chr1:51121113-51210447*CircR2Disease*breast cancer
430*hsa_circ_406697*****Breast Neoplasms*Downregulated*qPCR etc.*Human*hsa_circ_103110, hsa_circ_104689 and hsa_circ_104821 levels were elevated in breast cancer tissues, whereas hsa_circ_006054, hsa_circ_100219 and hsa_circ_406697 were downregulated. These circRNAs targeted complementary miRNA response elements.*2017-07-01*28484086.0**hsa_circ_406697*CircR2Disease*breast cancer
431*circABCB10*chr1:229665945-229678118*-*ABCB10*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008717*Breast Neoplasms*Upregulated*qPCR, Luciferase reporter assay, CCK-8 proliferation assay,Flow cytometry etc.*Human*Results identified a new functional circ-ABCB10 in breast cancer tumorigenesis, and reveal the important regulatory role of circ-ABCB10 through sponging miR-1271*2017-07-01*28744405.0**circABCB10/hsa_circ_0008717/chr1:229665945-229678118*CircR2Disease*breast cancer
432*hsa_circ_0008945*chr14:51208299-51211083*-*NIN*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008945*Breast Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-07-01*28744405.0**hsa_circ_0008945/chr14:51208299-51211083*CircR2Disease*breast cancer
433*hsa_circ_0000732*chr17:1540002-1540356*-*SCARF1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000732*Breast Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-07-01*28744405.0**hsa_circ_0000732/chr17:1540002-1540356*CircR2Disease*breast cancer
434*hsa_circ_0000098*chr1:101372407-101387397*+*SLC30A7*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000098*Breast Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-07-01*28744405.0**hsa_circ_0000098/chr1:101372407-101387397*CircR2Disease*breast cancer
435*hsa_circ_0001721*chr7:90355880-90356126*+*CDK14*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001721*Breast Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-07-01*28744405.0**hsa_circ_0001721/chr7:90355880-90356126*CircR2Disease*breast cancer
436*hsa_circ_0000911*chr19:17448965-17449496*-*GTPBP3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000911*Breast Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-07-01*28744405.0**hsa_circ_0000911/chr19:17448965-17449496*CircR2Disease*breast cancer
437*hsa_circ_0018293*chr10:47164293-47166311*-**http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0018293*Breast Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-07-01*28744405.0**hsa_circ_0018293/chr10:47164293-47166311*CircR2Disease*breast cancer
438*hsa_circ_0001283*chr3:39108038-39130809*+*WDR48*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001283*Breast Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-07-01*28744405.0**hsa_circ_0001283/chr3:39108038-39130809*CircR2Disease*breast cancer
439*hsa_circ_0000893*chr19:12790270-12791139*-*DHPS*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000893*Breast Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-07-01*28744405.0**hsa_circ_0000893/chr19:12790270-12791139*CircR2Disease*breast cancer
440*hsa_circ_0000981*chr2:20240809-20240905*-*LAPTM4A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000981*Breast Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-07-01*28744405.0**hsa_circ_0000981/chr2:20240809-20240905*CircR2Disease*breast cancer
441*hsa_circRNA_100338***SNX27**Carcinoma, Hepatocellular*Upregulated*qPCR, In vitro invasion assay, Luciferase activity assay etc.*Human*High expression of circRNA_100338, one of the upregulated circRNAs in HCC, is closely correlated with a low cumulative survival rate and metastatic progression in HCC patients with hepatitis B. Furthermore, our in silico and experimental analyses identified miR-141-3p as a direct target of circRNA_100338. Thus, circRNA_100338 functions as an endogenous sponge for miR-141-3p in HCC. In addition, we identified the crucial antagonistic roles of circRNA_100338 and miR-141-3p in the regulation of invasive potential in liver cancer cells. *2017-07-01*28710406.0**hsa_circRNA_100338/circSNX27*CircR2Disease*hepatocellular carcinoma
442*hsa_circRNA_104075***NUP153**Carcinoma, Hepatocellular*Upregulated*qPCR etc.*Human*Uclear*2017-07-01*28710406.0**hsa_circRNA_104075*CircR2Disease*hepatocellular carcinoma
443*hsa_circRNA 102049***TADA2A**Carcinoma, Hepatocellular*Downregulated*qPCR etc.*Human*Uclear*2017-07-01*28710406.0**hsa_circRNA 102049*CircR2Disease*hepatocellular carcinoma
445*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Carcinoma, Non-Small-Cell Lung*Upregulated/Downregulated*qPCR, CCK-8 assay, Colony formation assay, Western blot  etc.*Human*CircHIPK3 could promote cell proliferation by a circHIPK3/miR-379 pathway in NCI-H1299 and NCI-H2170 cells and might be a potential tumor biomarker for NSCLC*2017-07-01*28738961.0**hsa_circRNA_100782/circHIPK3/hsa_circ_0000284/chr11:33307958-33309057*CircR2Disease*non-small cell lung cancer
446*circRNA_000839*****Carcinoma, Hepatocellular*Upregulated*qPCR, Immunofluorescence staining, Western blot, Luciferase assay etc.*Human*miR-200b could mediate RhoA gene and circ_000839 to form endogenous competition*2017-07-01*28695771.0**circRNA_000839*CircR2Disease*hepatocellular carcinoma
447*hsa_circRNA_101238*chr13:28748408-28752072*+*PAN3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004372*Aortic Aneurysm, Thoracic*Upregulated*qPCR etc.*Human*The luciferase reporter was constructed to determine whether hsa_circRNA_101238 can directly target the hsa-miR-320a. The luciferase signal of hsa-miR-320a was suppressed by the wild-type hsa_circRNA_101238, whereas the luciferase signal of hsa-miR-320a was not affected by the mutant hsa_circRNA_101238. Quantitative real-time PCR and Western blot manifested the low expression of hsa-miR-320a and high of MMP9 in human TAD tissues, respectively.*2017-07-01*29137225.0**hsa_circRNA_101238/hsa_circ_0004372/chr13:28748408-28752072*CircR2Disease*thoracic aortic dissection
448*hsa_circRNA_104634*chr8:62593526-62596747*-*ASPH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0084615*Aortic Aneurysm, Thoracic*Upregulated*qPCR etc.*Human*The upregulated hsa_circRNA_104634 and hsa_circRNA_104349 interacted with hsa-miR-145-3p and hsa-miR-26a-3p, respectively that have been demonstrated to increase SMC phenotype or apoptosis*2017-07-01*29137225.0**hsa_circRNA_104634/hsa_circ_0084615/chr8:62593526-62596747*CircR2Disease*thoracic aortic dissection
449*hsa_circRNA_002271*chr2:20974569-20990158*-*C2orf43*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002271*Aortic Aneurysm, Thoracic*Upregulated*qPCR etc.*Human*Upregulated significantly in human TAD as compared to NA*2017-07-01*29137225.0**hsa_circRNA_002271/hsa_circ_0002271/chr2:20974569-20990158*CircR2Disease*thoracic aortic dissection
450*hsa_circRNA_102771*chr2:80772106-80783018*+*CTNNA2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0055377*Aortic Aneurysm, Thoracic*Upregulated*qPCR etc.*Human*Upregulated significantly in human TAD as compared to NA*2017-07-01*29137225.0**hsa_circRNA_102771/hsa_circ_0055377/chr2:80772106-80783018*CircR2Disease*thoracic aortic dissection
451*hsa_circRNA_104349*chr7:40027197-40027857*+*CDK13*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0079929*Aortic Aneurysm, Thoracic*Upregulated*qPCR etc.*Human*The upregulated hsa_circRNA_104634 and hsa_circRNA_104349 interacted with hsa-miR-145-3p and hsa-miR-26a-3p, respectively that have been demonstrated to increase SMC phenotype or apoptosis*2017-07-01*29137225.0**hsa_circRNA_104349/hsa_circ_0079929/chr7:40027197-40027857*CircR2Disease*thoracic aortic dissection
452*hsa_circRNA_102683*chr2:36668400-36669878*+*CRIM1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007386*Aortic Aneurysm, Thoracic*Downregulated*qPCR etc.*Human*The downregulated hsa_circRNA_102683 and hsa_circRNA_104033 inhibited hsa-miR-29b-1-5p and hsa-miR-195-3p, respectively, which has been shown to target the aortic wall apoptosis and ECM degradation or stimulation of the collagen remodeling*2017-07-01*29137225.0**hsa_circRNA_102683/hsa_circ_0007386/chr2:36668400-36669878*CircR2Disease*thoracic aortic dissection
453*hsa_circRNA_005525*chr18:55398858-55399064*-*ATP8B1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005525*Aortic Aneurysm, Thoracic*Downregulated*qPCR etc.*Human*Downregulated significantly in human TAD as compared to NA*2017-07-01*29137225.0**hsa_circRNA_005525/hsa_circ_0005525/chr18:55398858-55399064*CircR2Disease*thoracic aortic dissection
454*hsa_circRNA_103458*chr3:127393233-127393443*+*ABTB1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0067175*Aortic Aneurysm, Thoracic*Downregulated*qPCR etc.*Human*Downregulated significantly in human TAD as compared to NA*2017-07-01*29137225.0**hsa_circRNA_103458/hsa_circ_0067175/chr3:127393233-127393443*CircR2Disease*thoracic aortic dissection
455*CDR1as*chrX:139865339-139866824*+*CDR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001946*Colorectal Neoplasms*Upregulated*qPCR, Colony formation assay, Xenograft animal studies, IHC, Western blot etc.*Human*CiRS-7 is a promising prognostic biomarker in colorectal cancer patients and may serve as a therapeutic target for reducing EGFR-RAF1 activity in colorectal cancer patients.*2017-07-01*28174233.0**CDR1as/ciRS-7/hsa_circ_0001946/chrX:139865339-139866824*CircR2Disease*colorectal cancer
464*Circ-104916***NEK6**Stomach Neoplasms*Downregulated*qPCR, Western blot, In vitro cell migration and invasion assay etc.*Human*A lower expression of circ-104916 appeared in deeper invasion depth, higher tumor stage and more frequent lymphatic metastasis patients. Overexpression of circ-104916 effectively inhibited the proliferation, migration and invasion abilities of GC cells in vitro. Western blot showed that circ-104916 overexpression upregulated E-cadherin and downregulated N-cadherin, Vimentin and Slug, indicating that circ-104916 was involved in the epithelial-mesenchymal transition process.*2017-07-01*28761361.0**Circ-104916*CircR2Disease*gastric cancer
465*cir-GLI2*chr2:121708818-121713006*+*GLI2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0056288*Osteosarcoma*Upregulated*qPCR, Luciferase reporter gene assay, Colony formation assay, Flow cytometry, Transwell assay etc.*Human*cir-GLI2 silencing could effectively suppress the proliferation, migration, and invasion capacity of osteosarcoma cells, indicating the tumor-promoting role. Besides, bioinformatics analysis and luciferase reporter assay predicted the direct binding to miR-125b-5p, which has been reported to function as a tumor suppressor in osteosarcoma. Furthermore, functional experiments validated that cir-GLI2 exerted the tumor-promoting effects on osteosarcoma cells via negatively targeting miR-125b-5p.*2017-07-01*28695772.0**cir-GLI2/hsa_circ_0056288/chr2:121708818-121713006*CircR2Disease*osteosarcoma
466*circZNF609*chr15:64791491-64792365*+*ZNF609*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000615*Diabetic Retinopathy*Upregulated*qPCR etc.*Human*cZNF609 expression in the fibrovascular membranes of diabetic patients was significantly higher than that in the idiopathic epiretinal membranes of non-diabetic patients*2017-07-01*28824721.0**cZNF609/hsa_circ_0000615/chr15:64791491-64792365*CircR2Disease*diabetic retinopathy
467*circZNF609*chr15:64791491-64792365*+*ZNF609*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000615*Hypertension*Downregulated*qPCR etc.*Human*circulating levels of cZNF609 were down-regulated in the patients with coronary artery disease (CAD) or hypertension compared with healthy volunteers*2017-07-01*28824721.0**cZNF609/hsa_circ_0000615/chr15:64791491-64792365*CircR2Disease*hypertension
468*circZNF609*chr15:64791491-64792365*+*ZNF609*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000615*Coronary Artery Disease*Downregulated*qPCR etc.*Human*circulating levels of cZNF609 were down-regulated in the patients with coronary artery disease (CAD) or hypertension compared with healthy volunteers*2017-07-01*28824721.0**cZNF609/hsa_circ_0000615/chr15:64791491-64792365*CircR2Disease*coronary artery disease
469*circUBAP2***UBAP2**Osteosarcoma*Upregulated*qPCR etc.*Human*circUBAP2 was found to inhibit the expression of microRNA-143 (miR-143), thus enhancing the expression and function of anti-apoptotic Bcl-2, which is a direct target of miR-143*2017-06-01*28977896.0**circUBAP2*CircR2Disease*osteosarcoma
471*hsa_circ_0014717*chr1:156290629-156304709*-*CCT3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0014717*Stomach Neoplasms*Downregulated*qPCR etc.*Human*Hsa_circ_0014717 stably exists in human gastric juice and significantly decreased in chronic atrophic gastritis group*2017-06-01*28544609.0**hsa_circ_0014717/chr1:156290629-156304709*CircR2Disease*gastric cancer
472*hsa_circ_0007031*chr13:113158345-113181798*-*TUBGCP3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007031*Colorectal Neoplasms*Upregulated*qPCR etc.*Human*miR-885-3p targets hsa_circ_0007031, which was found highly upregulated in this study, we inferred that hsa_circ_0007031 might play a crucial role in the development of CRR.*2017-06-01*28656150.0**hsa_circ_0007031/chr13:113158345-113181798*CircR2Disease*colorectal cancer
473*hsa_circ_0000504*chr13:113170753-113181798*-*TUBGCP3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000504*Colorectal Neoplasms*Upregulated*qPCR etc.*Human*STAT3 was a target gene of hsa-miR-485-5p, which could interact with hsa_circ_0000504*2017-06-01*28656150.0**hsa_circ_0000504/chr13:113170753-113181798*CircR2Disease*colorectal cancer
474*hsa_circ_0007006*chr18:46783379-46808545*-*DYM*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007006*Colorectal Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-06-01*28656150.0**hsa_circ_0007006/chr18:46783379-46808545*CircR2Disease*colorectal cancer
475*hsa_circ_0074930*chr5:168233450-168250336*-*SLIT3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0074930*Colorectal Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2017-06-01*28656150.0**hsa_circ_0074930/chr5:168233450-168250336*CircR2Disease*colorectal cancer
476*hsa_circ_0048232*chr19:1417498-1422395*+*DAZAP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0048232*Colorectal Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-06-01*28656150.0**hsa_circ_0048232/chr19:1417498-1422395*CircR2Disease*colorectal cancer
477*hsa_circ_0006174*chr9:110064315-110068928*+*RAD23B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006174*Colorectal Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-06-01*28656150.0**hsa_circ_0006174/chr9:110064315-110068928*CircR2Disease*colorectal cancer
478*hsa_circ_0008509*chr12:78334098-78415642*+*NAV3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008509*Colorectal Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-06-01*28656150.0**hsa_circ_0008509/chr12:78334098-78415642*CircR2Disease*colorectal cancer
479*hsa_circ_0084021*chr8:38801306-38803739*+*PLEKHA2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0084021*Colorectal Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2017-06-01*28656150.0**hsa_circ_0084021/chr8:38801306-38803739*CircR2Disease*colorectal cancer
480*circRNA_104871***SUSD1**Arthritis, Rheumatoid*Upregulated*qPCR etc.*Human*Identified and verified five circRNAs (092516, 003524, 103047, 104871, 101873) that were significantly elevated in PBMCs from RA patients. Among these RA patients, we detected no significant correlation between the five circRNAs and the disease severity, including disease activity score (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and health assessment questionnaire (HAQ). Yet, ROC curve analysis suggested that circRNA_104871 has significant value of RA diagnosis (AUC=0.833, P<0.001), followed by circRNA_003524 (AUC = 0.683, P = 0.020), circRNA_101873 (AUC = 0.676, P = 0.026), and circRNA_103047 (AUC = 0.671, P = 0.030)*2017-06-01*28618429.0**circRNA_104871*CircR2Disease*rheumatoid arthritis
481*circRNA_003524***FAM168B**Arthritis, Rheumatoid*Upregulated*qPCR etc.*Human*Identified and verified five circRNAs (092516, 003524, 103047, 104871, 101873) that were significantly elevated in PBMCs from RA patients. Among these RA patients, we detected no significant correlation between the five circRNAs and the disease severity, including disease activity score (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and health assessment questionnaire (HAQ). Yet, ROC curve analysis suggested that circRNA_104871 has significant value of RA diagnosis (AUC=0.833, P<0.001), followed by circRNA_003524 (AUC = 0.683, P = 0.020), circRNA_101873 (AUC = 0.676, P = 0.026), and circRNA_103047 (AUC = 0.671, P = 0.030)*2017-06-01*28618429.0**circRNA_003524*CircR2Disease*rheumatoid arthritis
482*circRNA_101873***GLG1**Arthritis, Rheumatoid*Upregulated*qPCR etc.*Human*Identified and verified five circRNAs (092516, 003524, 103047, 104871, 101873) that were significantly elevated in PBMCs from RA patients. Among these RA patients, we detected no significant correlation between the five circRNAs and the disease severity, including disease activity score (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and health assessment questionnaire (HAQ). Yet, ROC curve analysis suggested that circRNA_104871 has significant value of RA diagnosis (AUC=0.833, P<0.001), followed by circRNA_003524 (AUC = 0.683, P = 0.020), circRNA_101873 (AUC = 0.676, P = 0.026), and circRNA_103047 (AUC = 0.671, P = 0.030)*2017-06-01*28618429.0**circRNA_101873*CircR2Disease*rheumatoid arthritis
483*circRNA_103047***PHF20**Arthritis, Rheumatoid*Upregulated*qPCR etc.*Human*Identified and verified five circRNAs (092516, 003524, 103047, 104871, 101873) that were significantly elevated in PBMCs from RA patients. Among these RA patients, we detected no significant correlation between the five circRNAs and the disease severity, including disease activity score (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and health assessment questionnaire (HAQ). Yet, ROC curve analysis suggested that circRNA_104871 has significant value of RA diagnosis (AUC=0.833, P<0.001), followed by circRNA_003524 (AUC = 0.683, P = 0.020), circRNA_101873 (AUC = 0.676, P = 0.026), and circRNA_103047 (AUC = 0.671, P = 0.030)*2017-06-01*28618429.0**circRNA_103047*CircR2Disease*rheumatoid arthritis
484*circRNA_092516***XBP1**Arthritis, Rheumatoid*Upregulated*qPCR etc.*Human*Identified and verified five circRNAs (092516, 003524, 103047, 104871, 101873) that were significantly elevated in PBMCs from RA patients. Among these RA patients, we detected no significant correlation between the five circRNAs and the disease severity, including disease activity score (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and health assessment questionnaire (HAQ). Yet, ROC curve analysis suggested that circRNA_104871 has significant value of RA diagnosis (AUC=0.833, P<0.001), followed by circRNA_003524 (AUC = 0.683, P = 0.020), circRNA_101873 (AUC = 0.676, P = 0.026), and circRNA_103047 (AUC = 0.671, P = 0.030)*2017-06-01*28618429.0**circRNA_092516*CircR2Disease*rheumatoid arthritis
485*hsa_circ_0006633*chr1:59805629-59844509*+*FGGY*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006633*Stomach Neoplasms*Downregulated*qPCR, Immunohistochemical analysis etc.*Human*Expression levels of hsa_circ_0006633 in four gastric cancer cell lines, HGC-27, SGC-7901, MGC-803, and AGS, were downregulated than those in normal gastric mucosal epithelial cell line GES-1. The lower expression of hsa_circ_0006633 was associated with cancer distal metastasis ( p = 0.037) and tissue carcinoembryonic antigen level ( p = 0.041). In addition, hsa_circ_0006633 expression was significantly decreased in gastritis and dysplasia tissues comparing with the healthy control. Moreover, plasma hsa_circ_0006633 levels were significantly increased in gastric cancer compared with healthy control.*2017-06-01*28656881.0**hsa_circ_0006633/chr1:59805629-59844509*CircR2Disease*gastric cancer
486*hsa_circ_0058246*chr2:219305444-219305585*+*VIL1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0058246*Stomach Neoplasms*Upregulated*qPCR etc.*Human*The expression of hsa_circ_0058246 was elevated in tumor specimens of patients with poor clinical outcomes.*2017-06-01*28639908.0**hsa_circ_0058246/chr2:219305444-219305585*CircR2Disease*gastric cancer
487*hsa_circ_0091742*chrX:152770695-152775004*+*BGN*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0091742*Stomach Neoplasms*Upregulated*qPCR etc.*Human*These circular RNAs play a critical role in gastric cancer tumorigenesis.*2017-06-01*28639908.0**hsa_circ_0091742/chrX:152770695-152775004*CircR2Disease*gastric cancer
488*hsa_circ_0089548*chr9:139399761-139410168*-*NOTCH1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0089548*Stomach Neoplasms*Upregulated*qPCR etc.*Human*These circular RNAs play a critical role in gastric cancer tumorigenesis.*2017-06-01*28639908.0**hsa_circ_0089548/chr9:139399761-139410168*CircR2Disease*gastric cancer
489*hsa_circ_0003707*chr11:35219667-35232996*+*CD44*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003707*Stomach Neoplasms*Upregulated*qPCR etc.*Human*These circular RNAs play a critical role in gastric cancer tumorigenesis.*2017-06-01*28639908.0**hsa_circ_0003707/chr11:35219667-35232996*CircR2Disease*gastric cancer
490*hsa_circ_0085553*chr8:129001407-129082518*+*PVT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0085553*Stomach Neoplasms*Upregulated*qPCR etc.*Human*These circular RNAs play a critical role in gastric cancer tumorigenesis.*2017-06-01*28639908.0**hsa_circ_0085553/chr8:129001407-129082518*CircR2Disease*gastric cancer
491*hsa_circ_0006022*chr8:56863017-56866543*+*LYN*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006022*Stomach Neoplasms*Upregulated*qPCR etc.*Human*These circular RNAs play a critical role in gastric cancer tumorigenesis.*2017-06-01*28639908.0**hsa_circ_0006022/chr8:56863017-56866543*CircR2Disease*gastric cancer
492*hsa_circ_0031979*chr14:54884565-54884669*+*CDKN3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0031979*Stomach Neoplasms*Downregulated*qPCR etc.*Human*These circular RNAs play a critical role in gastric cancer tumorigenesis.*2017-06-01*28639908.0**hsa_circ_0031979/chr14:54884565-54884669*CircR2Disease*gastric cancer
493*hsa_circ_0069131*chr4:7783102-7873807*-*AFAP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0069131*Stomach Neoplasms*Downregulated*qPCR etc.*Human*These circular RNAs play a critical role in gastric cancer tumorigenesis.*2017-06-01*28639908.0**hsa_circ_0069131/chr4:7783102-7873807*CircR2Disease*gastric cancer
494*circRNA_100269*****Stomach Neoplasms*Downregulated*qPCR, Dual-Luciferase assay etc.*Human*circRNA_100269 level was downregulated in GC and correlated negatively with that of miR-630*2017-06-01*28657541.0**circRNA_100269*CircR2Disease*gastric cancer
496*hsa_circRNA_000598*****Osteoarthritis*Upregulated*qPCR etc.*Human*The inhibition of circRNAs-MSR could inhibit the degradation of chondrocyte ECM and knockdown of circRNAs-MSR could be a potential therapeutic target for OA.*2017-06-01*28624198.0**hsa_circRNA_000598*CircR2Disease*osteoarthritis
497*hsa_circRNA_103387*****Osteoarthritis*Upregulated*qPCR etc.*Human*The inhibition of circRNAs-MSR could inhibit the degradation of chondrocyte ECM and knockdown of circRNAs-MSR could be a potential therapeutic target for OA.*2017-06-01*28624198.0**hsa_circRNA_103387*CircR2Disease*osteoarthritis
498*hsa_circRNA_101975*****Osteoarthritis*Upregulated*qPCR etc.*Human*The inhibition of circRNAs-MSR could inhibit the degradation of chondrocyte ECM and knockdown of circRNAs-MSR could be a potential therapeutic target for OA.*2017-06-01*28624198.0**hsa_circRNA_101975*CircR2Disease*osteoarthritis
499*hsa_circ_100226*chr1:51868106-51874004*-*EPS15*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005567*Osteoarthritis*Upregulated*qPCR, RNAi, Immunofluorescence analysis etc.*Human*circRNAs-MSR were silenced using small interfering RNA, and knockdown of circRNAs-MSR could suppress tumor necrosis factor alpha (TNF-α) expression and increase extracellular matrix (ECM) formation. *2017-06-01*28624198.0**circRNA-MSR/hsa_circ_0005567/chr1:51868106-51874004*CircR2Disease*osteoarthritis
500*hsa_circRNA_100750*chr11****Fatty Liver*Downregulated*qPCR etc.*Human*Unclear*2017-06-01*28717649.0**hsa_circRNA_002082/chr11*CircR2Disease*hepatic steatosis
501*hsa_circRNA_100750*chr11****Fatty Liver*Downregulated*qPCR etc.*Human*Unclear*2017-06-01*28717649.0**hsa_circRNA_000367/chr11*CircR2Disease*hepatic steatosis
502*CircDOCK1*chr10****Fatty Liver*Downregulated*qPCR etc.*Human*Unclear*2017-06-01*28717649.0**hsa_circRNA_004183/chr10*CircR2Disease*hepatic steatosis
503*circRNA0047905*chr9****Fatty Liver*Upregulated*qPCR etc.*Human*Unclear*2017-06-01*28717649.0**hsa_circRNA_007850/chr9*CircR2Disease*hepatic steatosis
504*hsa_circRNA_102619*chr2****Fatty Liver*Upregulated*qPCR etc.*Human*Unclear*2017-06-01*28717649.0**hsa_circRNA_004121/chr2*CircR2Disease*hepatic steatosis
505*rno_circRNA_001167*chr1****Fatty Liver*Upregulated*qPCR etc.*Human*Unclear*2017-06-01*28717649.0**hsa_circRNA_014724/chr1*CircR2Disease*hepatic steatosis
507*hsa_circ_0000096*chr1:100515464-100535241*+*HIAT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000096*Carcinoma, Renal Cell*Downregulated*qPCR, Luciferase reporter assay, Western blot, RNA pull-down assay, ChIP assay etc.*Human*circHIAT1 functioned as a metastatic inhibitor to suppress AR-enhanced ccRCC cell migration and invasion. Targeting this newly identified AR-circHIAT1-mediated miR-195-5p/29a-3p/29c-3p/CDC42 signals may help us develop potential new therapies to better suppress ccRCC metastasis.*2017-05-01*28089832.0**hsa_circ_0000096/circHIAT1/hsa_circ_001013/chr1:100515464-100535241*CircR2Disease*clear cell renal cell carcinoma
508*hsa_circ_0001313*chr3:56626997-56628056*+*CCDC66*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001313*Colorectal Neoplasms*Upregulated*qPCR etc.*Human*Functions as miR-33b, miR-93 and miR185 sponge for a subset of oncogenes. circCCDC66 controlled multiple pathological processes, including cell proliferation, migration, invasion, and anchorage-independent growth.*2017-05-01*28249903.0**hsa_circ_0001313/circCCDC66/chr3:56626997-56628056*CircR2Disease*colorectal cancer
509*hsa_circ_0001313*chr3:56626997-56628056*+*CCDC66*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001313*Pancreatic Neoplasms*Upregulated*qPCR etc.*Human*Functiona as miR-33b, miR-93 sponges*2017-05-01*28249903.0**hsa_circ_0001313/circCCDC66/chr3:56626997-56628056*CircR2Disease*pancreatic cancer
510*hsa_circ_0001313*chr3:56626997-56628056*+*CCDC66*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001313*Breast Neoplasms*Upregulated*qPCR etc.*Human*Function as miRNA sponge of miR-33b and miR-93*2017-05-01*28249903.0**hsa_circ_0001313/circCCDC66/chr3:56626997-56628056*CircR2Disease*breast cancer
511*hsa_circ_0001313*chr3:56626997-56628056*+*CCDC66*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001313*Uterine Cervical Neoplasms*Upregulated*qPCR etc.*Human*Function as miRNA sponge of miR-33b and miR-93*2017-05-01*28249903.0**hsa_circ_0001313/circCCDC66/chr3:56626997-56628056*CircR2Disease*cervical cancer
512*hsa_circRNA_100709*chr10:126370175-126384781*-*FAM53B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003570*Carcinoma, Hepatocellular*Downregulated*qPCR etc.*Human*hsa_circ_0003570 was gradually decreased from chronic hepatitis (CH), to liver cirrhosis (LC) and to HCC tissues (P<.01). Its expression levels were significantly correlated with tumor diameter (P=.035), differentiation (P=.013), microvascular invasion (P=.045), Barcelona Clinic Liver Cancer stages (P=.011), tumor-node-metastasis stages (P=.016), and serum alpha-fetoprotein levels (P=.031).*2017-05-01*28493512.0**hsa_circ_0003570/chr10:126370175-126384781*CircR2Disease*hepatocellular carcinoma
513*hsa_circ_0023404*chr11:71668272-71671937*+*RNF121*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023404*Carcinoma, Non-Small-Cell Lung*Upregulated*qPCR etc.*Human*There was a close correlation between the circRNA_100876 up-regulation expression and lymph node metastasis (P = 0.001) and tumor staging (P = 0.001) in NSCLC. In addition, Kaplan-Meier survival analysis demonstrated that the overall survival time of NSCLC patients with high circRNA_100876 expression was significantly shorter than those patients with low circRNA_100876 expression (P = 0.000).*2017-05-01*28343871.0**hsa_circ_0023404/circRNA_100876/circ-CER/chr11:71668272-71671937*CircR2Disease*non-small cell lung cancer
514*hsa_circ_0005870*chr3:47079155-47088111*-*SETD2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005870*Hypertension*Downregulated*qPCR etc.*Human*hsa-circ-0005870 may represent a novel biomarker for the diagnosis of hypertension, and hsa-circ-0005870-miRNA-mRNA network may provide potential mechanism for hypertension*2017-05-01*28534714.0**hsa_circ_0005870/chr3:47079155-47088111*CircR2Disease*hypertension
515*circ-Foxo3*chr6:108984657-108986092*+*FOXO3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006404**Upregulated*qPCR, Western blot, Immunohistochemistry etc.*Human*ID-1, E2F1, FAK, and HIF1α interact with circ-Foxo3 and are retained in the cytoplasm and could no longer exert their anti-senescent and anti-stress roles, resulting in increased cellular senescence.*2017-05-01*26873092.0**circ-Foxo3/hsa_circ_0006404/chr6:108984657-108986092*CircR2Disease*myocardial senescence
517*hsa_circ_0001895*chr9:134305476-134308181*+*PRRC2B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001895*Stomach Neoplasms*Downregulated*qPCR etc.*Human*Compared with healthy control tissues, it was downregulated not only in 69.8% (67/96) gastric cancer tissues but also in gastric precancerous lesions. Moreover, hsa_circ_0001895 expression levels were significantly correlated with cell differentiation, Borrmann type, and tissue carcino-embryonic antigen expression*2017-04-01*28443463.0**hsa_circ_0001895/circPRRC2B/hsa_circ_000760/chr9:134305476-134308181*CircR2Disease*gastric cancer
518*circ-BANP***BANP**Colorectal Neoplasms*Upregulated*qPCR, Western blot, RNAi, In situ hybridization,  Colony formation assay etc.*Human*Knockdown of circ-BANP with siRNA significantly attenuate the proliferation of CRC cells*2017-04-01*28103507.0**circ-BANP*CircR2Disease*colorectal cancer
519*circZKSCAN1*chr7:99621041-99621930*+*ZKSCAN1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001727*Carcinoma, Hepatocellular*Downregulated*qPCR etc.*Human*Silencing  circZKSCAN1 promoted cell proliferation, migration, and invasion. circZKSCAN1 mediated several cancer-related signaling pathways*2017-04-01*28211215.0**circZKSCAN1/hsa_circ_0001727/chr7:99621041-99621930*CircR2Disease*hepatocellular carcinoma
520*hsa_circ_0004018*chr17:1703150-1704318*-*SMYD4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004018*Carcinoma, Hepatocellular*Downregulated*qRT-PCR, Electrophoresis etc.*Human*The expression levels of hsa_circ_0004018 in HCC were significantly lower compared with para-tumorous tissue.sa_circ_0004018 harbored HCC-stage-specific expression features in diverse chronic liver diseases*2017-04-01*28938566.0**hsa_circ_0004018/chr17:1703150-1704318*CircR2Disease*hepatocellular carcinoma
521*circBRAF*chr7:140476711-140494267*-*BRAF*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006460*Glioblastoma*Downregulated*qPCR etc.*Human*CircBRAF was significantly lower in glioma patients with high pathological grade (WHO III & IV) than those with low grade (WHO I & II) (P < .001). Cox analysis revealed that high circBRAF expression was an independent biomarker for predicting good progression-free survival and overall survival in glioma patients (HR = 0.413, 95% CI 0.201-0.849; HR = 0.299, 95% CI 0.135-0.661; respectively)*2017-04-01*28236760.0**circBRAF/hsa_circ_0006460/chr7:140476711-140494267*CircR2Disease*glioblastoma
522*hsa_circ_0005603*chr17:11958205-12016677*-*MAP2K4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005603*Glioblastoma*Downregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**hsa_circ_0005603/chr17:11958205-12016677*CircR2Disease*glioblastoma
523*hsa_circ_0008345*chr8:141828375-141874498*-*PTK2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008345*Glioblastoma*Downregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**hsa_circ_0008345/chr8:141828375-141874498*CircR2Disease*glioblastoma
524*hsa_circ_0004872*chr22:22153300-22162135*-*MAPK1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004872*Glioblastoma*Downregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**hsa_circ_0004872/chr22:22153300-22162135*CircR2Disease*glioblastoma
525*hsa_circ_0006411*chr5:67522117-67522837*+*PIK3R1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006411*Glioblastoma*Downregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**hsa_circ_0006411/chr5:67522117-67522837*CircR2Disease*glioblastoma
526*hsa_circ_0003586*chr17:29550461-29554624*+*NF1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003586*Glioblastoma*Downregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**hsa_circ_0003586/chr17:29550461-29554624*CircR2Disease*glioblastoma
527*hsa_circ_0002968*chr10:49609654-49618211*+*MAPK8*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002968*Glioblastoma*Downregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**hsa_circ_0002968/chr10:49609654-49618211*CircR2Disease*glioblastoma
528*hsa_circ_0000199*chr1:243708811-243736350*-*AKT3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000199*Glioblastoma*Downregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**hsa_circ_0000199/chr1:243708811-243736350*CircR2Disease*glioblastoma
529*chr4:103501692-103504114*chr4:103501692-103504114*+***Glioblastoma*Downregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**chr4:103501692-103504114/chr4:103501692-103504114*CircR2Disease*glioblastoma
530*hsa_circ_0001566*chr5:179688683-179707608*-*MAPK9*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001566*Glioblastoma*Downregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**hsa_circ_0001566/chr5:179688683-179707608*CircR2Disease*glioblastoma
531*chr18:107887-108499*chr18:107887-108499*-***Glioblastoma*Upregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**chr18:107887-108499/chr18:107887-108499*CircR2Disease*glioblastoma
532*chr19:5761476-5761630*chr19:5761476-5761630*+***Glioblastoma*Upregulated*qPCR etc.*Human*Unclear*2017-04-01*28236760.0**chr19:5761476-5761630/chr19:5761476-5761630*CircR2Disease*glioblastoma
537*CDR1as*chrX:139865339-139866824*+*CDR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001946*Colorectal Neoplasms*Upregulated*qPCR, Western blot etc.*Human*CDR1as had a higher expression in CRC tissues compared to adjacent, normal mucosa and was positively associated with tumor size, T stage, lymph node metastasis, and poor overall survival (OS). Downregulation of CDR1as suppressed CRC cell proliferation and invasion and increased microRNA-7 (miR-7) expression. Intriguingly, ectopic expression of miR-7 in CRC cells consistently inhibited proliferation and invasion, and the miR-7 inhibitor was able to rescue the function of CDR1as knockdown. *2017-04-01*28435295.0**CDR1as/ciRS-7/hsa_circ_0001946/chrX:139865339-139866824*CircR2Disease*colorectal cancer
538*circPVT1*chr8:128902834-128903244*+*TCONS_00015354*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001821*Lung Neoplasms*Upregulated*qPCR, Western blot, RIP, Dual-Glo luciferase assay etc.*Human*Measurement of CircPVT1 levels in three sets of cancerous and non-cancerous cell lines (Figure ​(Figure6D)6D) revealed that both CircPVT1 and PVT1 were higher in lung (A549, H1299) and breast (MCF7) carcinoma cell lines than in non-cancerous cell lines from lung (epithelial BEAS-2B cells and IMR-90 fibroblasts) and breast (MCF10A epithelial cells). By acting as a decoy for let-7, CircPVT1 promotes cell proliferation.*2017-04-01*27928058.0**circPVT1/hsa_circ_0001821/chr8:128902834-128903244*CircR2Disease*lung cancer
539*circPVT1*chr8:128902834-128903244*+*TCONS_00015354*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001821*Breast Neoplasms*Upregulated*qPCR, Western blot, RIP, Dual-Glo luciferase assay etc.*Human*Measurement of CircPVT1 levels in three sets of cancerous and non-cancerous cell lines (Figure ​(Figure6D)6D) revealed that both CircPVT1 and PVT1 were higher in lung (A549, H1299) and breast (MCF7) carcinoma cell lines than in non-cancerous cell lines from lung (epithelial BEAS-2B cells and IMR-90 fibroblasts) and breast (MCF10A epithelial cells)*2017-04-01*27928058.0**circPVT1/hsa_circ_0001821/chr8:128902834-128903244*CircR2Disease*breast cancer
540*hsa_circRNA_101308*****Stomach Neoplasms*Upregulated*qPCR etc.*Human*hsa_circRNA_101308, hsacircRNA_104423, hsa_circRNA_104916, and hsa_circRNA_100269, this four-circRNA-based classifier yielded a predictive ability to the early recurrence of stage III gastric cancer after radical surgery.*2017-04-01*28206972.0**hsa_circRNA_101308*CircR2Disease*gastric cancer
541*hsa_circ_0001721*****Stomach Neoplasms*Downregulated*qPCR etc.*Human*hsa_circRNA_101308, hsacircRNA_104423, hsa_circRNA_104916, and hsa_circRNA_100269, this four-circRNA-based classifier yielded a predictive ability to the early recurrence of stage III gastric cancer after radical surgery.*2017-04-01*28206972.0**hsa_circRNA_104423*CircR2Disease*gastric cancer
542*hsa_circRNA_100269*****Stomach Neoplasms*Downregulated*qPCR etc.*Human*hsa_circRNA_101308, hsacircRNA_104423, hsa_circRNA_104916, and hsa_circRNA_100269, this four-circRNA-based classifier yielded a predictive ability to the early recurrence of stage III gastric cancer after radical surgery.*2017-04-01*28206972.0**hsa_circRNA_100269*CircR2Disease*gastric cancer
543*hsa_circRNA_104916*****Stomach Neoplasms*Downregulated*qPCR etc.*Human*hsa_circRNA_101308, hsacircRNA_104423, hsa_circRNA_104916, and hsa_circRNA_100269, this four-circRNA-based classifier yielded a predictive ability to the early recurrence of stage III gastric cancer after radical surgery.*2017-04-01*28206972.0**hsa_circRNA_104916*CircR2Disease*gastric cancer
544*hsa_circ_0016347*****Osteosarcoma*Upregulated*qPCR, Luciferase assay, Immunocytochemistry, Xenograft mouse model etc.*Human*circ-0016347 acted as a positive regulator in osteosarcoma cells proliferation and invasion. Moreover, circ-0016347 was identified as a sponge of miR-214 that upregulated the expression of caspase-1, which is the functional target of miR-214. *2017-04-01*28424426.0**hsa_circ_0016347*CircR2Disease*osteosarcoma
545*hsa_circ_0000190*chr1:224553580-224559125*+*CNIH4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000190*Stomach Neoplasms*Downregulated*qPCR etc.*Human*Its expression levels were significantly correlated with tumor diameter (P=0.034), lymphatic metastasis (P=0.026), distal metastasis (P=0.001), TNM stage (P=0.001), and CA19-9 levels (P=0.019). *2017-03-01*28130019.0**hsa_circ_0000190/chr1:224553580-224559125*CircR2Disease*gastric cancer
546*circPVT1*chr8:128902834-128903244*+*PVT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001821*Stomach Neoplasms*Upregulated*qPCR, Luciferase reporter assay etc.*Human*The expression of circPVT1 is often upregulated in GC tissues due to the amplification of its genomic locus, promotes cell proliferation：miR-125a/b,circPVT1 acts as a proliferative factor and a good prognostic marker in gastric cancer.*2017-03-01*27986464.0**circPVT1/hsa_circ_0001821/chr8:128902834-128903244*CircR2Disease*gastric cancer
547*hsa_circRNA_400071*****Stomach Neoplasms*Upregulated*qPCR etc.*Human*We randomly verified three circRNAs (hsa_circRNA_400071, hsa_circRNA_000792 and hsa_circRNA_000543) with upregulated expression and three circRNAs (hsa_circRNA_001959, hsa_circRNA_400066 and hsa_circRNA_001066) with downregulated expression.*2017-03-01*28184940.0**hsa_circRNA_400071*CircR2Disease*gastric cancer
548*hsa_circRNA_000792*****Stomach Neoplasms*Upregulated*qPCR etc.*Human*We randomly verified three circRNAs (hsa_circRNA_400071, hsa_circRNA_000792 and hsa_circRNA_000543) with upregulated expression and three circRNAs (hsa_circRNA_001959, hsa_circRNA_400066 and hsa_circRNA_001066) with downregulated expression.*2017-03-01*28184940.0**hsa_circRNA_000792*CircR2Disease*gastric cancer
549*hsa_circRNA_000543*****Stomach Neoplasms*Upregulated*qPCR etc.*Human*We randomly verified three circRNAs (hsa_circRNA_400071, hsa_circRNA_000792 and hsa_circRNA_000543) with upregulated expression and three circRNAs (hsa_circRNA_001959, hsa_circRNA_400066 and hsa_circRNA_001066) with downregulated expression.*2017-03-01*28184940.0**hsa_circRNA_000543*CircR2Disease*gastric cancer
550*hsa_circRNA_001959*****Stomach Neoplasms*Downregulated*qPCR etc.*Human*We randomly verified three circRNAs (hsa_circRNA_400071, hsa_circRNA_000792 and hsa_circRNA_000543) with upregulated expression and three circRNAs (hsa_circRNA_001959, hsa_circRNA_400066 and hsa_circRNA_001066) with downregulated expression.*2017-03-01*28184940.0**hsa_circRNA_001959*CircR2Disease*gastric cancer
551*hsa_circRNA_400066*****Stomach Neoplasms*Downregulated*qPCR etc.*Human*We randomly verified three circRNAs (hsa_circRNA_400071, hsa_circRNA_000792 and hsa_circRNA_000543) with upregulated expression and three circRNAs (hsa_circRNA_001959, hsa_circRNA_400066 and hsa_circRNA_001066) with downregulated expression.*2017-03-01*28184940.0**hsa_circRNA_400066*CircR2Disease*gastric cancer
552*hsa_circRNA_001066*****Stomach Neoplasms*Downregulated*qPCR etc.*Human*We randomly verified three circRNAs (hsa_circRNA_400071, hsa_circRNA_000792 and hsa_circRNA_000543) with upregulated expression and three circRNAs (hsa_circRNA_001959, hsa_circRNA_400066 and hsa_circRNA_001066) with downregulated expression.*2017-03-01*28184940.0**hsa_circRNA_001066*CircR2Disease*gastric cancer
553*circZFR*chr5*-*ZFR**Colorectal Neoplasms*Downregulated*qPCR etc.*Human*The expression level of hsa_circRNA_103809 was significantly correlated with lymph node metastasis (p = 0.021) and tumor-node-metastasis stage (p = 0.011)*2017-03-01*28349836.0**hsa_circRNA_103809/chr5*CircR2Disease*colorectal cancer
554*hsa_circ_0003221*chr8*-*PTK2**Colorectal Neoplasms*Downregulated*qPCR etc.*Human*The expression level of hsa_circRNA_104700 was significantly correlated with distal metastasis (p = 0.036)*2017-03-01*28349836.0**hsa_circRNA_104700/chr8*CircR2Disease*colorectal cancer
555*hsa circ 0031288*chr14:23793346-23793498*+*PABPN1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0031288*Uterine Cervical Neoplasms*Upregulated*qPCR, Western blot, RIP, Biotin pulldown assay etc.*Human*One of the most prominent HuR target circRNAs was hsa_circ_0031288, renamed CircPABPN1 as it arises from the PABPN1 pre-mRNA. Further analysis revealed that HuR did not influence CircPABPN1 abundance; interestingly, however, high levels of CircPABPN1 suppressed HuR binding to PABPN1 mRNA. Evaluation of PABPN1 mRNA polysomes indicated that PABPN1 translation was modulated positively by HuR and hence negatively by CircPABPN1.*2017-03-01*28080204.0**hsa circ 0031288/circPABPN1/chr14:23793346-23793498*CircR2Disease*cervical carcinoma
556*hsa_circ_0002343*chr1:235643369-235658138*-*B3GALNT2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002343*Uterine Cervical Neoplasms*Upregulated*qPCR, Western blot, RIP, Biotin pulldown assay etc.*Human*Unclear*2017-03-01*28080204.0**hsa_circ_0002343/chr1:235643369-235658138*CircR2Disease*cervical carcinoma
557*hsa_circ_0069399*chr4:36230203-36231267*-*ARAP2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0069399*Uterine Cervical Neoplasms*Upregulated*qPCR, Western blot, RIP, Biotin pulldown assay etc.*Human*Unclear*2017-03-01*28080204.0**hsa_circ_0069399/chr4:36230203-36231267*CircR2Disease*cervical carcinoma
558*hsa_circRNA_102683*chr2:36668400-36669878*+*CRIM1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007386*Uterine Cervical Neoplasms*Upregulated*qPCR, Western blot, RIP, Biotin pulldown assay etc.*Human*Unclear*2017-03-01*28080204.0**hsa_circ_0007386/chr2:36668400-36669878*CircR2Disease*cervical carcinoma
559*hsa_circ_0008844*chr1:40422758-40424497*+*MFSD2A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008844*Uterine Cervical Neoplasms*Upregulated*qPCR, Western blot, RIP, Biotin pulldown assay etc.*Human*Unclear*2017-03-01*28080204.0**hsa_circ_0008844/chr1:40422758-40424497*CircR2Disease*cervical carcinoma
560*hsa_circ_0001212*chr22:24056373-24057381*-*GUSBP11*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001212*Uterine Cervical Neoplasms*Upregulated*qPCR, Western blot, RIP, Biotin pulldown assay etc.*Human*Unclear*2017-03-01*28080204.0**hsa_circ_0001212/chr22:24056373-24057381*CircR2Disease*cervical carcinoma
561*hsa_circ_0001187*chr21:37619814-37620866*+*DOPEY2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001187*Uterine Cervical Neoplasms*Upregulated*qPCR, Western blot, RIP, Biotin pulldown assay etc.*Human*Unclear*2017-03-01*28080204.0**hsa_circ_0001187/chr21:37619814-37620866*CircR2Disease*cervical carcinoma
562*hsa_circ_0007928*chr4:52729602-52752804*+*DCUN1D4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007928*Uterine Cervical Neoplasms*Upregulated*qPCR, Western blot, RIP, Biotin pulldown assay etc.*Human*Unclear*2017-03-01*28080204.0**hsa_circ_0007928/chr4:52729602-52752804*CircR2Disease*cervical carcinoma
563*hsa_circ_0004277*chr10:1125950-1126416*+*WDR37*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004277*Leukemia, Myeloid, Acute*Downregulated*qPCR etc.*Human*Chemotherapy could significantly restore the expression of hsa_circ_0004277, indicating the increasing level of hsa_circ_0004277 was associated with successful treatment. *2017-03-01*28282919.0**hsa_circ_0004277/chr10:1125950-1126416*CircR2Disease*acute myeloid leukemia
564*hsa_circ_0035381*chr15:55621921-55634000*+*PIGB*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0035381*Leukemia, Myeloid, Acute*Upregulated*qPCR etc.*Human*Unclear*2017-03-01*28282919.0**hsa_circ_0035381/chr15:55621921-55634000*CircR2Disease*acute myeloid leukemia
565*hsa_circ_0004136*chr6:73713630-73751785*+*KCNQ5*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004136*Leukemia, Myeloid, Acute*Upregulated*qPCR etc.*Human*Unclear*2017-03-01*28282919.0**hsa_circ_0004136/chr6:73713630-73751785*CircR2Disease*acute myeloid leukemia
566*hsa_circ_0058058*chr2:216177220-216190861*+*ATIC*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0058058*Leukemia, Myeloid, Acute*Upregulated*qPCR etc.*Human*Unclear*2017-03-01*28282919.0**hsa_circ_0058058/chr2:216177220-216190861*CircR2Disease*acute myeloid leukemia
567*hsa_circ_0017446*chr10:1125950-1132297*+*WDR37*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0017446*Leukemia, Myeloid, Acute*Downregulated*qPCR etc.*Human*Unclear*2017-03-01*28282919.0**hsa_circ_0017446/chr10:1125950-1132297*CircR2Disease*acute myeloid leukemia
568*hsa_circRNA_104565*chr8:18622958-18662408*-*PSD3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002111*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_104565/hsa_circ_0002111/chr8:18622958-18662408*CircR2Disease*papillary thyroid carcinoma
569*hsa_circRNA_104566*chr8:18656804-18662408*-*PSD3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004458*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_104566/hsa_circ_0004458/chr8:18656804-18662408*CircR2Disease*papillary thyroid carcinoma
570*hsa_circRNA_100395*chr1:173726114-173744981*+*KLHL20*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0015278*Thyroid Cancer, Papillary*Downregulated*qPCR etc.*Human*Downregulated circRNA (hsa_circRNA_100395) showed interactive potential with two cancer-related miRNAs (miR-141-3p and miR-200a-3p)*2017-03-01*28288173.0**hsa_circRNA_100395/hsa_circ_0015278/chr1:173726114-173744981*CircR2Disease*papillary thyroid carcinoma
571*hsa_circRNA_104595*chr8:38287199-38287466*-*FGFR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008016*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_104595/hsa_circ_0008016/chr8:38287199-38287466*CircR2Disease*papillary thyroid carcinoma
572*hsa_circRNA_103110*chr21:16386664-16415895*-*NRIP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004771*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_103110/hsa_circ_0004771/chr21:16386664-16415895*CircR2Disease*papillary thyroid carcinoma
573*hsa_circRNA_100777*chr11:30557540-30602041*-*MPPED2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0021553*Thyroid Cancer, Papillary*Downregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_100777/hsa_circ_0021553/chr11:30557540-30602041*CircR2Disease*papillary thyroid carcinoma
574*hsa_circRNA_104348*chr7:37250990-37382367*-*ELMO1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0079891*Thyroid Cancer, Papillary*Downregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_104348/hsa_circ_0079891/chr7:37250990-37382367*CircR2Disease*papillary thyroid carcinoma
575*hsa_circRNA_103454*chr3:125032151-125032500*-*ZNF148*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0067103*Thyroid Cancer, Papillary*Downregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_103454/hsa_circ_0067103/chr3:125032151-125032500*CircR2Disease*papillary thyroid carcinoma
576*hsa_circRNA_105038*chrX:153581139-153581292*-*FLNA*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0091894*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_105038/hsa_circ_0091894/chrX:153581139-153581292*CircR2Disease*papillary thyroid carcinoma
577*hsa_circRNA_400064*chr21:45545508-45545708*+*PWP2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0092315*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_400064/hsa_circ_0092315/chr21:45545508-45545708*CircR2Disease*papillary thyroid carcinoma
578*hsa_circRNA_104268*chr6:170033042-170058454*-*WDR27*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0078738*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_104268/hsa_circ_0078738/chr6:170033042-170058454*CircR2Disease*papillary thyroid carcinoma
579*hsa_circRNA_103307*chr3:18456602-18462483*-*SATB1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0064557*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_103307/hsa_circ_0064557/chr3:18456602-18462483*CircR2Disease*papillary thyroid carcinoma
580*hsa_circRNA_001379*chr14:20811398-20811483*+*RPPH1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000516*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_001379/hsa_circ_0000516/chr14:20811398-20811483*CircR2Disease*papillary thyroid carcinoma
581*hsa_circRNA_101356*chr14:55168779-55169298*+*SAMD4A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004846*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_101356/hsa_circ_0004846/chr14:55168779-55169298*CircR2Disease*papillary thyroid carcinoma
582*hsa_circRNA_102002*chr17:20910208-20911309*-*USP22*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0003505*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_102002/hsa_circ_0003505/chr17:20910208-20911309*CircR2Disease*papillary thyroid carcinoma
583*hsa_circRNA_104433*chr7:98984307-98987635*+*ARPC1B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0081342*Thyroid Cancer, Papillary*Upregulated*qPCR etc.*Human*May as miRNA sponges*2017-03-01*28288173.0**hsa_circRNA_104433/hsa_circ_0081342/chr7:98984307-98987635*CircR2Disease*papillary thyroid carcinoma
584*hsa_circ_0054633*chr2:55861197-55913579*-*PNPT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0054633*Diabetes Mellitus, Type 2*Upregulated*qPCR etc.*Human*Hsa_circ_0054633 presented a certain diagnostic capability for pre-diabetes and T2DM.*2017-03-01*27878383.0**hsa_circ_0054633/chr2:55861197-55913579*CircR2Disease*type 2 diabetes mellitus
585*hsa_circ_0018508*chr10:70174795-70229920*-*DNA2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0018508*Diabetes Mellitus, Type 2*Upregulated*qPCR etc.*Human*Unclear*2017-03-01*27878383.0**hsa_circ_0018508/chr10:70174795-70229920*CircR2Disease*type 2 diabetes mellitus
586*hsa_circ_0068087*chr3:179113875-179137293*-*GNB4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0068087*Diabetes Mellitus, Type 2*Upregulated*qPCR etc.*Human*Unclear*2017-03-01*27878383.0**hsa_circ_0068087/chr3:179113875-179137293*CircR2Disease*type 2 diabetes mellitus
587*CircSLC8A1-1***SLC8A1**Heart Diseases*Upregulated*qPCR, smRNA-FISH etc.*Human*Flanking introns of the most abundantly expressed circRNA, circSLC8A1-1, are unusually long (250 618 nt) and are enriched with Alu elements.*2017-03-01*28082450.0**CircSLC8A1-1*CircR2Disease*heart disease
589*GSDMB ecircRNA*chr17:38065210-38066177*-*GSDMB*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0106803*Multiple Sclerosis*Upregulated*qPCR, Fluorescent-Competitive RT-PCR, and Semi-Quantitative Real-Time RT-PCR etc.*Human*both AS isoforms and the identified ecircRNA were significantly dysregulated in peripheral blood mononuclear cells of relapsing-remitting MS patients compared to controls*2017-03-01*28272342.0**GSDMB ecircRNA/hsa_circ_0106803/chr17:38065210-38066177*CircR2Disease*multiple sclerosis
590*hsa_circ_0000096*chr1:100515464-100535241*+*HIAT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000096*Stomach Neoplasms*Downregulated*qPCR etc.*Human*knockdown of hsa_circ_0000096 significantly inhibited cell proliferation and migration in vitro and in vivo. The results of both immunohistochemical and western blot analyses showed that the protein levels of cyclin D1, cyclin-dependent kinase 6 (CDK6), matrix metalloproteinase-2 and MMP-9 were significantly reduced in vitro and in vivo. A gastric cancer xenograft nude mouse model indicated that Ki67 and VEGF were reduced in a dose-dependent manner following knockdown of hsa_circ_0000096. However, the expression of E-cadherin increased*2017-02-01*28081541.0**hsa_circ_0000096/circHIAT1/hsa_circ_001013/chr1:100515464-100535241*CircR2Disease*gastric cancer
591*circTTBK2*chr15:43120125-43164956*-*TTBK2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000594*Glioma*Upregulated*qPCR, FISH, Western blot, Luciferase assays, RIP, ChIP assay, Tumor xenografts in nude mice etc.*Human*Enhanced expression of circ-TTBK2 promoted cell proliferation, migration, and invasion, while inhibited apoptosis. MiR-217 was downregulated in glioma tissues and cell lines. circ-TTBK2, but not linear TTBK2, acted as miR-217 sponge in a sequence-specific manner. In addition, upregulated circ-TTBK2 decreased miR-217 expression and there was a reciprocal negative feedback between them in an Argonaute2-dependent manner. Moreover, reintroduction of miR-217 significantly reversed circ-TTBK2-mediated promotion of glioma progression. HNF1β was a direct target of miR-217, and played oncogenic role in glioma cells. Remarkably, circ-TTBK2 knockdown combined with miR-217 overexpression led to tumor regression in vivo.*2017-02-01*28219405.0**circTTBK2/hsa_circ_0000594/chr15:43120125-43164956*CircR2Disease*glioma
592*circ-Foxo3***FOXO3**Breast Neoplasms*Downregulated*qPCR, Western blot, Immunoprecipilation assay, Northern blot etc.*Human*We found that silencing endogenous circ-Foxo3 enhanced cell viability, whereas ectopic expression of circ-Foxo3 triggered stress-induced apoptosis and inhibited the growth of tumor xenografts. Also, expression of circ-Foxo3 increased Foxo3 protein levels but repressed p53 levels. By binding to both, circ-Foxo3 promoted MDM2-induced p53 ubiquitination and subsequent degradation, resulting in an overall decrease of p53. With low binding affinity to Foxo3 protein, circ-Foxo3 prevented MDM2 from inducing Foxo3 ubiquitination and degradation, resulting in increased levels of Foxo3 protein. As a result, cell apoptosis was induced by upregulation of the Foxo3 downstream target PUMA.*2017-02-01*27886165.0**circ-Foxo3*CircR2Disease*breast cancer
593*hsa_circ_0124644*chr3:76758592-76759779*+*ROBO2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0124644*Coronary Artery Disease*Upregulated*qPCR etc.*Human*hsa_circ_0124644 was tested in an independent cohort consisting of 115 control individuals and 137 CAD patients. After we included the risk factors for CAD, the AUC slightly increased from 0.769 (95% confidence interval = [0.710–0.827], P < 0.001) to 0.804 ([0.751–0.857], P < 0.001), and when combined with hsa_circ_0098964, the diagnostic value slightly increased.*2017-01-01*28045102.0**hsa_circ_0124644/chr3:76758592-76759779*CircR2Disease*coronary artery disease
594*hsa_circ_0082081*chr7:122120905-122377122*-*CADPS2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0082081*Coronary Artery Disease*Upregulated*qPCR etc.*Human*Unclear*2017-01-01*28045102.0**hsa_circ_0082081/chr7:122120905-122377122*CircR2Disease*coronary artery disease
595*hsa_circ_0113854*chr1:63246096-63270926*+*ATG4C*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0113854*Coronary Artery Disease*Upregulated*qPCR etc.*Human*Unclear*2017-01-01*28045102.0**hsa_circ_0113854/chr1:63246096-63270926*CircR2Disease*coronary artery disease
596*hsa_circ_0098964*chr12:64474065-64521504*+*SRGAP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0098964*Coronary Artery Disease*Upregulated*qPCR etc.*Human*Unclear*2017-01-01*28045102.0**hsa_circ_0098964/chr12:64474065-64521504*CircR2Disease*coronary artery disease
597*hsa-circRNA5974-1*****Coronary Artery Disease*Upregulated*qPCR etc.*Human*Unclear*2017-01-01*28045102.0**hsa-circRNA5974-1*CircR2Disease*coronary artery disease
598*hsa_circ_0001649*chr6:146209155-146216113*-*SHPRH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001649*Stomach Neoplasms*Downregulated*qPCR etc.*Human*The expression level of hsa_circ_0001649 was significantly correlated with pathological differentiation (P = 0.039)*2017-01-01*28167847.0**hsa_circ_0001649/chr6:146209155-146216113*CircR2Disease*gastric cancer
600*CDR1as*chrX:139865339-139866824*+*CDR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001946*Carcinoma, Hepatocellular*Downregulated*qPCR, Western blot etc.*Human*The expression levels of ciRS-7 were comparable between HCC and matched non-tumor tissues. However, the highly ciRS-7 expression in HCC tissues was significantly correlated with hepatic MVI, AFP level and younger age and thus partly related with the deterioration of HCC. Especially, ciRS-7 was one of the independent factors of hepatic MVI.*2017-01-01*27614453.0**CDR1as/ciRS-7/hsa_circ_0001946/chrX:139865339-139866824*CircR2Disease*hepatocellular carcinoma
601*circZNF609*chr15:64791491-64792365*+*ZNF609*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000615*Hirschsprung Disease*Downregulated*qPCR, Western blot, Dual-luciferase reporter assay, RIP etc.*Human*Suppression of cir-ZNF609 inhibited the proliferation and migration of cells. We screened out several putative cir-ZNF609 ceRNAs of which the AKT3 transcript was selected. Finally, RNA immunoprecipitation and luciferase reporter assays demonstrated that cir-ZNF609 may act as a sponge for miR-150-5p to modulate the expression of AKT3. In conclusion, these findings illustrated that cir-ZNF609 took part in the onset of HSCR through the crosstalk with AKT3 by competing for shared miR-150-5p.*2017-01-01*27903978.0**Circ-ZNF609/hsa_circ_0000615/chr15:64791491-64792365*CircR2Disease*hirschsprung disease
602*hsa_circ_0005785*chr12:110819556-110834257*-*ANAPC7*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005785*Carcinoma, Pancreatic Ductal*Downregulated*qPCR etc.*Human*hsa_circ_0005785 is potentially able to bind miR181a and miR181b. Moreover, miR-181a played a critical role in regulating pancreatic cancer growth and migration. MiR-181b was associated with the resistance of pancreatic cancer cells to gemcitabine.*2016-12-01*27997903.0**hsa_circ_0005785/chr12:110819556-110834257*CircR2Disease*pancreatic ductal adenocarcinoma
603*CDR1as*chrX:139865339-139866824*+*CDR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001946*Carcinoma, Pancreatic Ductal*Upregulated*qPCR etc.*Human*Two up-regulated circRNAs and five down-regulated circRNAs (including hsa_circ_0001946, hsa_circ_0005397, hsa_circ_0006913, hsa_circ_0000257, hsa_circ_0005785, hsa_circ_0041150, and hsa_circ_0008719). We validated their expression levels via qRT-PCR in 20 sets of PDAC tissues and adjacent normal tissues*2016-12-01*27997903.0**hsa_circ_0001946/chrX:139865339-139866824*CircR2Disease*pancreatic ductal adenocarcinoma
604*hsa_circ_0005397*chr17:30500849-30503232*+*RHOT1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005397*Carcinoma, Pancreatic Ductal*Upregulated*qPCR etc.*Human*Two up-regulated circRNAs and five down-regulated circRNAs (including hsa_circ_0001946, hsa_circ_0005397, hsa_circ_0006913, hsa_circ_0000257, hsa_circ_0005785, hsa_circ_0041150, and hsa_circ_0008719). We validated their expression levels via qRT-PCR in 20 sets of PDAC tissues and adjacent normal tissues*2016-12-01*27997903.0**hsa_circ_0005397/chr17:30500849-30503232*CircR2Disease*pancreatic ductal adenocarcinoma
605*hsa_circ_0006913*chr1:27087346-27089776*+*ARID1A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0006913*Carcinoma, Pancreatic Ductal*Downregulated*qPCR etc.*Human*Two up-regulated circRNAs and five down-regulated circRNAs (including hsa_circ_0001946, hsa_circ_0005397, hsa_circ_0006913, hsa_circ_0000257, hsa_circ_0005785, hsa_circ_0041150, and hsa_circ_0008719). We validated their expression levels via qRT-PCR in 20 sets of PDAC tissues and adjacent normal tissues*2016-12-01*27997903.0**hsa_circ_0006913/chr1:27087346-27089776*CircR2Disease*pancreatic ductal adenocarcinoma
606*hsa_circ_0000257*chr10:103916775-103917971*+*NOLC1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000257*Carcinoma, Pancreatic Ductal*Downregulated*qPCR etc.*Human*Two up-regulated circRNAs and five down-regulated circRNAs (including hsa_circ_0001946, hsa_circ_0005397, hsa_circ_0006913, hsa_circ_0000257, hsa_circ_0005785, hsa_circ_0041150, and hsa_circ_0008719). We validated their expression levels via qRT-PCR in 20 sets of PDAC tissues and adjacent normal tissues*2016-12-01*27997903.0**hsa_circ_0000257/chr10:103916775-103917971*CircR2Disease*pancreatic ductal adenocarcinoma
607*hsa_circ_0041150*chr17:131558-177370*-*RPH3AL*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0041150*Carcinoma, Pancreatic Ductal*Downregulated*qPCR etc.*Human*Two up-regulated circRNAs and five down-regulated circRNAs (including hsa_circ_0001946, hsa_circ_0005397, hsa_circ_0006913, hsa_circ_0000257, hsa_circ_0005785, hsa_circ_0041150, and hsa_circ_0008719). We validated their expression levels via qRT-PCR in 20 sets of PDAC tissues and adjacent normal tissues*2016-12-01*27997903.0**hsa_circ_0041150/chr17:131558-177370*CircR2Disease*pancreatic ductal adenocarcinoma
608*hsa_circ_0008719*chr19:40761064-40771258*-*AKT2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008719*Carcinoma, Pancreatic Ductal*Downregulated*qPCR etc.*Human*Two up-regulated circRNAs and five down-regulated circRNAs (including hsa_circ_0001946, hsa_circ_0005397, hsa_circ_0006913, hsa_circ_0000257, hsa_circ_0005785, hsa_circ_0041150, and hsa_circ_0008719). We validated their expression levels via qRT-PCR in 20 sets of PDAC tissues and adjacent normal tissues*2016-12-01*27997903.0**hsa_circ_0008719/chr19:40761064-40771258*CircR2Disease*pancreatic ductal adenocarcinoma
609*MCF7_circ_000595*chr14:102466325-102500789*+*DYNC1H1**Breast Neoplasms*Upregulated*qPCR etc.*Human*This circRNA was found at chr14:102,466,325–102,500,789 and had 12 supporting junction-spanning reads. This circRNA was a spliced product of gene DYNC1H1 and spanned from exons 17 to 56 of the gene. Considering that the exon-intron structure remains intact, the size of this circRNA is about 7 kb and may play a role in post-transcriptional regulation. Notably, the circRNA contained microRNA response elements (MRE) for miR-150 and miR-661 with 29 and 23 unique binding sites respectively. These two microRNAs have been previously reported to have associations with cancer*2016-12-01*27829232.0**MCF7_circ_000595/chr14:102466325-102500789*CircR2Disease*breast cancer
610*CDR1as*chrX:139865339-139866824*+*CDR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001946*Alzheimer Disease*Downregulated*qPCR, Northern blot, Western blot etc.*Human*ciRS-7 contains about ~70 tandem anti-miRNA-7 sequences and acts as an endogenous, anti-complementary miRNA-7 “sponge” that attracts, binds, and, hence, quenches, natural miRNA-7 functions. Deficits in ciRS-7-mediated “sponging events”, resulting in excess ambient miRNA-7 appear to drive the selective down-regulation in the expression of miRNA-7-sensitive mRNA targets, such as that encoding the ubiquitin conjugating enzyme E2A (UBE2A; chr Xq24). *2016-12-01*27929395.0**CDR1as/ciRS-7/hsa_circ_0001946/chrX:139865339-139866824*CircR2Disease*alzheimer’s disease
611*hsa_circ_101222*chr13:20067587-20077417*-*TPTE2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0029601*Pre-Eclampsia*Upregulated*qPCR etc.*Human*CircRNA and plasma proteins may have some predictive value for PE (such as circ_101222 and ENG). The performance of each of these factors may be strengthened when plasma proteins are used in combination with circRNA.*2016-12-01*26846540.0**hsa_circ_101222/hsa_circ_0029601/chr13:20067587-20077417*CircR2Disease*pre-eclampsia
612*hsa_circ_0000069*chr1:47745912-47748131*-*STIL*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000069*Colorectal Neoplasms*Upregulated*qPCR, Flow cytometric analysis, Cell migration and invasion assay etc.*Human*hsa_circ_0000069 could affect CRC cell proliferation, migration, invasion, and cell cycle in vitro*2016-12-01*28003761.0**hsa_circ_0000069/chr1:47745912-47748131*CircR2Disease*colorectal cancer
613*IQCK*chr16:19741751-19745149*+*IQCK*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0038374*Multiple System Atrophy*Upregulated*qPCR etc.*Human*Five circRNAs, namely IQCK, MAP4K3, EFCAB11, DTNA, and MCTP1, were identified and validated as specifically over-expressed in MSA frontal cortex.  Further analysis of expression of five MSA-specific circRNAs revealed their over-expression in the white matter of the MSA cortical tissue. *2016-11-01*27470294.0**IQCK/hsa_circ_0038374/chr16:19741751-19745149*CircR2Disease*multiple system atrophy
614*MAP4K3*chr2:39559057-39564722*-*MAP4K3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0054211*Multiple System Atrophy*Upregulated*qPCR etc.*Human*Five circRNAs, namely IQCK, MAP4K3, EFCAB11, DTNA, and MCTP1, were identified and validated as specifically over-expressed in MSA frontal cortex.  Further analysis of expression of five MSA-specific circRNAs revealed their over-expression in the white matter of the MSA cortical tissue. *2016-11-01*27470294.0**MAP4K3/hsa_circ_0054211/chr2:39559057-39564722*CircR2Disease*multiple system atrophy
615*EFCAB11*chr14:90397884-90398971*-*EFCAB11*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0032891*Multiple System Atrophy*Upregulated*qPCR etc.*Human*Five circRNAs, namely IQCK, MAP4K3, EFCAB11, DTNA, and MCTP1, were identified and validated as specifically over-expressed in MSA frontal cortex.  Further analysis of expression of five MSA-specific circRNAs revealed their over-expression in the white matter of the MSA cortical tissue. *2016-11-01*27470294.0**EFCAB11/hsa_circ_0032891/chr14:90397884-90398971*CircR2Disease*multiple system atrophy
616*DTNA*chr18:32335939-32374214*+*DTNA*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0108308*Multiple System Atrophy*Upregulated*qPCR etc.*Human*Five circRNAs, namely IQCK, MAP4K3, EFCAB11, DTNA, and MCTP1, were identified and validated as specifically over-expressed in MSA frontal cortex.  Further analysis of expression of five MSA-specific circRNAs revealed their over-expression in the white matter of the MSA cortical tissue. *2016-11-01*27470294.0**DTNA/hsa_circ_0108308/chr18:32335939-32374214*CircR2Disease*multiple system atrophy
617*MCTP1*chr5:94204037-94248681*-*MCTP1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005540*Multiple System Atrophy*Upregulated*qPCR etc.*Human*Five circRNAs, namely IQCK, MAP4K3, EFCAB11, DTNA, and MCTP1, were identified and validated as specifically over-expressed in MSA frontal cortex.  Further analysis of expression of five MSA-specific circRNAs revealed their over-expression in the white matter of the MSA cortical tissue. *2016-11-01*27470294.0**MCTP1/hsa_circ_0005540/chr5:94204037-94248681*CircR2Disease*multiple system atrophy
618*circFAT1*chr4:187627717-187630999**FAT1**Colonic Neoplasms*Downregulated*qPCR etc.*Human*circFAT1 was significantly down-regulated in the mutant KRAS cell line,circFAT1 was significantly down regulated in DKO-1 as compared to DKs-8 *2016-11-01*27892494.0**circFAT1/chr4:187627717-187630999*CircR2Disease*colon cancer
619*circARHGAP5*chr14:32559708-32563592**ARHGAP5**Colonic Neoplasms*Downregulated*qPCR etc.*Human*Two significantly regulated circRNAs between KRAS mutant and WT exosomes were down-regulated in KRAS mutant (circFAT1 and circARHGAP5)*2016-11-01*27892494.0**circARHGAP5/chr14:32559708-32563592*CircR2Disease*colon cancer
620*circRTN4*chr2:55209651-55214834**RTN4**Colonic Neoplasms*Downregulated*qPCR etc.*Human*circRTN4 was significantly up regulated in DLD-1 exosomes*2016-11-01*27892494.0**circRTN4/chr2:55209651-55214834*CircR2Disease*colon cancer
621*circRHOBTB3*chr5:95091100-95099324**RHOBTB3**Colonic Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2016-11-01*27892494.0**circRHOBTB3/chr5:95091100-95099324*CircR2Disease*colon cancer
622*circSMARC1A*chr4:144464662-144465125**SMARC1A**Colonic Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2016-11-01*27892494.0**circSMARC1A/chr4:144464662-144465125*CircR2Disease*colon cancer
623*Titin circRNAs*****Cardiomyopathy, Dilated*Downregulated*qPCR etc.*Human*RBM20 is crucial for the formation of a subset of circRNAs that originate from the I-band of the titin gene. RBM20, by excluding specific exons from the pre-mRNA, provides the substrate to form this class of RBM20-dependent circRNAs.*2016-10-01*27531932.0**Titin circRNAs/cTtns/RBM20-dependent TTN circRNAs*CircR2Disease*dilated cardiomyopathy
625*hsa_circ_0067934*chr3:170013698-170015181*+*PRKCI*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0067934*Esophageal Squamous Cell Carcinoma*Upregulated*qPCR,In vitro cell migration and invasion assay, FISH, Western blot etc.*Human*The high expression level of hsa_circ_0067934 was associated with poor differentiation (P = 0.025), I-II T stage (P = 0.04), and I-II TNM stage (P = 0.021). *2016-10-01*27752108.0**hsa_circ_0067934/chr3:170013698-170015181*CircR2Disease*esophageal squamous cell carcinoma
632*hsa_circ_0004383*chr6:87920168-87928449*+*ZNF292*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004383*Glioma*Upregulated*qPCR, Western blot, Reporter gene assay etc.*Human*cZNF292 silencing suppresses tube formation by inhibiting glioma cell proliferation and cell cycle progression. Cell cycle progression in human glioma U87MG and U251 cells was halted at S/G2/M phase via the Wnt/β-catenin signaling pathway and related genes such as PRR11, Cyclin A, p-CDK2, VEGFR-1/2, p-VEGFR-1/2 and EGFR. *2016-09-01*27613831.0**hsa_circ_0004383/cZNF292/chr6:87920168-87928449*CircR2Disease*glioma
633*hsa_circ_103736*chr4:128995614-128996148*+*LARP1B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0070933**Upregulated*qPCR etc.*Human*May as miRNA sponges*2016-09-01*27298156.0**hsa_circ_103736/hsa_circ_0070933/chr4:128995614-128996148*CircR2Disease*cutaneous squamous cell carcinoma
634*hsa_circ_103737*chr4:128995614-129012667*+*LARP1B*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0070934**Upregulated*qPCR etc.*Human*May as miRNA sponges*2016-09-01*27298156.0**hsa_circ_103737/hsa_circ_0070934/chr4:128995614-129012667*CircR2Disease*cutaneous squamous cell carcinoma
635*hsa_circ_101555*chr15:64495280-64508912*-*CSNK1G1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001955**Upregulated*qPCR etc.*Human*May as miRNA sponges*2016-09-01*27298156.0**hsa_circ_101555/hsa_circ_0001955/chr15:64495280-64508912*CircR2Disease*cutaneous squamous cell carcinoma
637*circZNF609*chr15:64791491-64792365*+*ZNF609*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000615*Myocardial Infarction*Downregulated*qPCR etc.*Human*Expression levels of MICRA were lower in MI patients of the test cohort compared with healthy volunteers*2016-09-01*27609688.0**hsa_circ_0000615/MICRA/chr15:64791491-64792365*CircR2Disease*myocardial infarction
638*hsa_circRNA_103636*chr4:52729602-52744020*+*DCUN1D4*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001410*Depressive Disorder, Major*Downregulated*qPCR etc.*Human*Four differentially expressed circRNAs were identified between MDD patients and controls, and only down-regulated hsa_circRNA_103636 was significantly altered after the 8-week treatment in MDD patients.*2016-09-01*27404501.0**hsa_circRNA_103636/hsa_circ_0001410/chr4:52729602-52744020*CircR2Disease*major depressive disorder
639*hsa_circRNA_002143*chrUn_gl000220:100404-123082*+*LOC100507412*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001907*Depressive Disorder, Major*Upregulated*qPCR etc.*Human*Unclear*2016-09-01*27404501.0**hsa_circRNA_002143/hsa_circ_0001907/chrUn_gl000220:100404-123082*CircR2Disease*major depressive disorder
640*hsa_circRNA_100679*chr10:105382226-105420872*-*SH3PXD2A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005620*Depressive Disorder, Major*Downregulated*qPCR etc.*Human*Unclear*2016-09-01*27404501.0**hsa_circRNA_100679/hsa_circ_0005620 /chr10:105382226-105420872*CircR2Disease*major depressive disorder
641*hsa_circRNA_102802*chr2:112101637-112101814*-*TCONS_l2_00014790*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0056048*Depressive Disorder, Major*Upregulated*qPCR etc.*Human*Unclear*2016-09-01*27404501.0**hsa_circRNA_102802/hsa_circ_0056048/chr2:112101637-112101814*CircR2Disease*major depressive disorder
642*hsa_circRNA_104953*chr9:135917473-135919313*+*GTF3C5*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0089310*Depressive Disorder, Major*Downregulated*qPCR etc.*Human*Unclear*2016-09-01*27404501.0**hsa_circRNA_104953/hsa_circ_0089310/chr9:135917473-135919313*CircR2Disease*major depressive disorder
643*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Pre-Eclampsia*Upregulated*qPCR etc.*Human*The expression levels of hsa_circRNA_100782 (p < 0.05), hsa_circRNA_102682 (p < 0.05), and hsa_circRNA_104820 (p < 0.0001) were validated as significantly up-regulated in the experimental group compared with the controls.*2016-09-01*27606420.0**hsa_circRNA_100782/circHIPK3/hsa_circ_0000284/chr11:33307958-33309057*CircR2Disease*pre-eclampsia
644*hsa_circRNA_102682*chr2:36623756-36749456*+*CRIM1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005442*Pre-Eclampsia*Upregulated*qPCR etc.*Human*The expression levels of hsa_circRNA_100782 (p < 0.05), hsa_circRNA_102682 (p < 0.05), and hsa_circRNA_104820 (p < 0.0001) were validated as significantly up-regulated in the experimental group compared with the controls.*2016-09-01*27606420.0**hsa_circRNA_102682/circCRIM1/hsa_circ_0005442/chr2:36623756-36749456*CircR2Disease*pre-eclampsia
645*hsa_circRNA_104820*chr9:96233422-96259881*+*FAM120A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005218*Pre-Eclampsia*Upregulated*qPCR etc.*Human*The expression levels of hsa_circRNA_100782 (p < 0.05), hsa_circRNA_102682 (p < 0.05), and hsa_circRNA_104820 (p < 0.0001) were validated as significantly up-regulated in the experimental group compared with the controls.*2016-09-01*27606420.0**hsa_circRNA_104820/circFAM120A/hsa_circ_0005218/chr9:96233422-96259881*CircR2Disease*pre-eclampsia
646*Cir-ITCH*chr20:33001547-33037285*+*ITCH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001141*Lung Neoplasms*Downregulated*qPCR, Luciferase assay, Western blot, Cell viability assay etc.*Human*cir-ITCH acted as sponge of oncogenic miR-7 and miR-214 to enhance ITCH expression and thus suppressed the activation of Wnt/β-catenin signaling, Sponge miR-7, miR-17, and miR-214 to increase ITCH expression, then degrade Dvl2 phosphorylation to further inhibit the Wnt signaling pathway *2016-08-01*27642589.0**Cir-ITCH/hsa_circ_0001141/hsa_circ_001763/chr20:33001547-33037285*CircR2Disease*lung cancer
647*circANRIL***ANRIL**Atherosclerosis*Downregulated*qPCR, Western blot, Northern blot, ISH, Immunofluorescent staining, RIP etc.*Human*circANRIL induces nucleolar stress and p53 activation, resulting in the induction of apoptosis and inhibition of proliferation, which are key cell functions in atherosclerosis.*2016-08-01*27539542.0**circANRIL*CircR2Disease*atherosclerosis
648*circTCF25*chr16:89962397-89967202*+*TCF25*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0041103*Urinary Bladder Neoplasms*Upregulated*qPCR, Western blot etc.*Human*circTCF25 could sequester miR-103a-3p/miR-107, which potentially lead to the up-regulation of thirteen targets related to cell proliferation, migration and invasion.over-expression of circTCF25 could down-regulate miR-103a-3p and miR-107, increase CDK6 expression, and promote proliferation and migration in vitro and vivo. *2016-08-01*27484176.0**circTCF25/hsa_circ_0041103/chr16:89962397-89967202*CircR2Disease*bladder cancer
649*circFAM169A*chr5:74109664-74137504*-*FAM169A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0007158*Urinary Bladder Neoplasms*Downregulated*qPCR etc.*Human*circFAM169A (hsa_circ_0007158) and circTRIM24 (hsa_circ_0082582) are significantly down-regulated in bladder carcinoma groups*2016-08-01*27484176.0**circFAM169A/hsa_circ_0007158/chr5:74109664-74137504*CircR2Disease*bladder cancer
650*circTRIM24*chr7:138203933-138255748*+*TRIM24*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0082582*Urinary Bladder Neoplasms*Downregulated*qPCR etc.*Human*circFAM169A (hsa_circ_0007158) and circTRIM24 (hsa_circ_0082582) are significantly down-regulated in bladder carcinoma groups*2016-08-01*27484176.0**circTRIM24/hsa_circ_0082582/chr7:138203933-138255748*CircR2Disease*bladder cancer
651*circZFR*chr5:32379220-32388780*-*ZFR*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0072088*Urinary Bladder Neoplasms*Upregulated*qPCR etc.*Human*circTCF25 (hsa_circ_0041103), circZFR (hsa_circ_0072088), circPTK2 (hsa_circ_0005273) and circBC048201 (hsa_circ_0061265) are significantly higher expressed in carcinoma tissues*2016-08-01*27484176.0**circZFR/hsa_circ_0072088/chr5:32379220-32388780*CircR2Disease*bladder cancer
652*circBC048201*chr21:15456270-15456465*+**http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0061265*Urinary Bladder Neoplasms*Upregulated*qPCR etc.*Human*circTCF25 (hsa_circ_0041103), circZFR (hsa_circ_0072088), circPTK2 (hsa_circ_0005273) and circBC048201 (hsa_circ_0061265) are significantly higher expressed in carcinoma tissues*2016-08-01*27484176.0**circBC048201/hsa_circ_0061265/chr21:15456270-15456465*CircR2Disease*bladder cancer
653*hsa_circ_0003221*chr8:141710989-141716304*-*PTK2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005273*Urinary Bladder Neoplasms*Upregulated*qPCR etc.*Human*circTCF25 (hsa_circ_0041103), circZFR (hsa_circ_0072088), circPTK2 (hsa_circ_0005273) and circBC048201 (hsa_circ_0061265) are significantly higher expressed in carcinoma tissues*2016-08-01*27484176.0**circPTK2/hsa_circ_0005273/chr8:141710989-141716304*CircR2Disease*bladder cancer
654*circRNA_104983*chrX:17705861-17710588*+*NHS*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0089974*Esophageal Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2016-07-01*27465405.0**circRNA_104983/hsa_circ_0089974/chrX:17705861-17710588*CircR2Disease*esophageal cancer
655*circRNA_001059*chr14:74551677-74551959*+*LIN52*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000554*Esophageal Neoplasms*Upregulated*qPCR etc.*Human*"CircRNA_001059 and circRNA_000167 were the two largest nodes in circRNA/microRNA co-expression network. circRNA_ 001059 may act as an inhibitor of miRNA by
binding several specific miRNAs, including miR-30c-1*,
miR-30c-2*, miR-122*, miR-139-3p, miR-339-5p and miR-
1912."*2016-07-01*27465405.0**circRNA_001059/hsa_circ_0000554/chr14:74551677-74551959*CircR2Disease*esophageal cancer
656*circRNA_100984*chr11:126142863-126143349*+*FOXRED1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0002019*Esophageal Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2016-07-01*27465405.0**circRNA_100984/hsa_circ_0002019/chr11:126142863-126143349*CircR2Disease*esophageal cancer
657*circRNA_100367*chr1:160206924-160231148*-*DCAF8*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0014879*Esophageal Neoplasms*Upregulated*qPCR etc.*Human*Unclear*2016-07-01*27465405.0**circRNA_100367/hsa_circ_0014879/chr1:160206924-160231148*CircR2Disease*esophageal cancer
658*circRNA_101877*chr16:74670243-74671868*-*RFWD3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004519*Esophageal Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2016-07-01*27465405.0**circRNA_101877/hsa_circ_0004519/chr16:74670243-74671868*CircR2Disease*esophageal cancer
659*hsa_circ_0058058*chr2:216177220-216190861*+*ATIC*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0058058*Esophageal Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2016-07-01*27465405.0**circRNA_102913/hsa_circ_0058058/chr2:216177220-216190861*CircR2Disease*esophageal cancer
660*circRNA_000695*chr3:128102470-128102926*+*EEFSEC*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001336*Esophageal Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2016-07-01*27465405.0**circRNA_000695/hsa_circ_0001336/chr3:128102470-128102926*CircR2Disease*esophageal cancer
661*hsa_circRNA_000167*chr14:20811404-20811554*-*RPPH1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000518*Esophageal Neoplasms*Downregulated*qPCR etc.*Human*CircRNA_001059 and circRNA_000167 were the two largest nodes in circRNA/microRNA co-expression network.*2016-07-01*27465405.0**circRNA_000167/hsa_circ_0000518/chr14:20811404-20811554*CircR2Disease*esophageal cancer
662*circRNA_101419*chr14:81837331-81837529*-*STON2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0032832*Esophageal Neoplasms*Downregulated*qPCR etc.*Human*Unclear*2016-07-01*27465405.0**circRNA_101419/hsa_circ_0032832/chr14:81837331-81837529*CircR2Disease*esophageal cancer
664*CDR1as*chrX:139865339-139866824*+*CDR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001946*Carcinoma, Hepatocellular*Upregulated*qPCR, Western blot etc.*Human*Knockdown of Cdr1as suppressed the HCC cell proliferation and invasion. Overexpression of miR-7 inhibited the HCC cell proliferation and invasion. Overexpression of miR-7 could suppress the direct target gene CCNE1 and PIK3CD expression. Knockdown of Cdr1as suppressed the expression of miR-7 and also inhibited the CCNE1 and PIK3CD expression. Furthermore, knockdown of Cdr1as suppressed the HCC cell proliferation and invasion through targeting miR-7. These data suggested that Cdr1as acted as an oncogene partly through targeting miR-7 in HCC.*2016-07-01*27391479.0**CDR1as/ciRS-7/hsa_circ_0001946/chrX:139865339-139866824*CircR2Disease*hepatocellular carcinoma
677*hsa_circ_0005075*chr1:21377358-21415706*-*EIF4G3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005075*Carcinoma, Hepatocellular*Upregulated*qPCR etc.*Human*Hsa_circ_0005075 expression correlated with HCC tumor size (P = 0.042), and showed good diagnostic potential (AUROC = 0.94). Gene oncology analysis revealed that hsa_circ_0005075 could participate in cell adhesion during HCC development.May as hsa_circ_0005075-miR-23B-5P/93-3P/581/23A-5P sponges*2016-05-01*27258521.0**hsa_circ_0005075/chr1:21377358-21415706*CircR2Disease*hepatocellular carcinoma
678*hsa_circRNA_104084*chr6:22020567-22056919*+*LINC00340*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0075829*Carcinoma, Basal Cell*Upregulated*qPCR etc.*Human*PCR validation showed that all three upregulated circRNAs were also upregulated in a second group of BCC and controls. In detail, the following ratios of gene expression were calculated (BCC/control): hsa_ circ_00075829 (549.55), hsa_circ_0008732 (7.74) and hsa_circ_0005912 (1.23).*2016-05-01*27097056.0**hsa_circ_0075829/chr6:22020567-22056919*CircR2Disease*basal cell carcinoma
679*hsa_circ_0008732*chr9:16727794-16738483*-*BNC2*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008732*Carcinoma, Basal Cell*Upregulated*qPCR etc.*Human*PCR validation showed that all three upregulated circRNAs were also upregulated in a second group of BCC and controls. In detail, the following ratios of gene expression were calculated (BCC/control): hsa_ circ_00075829 (549.55), hsa_circ_0008732 (7.74) and hsa_circ_0005912 (1.23).*2016-05-01*27097056.0**hsa_circ_0008732/chr9:16727794-16738483*CircR2Disease*basal cell carcinoma
680*hsa_circ_0005912*chr4:54265896-54294350*+*FIP1L1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0005912*Carcinoma, Basal Cell*Upregulated*qPCR etc.*Human*PCR validation showed that all three upregulated circRNAs were also upregulated in a second group of BCC and controls. In detail, the following ratios of gene expression were calculated (BCC/control): hsa_ circ_00075829 (549.55), hsa_circ_0008732 (7.74) and hsa_circ_0005912 (1.23).*2016-05-01*27097056.0**hsa_circ_0005912/chr4:54265896-54294350*CircR2Disease*basal cell carcinoma
681*hsa_circ_0000677*chr16:16101672-16162159*+*ABCC1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000677*Colorectal Neoplasms*Upregulated*qPCR, Luciferase activity assay, Western blot, In vitro and in vivo tumorigenicity assay etc.*Human*hsa_circ_001569 sponged with miR-145 and promoted miR-145 target genes E2F5, BAG4 and FMNL2 then acted as a positive regulator in cell proliferation and invasion*2016-05-01*27058418.0**hsa_circ_0000677/hsa_circ_001569/circABCC/chr16:16101672-16162159*CircR2Disease*colorectal cancer
682*circSMARCA5*chr4:144464661-144465125**SMARCA5**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_SMARCA5/chr4:144464661-144465125*CircR2Disease*glioma
683*Circ_KCNN2*chr5:113740134-113740553**KCNN2**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_KCNN2/chr5:113740134-113740553*CircR2Disease*glioma
684*hsa_circ_0000284*chr11:33307958-33309057**HIPK3**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_HIPK3/chr11:33307958-33309057*CircR2Disease*glioma
685*Circ_FKBP8*chr19:18650180-18650530**FKBP8**Glioma*Downregulated*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_FKBP8/chr19:18650180-18650530*CircR2Disease*glioma
686*Circ_RIMS1*chr6:73016960-73043538**RIMS1**Glioma*Downregulated*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_RIMS1/chr6:73016960-73043538*CircR2Disease*glioma
687*Circ_VCAN*chr5:82832825-82838087**VCAN**Glioma*Upregulated*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_VCAN/chr5:82832825-82838087*CircR2Disease*glioma
688*Circ_CORO1C*chr12:109046047-109048186**CORO1C**Glioma*Downregulated*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_CORO1C/chr12:109046047-109048186*CircR2Disease*glioma
689*Circ_MAN1A2*chr1:117944807-117963271**MAN1A2**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_MAN1A2/chr1:117944807-117963271*CircR2Disease*glioma
690*Circ_SLC8A1*chr2:40655612-40657444**SLC8A1**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_SLC8A1/chr2:40655612-40657444*CircR2Disease*glioma
691*Circ_STXBP5L*chr3:121097562-121100379**STXBP5L**Glioma*Downregulated*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_STXBP5L/chr3:121097562-121100379*CircR2Disease*glioma
692*Circ_ZNF148*chr3:125032151-125050082**ZNF148**Glioma*Downregulated*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_ZNF148/chr3:125032151-125050082*CircR2Disease*glioma
693*Circ_UNC79*chr14:93934016-93954101**UNC79**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_UNC79/chr14:93934016-93954101*CircR2Disease*glioma
694*Circ_EML5*chr14:89192884-89212627**EML5**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_EML5/chr14:89192884-89212627*CircR2Disease*glioma
695*Circ_CEP192*chr18:12999419-13019205**CEP192**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_CEP192/chr18:12999419-13019205*CircR2Disease*glioma
696*Circ_RNF10*chr12:120995084-120995485**RNF10**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_RNF10/chr12:120995084-120995485*CircR2Disease*glioma
697*Circ_SAFB2*chr19:5604593-5604947**SAFB2**Glioma*Downregulated*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_SAFB2/chr19:5604593-5604947*CircR2Disease*glioma
698*Circ_ADCY1*chr7:45688268-45701813**ADCY1**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_ADCY1/chr7:45688268-45701813*CircR2Disease*glioma
699*circETFA*chr15:76566752-76588078**ETFA**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_ETFA/chr15:76566752-76588078*CircR2Disease*glioma
700*Circ_MED12L*chr3:150834124-150845771**MED12L**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_MED12L/chr3:150834124-150845771*CircR2Disease*glioma
701*Circ_CRKL*chr22:21288066-21288532**CRKL**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_CRKL/chr22:21288066-21288532*CircR2Disease*glioma
702*Circ_R3HDM1*chr2:136432901-136437894**R3HDM1**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_R3HDM1/chr2:136432901-136437894*CircR2Disease*glioma
703*Circ_MCTP1*chr5:94224583-94248681**MCTP1**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_MCTP1/chr5:94224583-94248681*CircR2Disease*glioma
704*Circ_BEND6*chr656846508-56857353**BEND6**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_BEND6/chr656846508-56857353*CircR2Disease*glioma
705*Circ_ERC1*chr12:1399017-1481143**ERC1**Glioma*Unclear*qPCR etc.*Human*By applying UROBORUS to RNA-seq data from 46 gliomas and normal brain samples, we detected thousands of circRNAs supported by at least two read counts, followed by successful experimental validation on 24 circRNAs from the randomly selected 27 circRNAs.*2016-05-01*26873924.0**Circ_ERC1/chr12:1399017-1481143*CircR2Disease*glioma
706*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Urinary Bladder Neoplasms*Upregulated*qPCR, RNA FISH, Northern blot, RIP , Luciferase reporter assay etc.*Human*circHIPK3 directly binds to miR-124 and inhibits miR-124 activity.*2016-04-01*27050392.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*bladder urothelial carcinoma
707*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Breast Neoplasms*Downregulated*qPCR, RNA FISH, Northern blot, RIP , Luciferase reporter assay etc.*Human*circHIPK3 directly binds to miR-124 and inhibits miR-124 activity.*2016-04-01*27050392.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*breast cancer
708*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Colorectal Neoplasms*Downregulated*qPCR, RNA FISH, Northern blot, RIP , Luciferase reporter assay etc.*Human*circHIPK3 directly binds to miR-124 and inhibits miR-124 activity.*2016-04-01*27050392.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*colorectal cancer
709*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Carcinoma, Hepatocellular*Downregulated*qPCR, RNA FISH, Northern blot, RIP , Luciferase reporter assay etc.*Human*circHIPK3 directly binds to miR-124 and inhibits miR-124 activity.*2016-04-01*27050392.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*hepatocellular carcinoma
710*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Stomach Neoplasms*Downregulated*qPCR, RNA FISH, Northern blot, RIP , Luciferase reporter assay etc.*Human*circHIPK3 directly binds to miR-124 and inhibits miR-124 activity.*2016-04-01*27050392.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*gastric cancer
711*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Carcinoma, Renal Cell*Upregulated*qPCR, RNA FISH, Northern blot, RIP , Luciferase reporter assay etc.*Human*circHIPK3 directly binds to miR-124 and inhibits miR-124 activity.*2016-04-01*27050392.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*kidney clear cell carcinoma
712*hsa_circ_0000284*chr11:33307958-33309057*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000284*Prostatic Neoplasms*Downregulated*qPCR, RNA FISH, Northern blot, RIP , Luciferase reporter assay etc.*Human*circHIPK3 directly binds to miR-124 and inhibits miR-124 activity.*2016-04-01*27050392.0**hsa_circ_0000284/circHIPK3/chr11:33307958-33309057*CircR2Disease*prostate adenocarcinoma
715*hsa_circ_0023404*chr11:71668272-71671937*+*RNF121*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023404*Osteoarthritis*Upregulated*qPCR, RNA FISH, Northern blot, RIP , Luciferase reporter assay etc.*Human*CircRNA-CER expression increased with interleukin-1 and tumor necrosis factor levels in chondrocytes. Silencing of circRNA-CER using small interfering RNA suppressed MMP13 expression and increased ECM formation. CircRNA-CER could compete for miR-136 with MMP13. Results demonstrated that circRNA-CER regulated MMP13 expression by functioning as a competing endogenous RNA (ceRNA) and participated in the process of chondrocyte ECM degradation.*2016-03-01*26931159.0**Circ-CER/circRNA_100876/hsa_circ_0023404/chr11:71668272-71671937*CircR2Disease*osteoarthritis
717*hsa_circRNA_100855*chr11:66515849-66590145*+*C11orf80*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023028*Squamous Cell Carcinoma of Head and Neck*Upregulated*qPCR etc.*Human*Patients with T3-4 stage, neck nodal metastasis or advanced clinical stage had higher hsa_circRNA_100855 expression.*2016-02-01*27158380.0**hsa_circRNA_100855/hsa_circ_0023028/chr11:66515849-66590145*CircR2Disease*laryngeal squamous cell cancer tissues
718*hsa_circRNA_104912*chr9:126,438,998-126,641,300*-*DENND1A*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0088442*Squamous Cell Carcinoma of Head and Neck*Downregulated*qPCR etc.*Human*Patients with T3-4 stage, neck nodal metastasis, poor differentiation or advanced clinical stage had a lower hsa_circRNA_104912 expression. *2016-02-01*27158380.0**hsa_circRNA_104912/hsa_circ_0088442/chr9:126,438,998-126,641,300*CircR2Disease*laryngeal squamous cell cancer tissues
720*circRNA_081881*****Myocardial Infarction*Downregulated*Western blot*Human*Sponge miR-548 to regulate PPARγ*2016-01-01***circRNA_081881*CircR2Disease*myocardial infarction
721*hsa_circ_0001649*chr6:146209155-146216113*-*SHPRH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0023028*Carcinoma, Hepatocellular*Downregulated*qPCR etc.*Human*hsa_circ_0001649 expression was correlated with tumor size (p = 0.045) and the occurrence of tumor embolus (p = 0.017) in HCC，hsa_circ_0001649depletion in hepatoma cell lines enhances mRNA of matrix metallopetidases(MMPs) which promote HCC metastasis, indicating its role in metastasis of HCC.*2016-01-01*26600397.0**hsa_circ_0001649/chr6:146209155-146216113*CircR2Disease*hepatocellular carcinoma
722*CDR1as*chrX:139865339-139866824*+*CDR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001946*Glioblastoma*Downregulated*qPCR, Western blot, MTT assay etc.*Human*Through a combined in silico and in vitro approach, we identified CDR1-AS, CDR1, VSNL1 as downstream miR-671-5p targets in GBM. Expression of these genes significantly decreased both in GBM biopsies and cell lines and negatively correlated with that of miR-671-5p. Based on our data, we propose that the axis miR-671-5p / CDR1-AS / CDR1 / VSNL1 is functionally altered in GBM cells and is involved in the modification of their biopathological profile.*2016-01-01*26683098.0**CDR1as/ciRS-7/hsa_circ_0001946/chrX:139865339-139866824*CircR2Disease*glioblastoma
723*hsa_circ_001988*chr4:153332454-153333681*-*FBXW7*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001451*Colorectal Neoplasms*Downregulated*qPCR etc.*Human*The expression of hsa_circ_001988 was significantly correlated with differentiation (P<0.05) and perineural invasion (P<0.05)*2015-12-01*26884878.0**hsa_circ_001988/hsa_circ_0001451/chr4:153332454-153333681*CircR2Disease*colorectal cancer
724*circular RNA100783*chr11:33307958-33350179*+*HIPK3*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0008887*Immunosenescence*Upregulated*qPCR etc.*Human*circular RNA100783 may represent a novel biomarker for the longitudinal tracking ofCD28-related CD8(+) T cell ageing and global immunosenescence.*2015-10-01*26451160.0**circular RNA100783/hsa_circ_0008887/chr11:33307958-33350179*CircR2Disease*immunosenescence
725*hsa_circ_0004383*chr6:87920168-87928449*+*ZNF292*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0004383*Coronary Artery Disease*Upregulated*qPCR etc.*Human*Regulated by hypoxia in endothelial cells and controls angiogenesis*2015-10-01*26377962.0**hsa_circ_0004383/cZNF292/chr6:87920168-87928449*CircR2Disease*ischaemic heart disease
726*circ-KLDHC10*chr7:129756284-129762042*+*KLHDC10*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0082333*Colorectal Neoplasms*Upregulated*qPCR etc.*Human*qRT-PCR analysis of circ-KLDHC10 levels in normal serum and CRC serum (n = 11, respectively).*2015-08-01*26138677.0**circ-KLDHC10/hsa_circ_0082333/chr7:129756284-129762042*CircR2Disease*colorectal cancer
728*Cir-ITCH*chr20:33001547-33037285*+*ITCH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001141*Colorectal Neoplasms*Downregulated*qPCR, Transient transfections and luciferase assay, Western blot etc.*Human*cir-ITCH could increase the level of ITCH, which is involved in the inhibition of the Wnt/β-catenin pathway, sponges contain miR-7, miR-17,miR-20a, miR-214,miR-128, miR-216b*2015-06-01*26110611.0**Cir-ITCH/hsa_circ_0001141/hsa_circ_001763/chr20:33001547-33037285*CircR2Disease*colorectal cancer
729*hsa_circ_0000140*chr1:155891165-155895634*-*KIAA0907*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0000140*Stomach Neoplasms*Downregulated*qPCR etc.*Human*Lower expression levels were significantly correlated with distal metastasis (P=0.036), TNM stage (P=0.042), gender (P=0.002) and age (P=0.022). *2015-04-01*25689795.0**hsa_circ_0000140/hsa_circ_002059/chr1:155891165-155895634*CircR2Disease*gastric cancer
730*Cir-ITCH*chr20:33001547-33037285*+*ITCH*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001141*Esophageal Squamous Cell Carcinoma*Downregulated*qPCR, Western blot, Cell viability assay, Colony formation assay, Xenografts in mice etc.*Human*Sponge miR-7, miR-17, and miR-214 to increase ITCH expression, then degrade Dvl2 phosphorylation to further inhibit the Wnt signaling pathway*2015-03-01*25749389.0**Cir-ITCH/hsa_circ_0001141/hsa_circ_001763/chr20:33001547-33037285*CircR2Disease*esophageal squamous cell carcinoma
731*circ3204*chr15:63824845-63855207*+***Colorectal Neoplasms*Downregulated*qPCR etc.*Human*circ3204/USP3 in the same direction were observed*2015-01-01*25624062.0**circ3204/chr15:63824845-63855207*CircR2Disease*colorectal cancer
732*circ6229*chr14:21971315-21972024*-***Colorectal Neoplasms*Downregulated*qPCR etc.*Human*circ6229/METTL3 significant negative correlation between proliferation was found*2015-01-01*25624062.0**circ6229/chr14:21971315-21972024*CircR2Disease*colorectal cancer
733*circ7374*chr17:38638380-38638668*-***Colorectal Neoplasms*Upregulated*qPCR etc.*Human*circ7374/TNS4 significant negative correlation between proliferation was found.circ7374 (288 nucleotides) was much more enriched (16,000 to 130,000-fold) indicating higher in vitro stability of shorter circRNAs.*2015-01-01*25624062.0**circ7374/chr17:38638380-38638668*CircR2Disease*colorectal cancer
734*circ7780*chr7:153555574-153562137*+***Colorectal Neoplasms*Downregulated*qPCR etc.*Human*All four ratios and the expression of circ7780 correlated negatively with the proliferation index, two ratios significantly (p<0.05) and two ratios and circ7780 expression as trend *2015-01-01*25624062.0**circ7780/chr7:153555574-153562137*CircR2Disease*colorectal cancer
735*circ0817*chr11:107916996-107925682*+***Colorectal Neoplasms*Downregulated*qPCR etc.*Human*circ0817/CUL5  in the same direction were observed*2015-01-01*25624062.0**circ0817/chr11:107916996-107925682*CircR2Disease*colorectal cancer
736*CDR1as*chrX:139865339-139866824*+*CDR1*http://www.circbase.org/cgi-bin/singlerecord.cgi?id=hsa_circ_0001946*Alzheimer Disease*Downregulated*Northern blot, circRNA probe RNaseR etc.*Human*AD ciRS-7 is significantly reduced to about 0.18-fold of control (con) in a study of 20 control and AD (AD) hippocampal CA1 samples; this implicates loss of miRNA-7 sponge effects, an ambient up-regulation of miRNA-7 (as is observed), and down-regulation of a family of miRNA-7-sensitive mRNAs in the sporadic AD brain*2013-12-01*24427167.0**CDR1as/ciRS-7/hsa_circ_0001946/chrX:139865339-139866824*CircR2Disease*alzheimer’s disease
737*hsa-circRNA 2149*****Immune System Diseases*Upregulated*qPCR, Northern blot etc.*Human*Hsa-circRNA2149 has been detected in CD19+ leukocytes but not CD34+ leukocytes, neutrophils or HEK293 cells.*2013-03-01*23446348.0**hsa-circRNA 2149*CircR2Disease*nervous inflammatory diseases or immune disorders
738*circANRIL***ANRIL**Atherosclerosis*Downregulated*qPCR, Loop PCR etc.*Human*ANRIL encodes a heterogeneous species of rare RNA transcripts. Moreover, we identified novel, circular ANRIL isoforms (cANRIL) whose expression correlated with INK4/ARF transcription and ASVD risk.*2010-12-01*21151960.0**circANRIL*CircR2Disease*atherosclerotic vascular disease
